 
Document Type:  Study Protocol 
Official Title:  A randomized controlled trial of rivaroxaban for the prevention 
of major cardiovascular events in patients with coronary or peripheral artery disease (COMPASS - Cardiovascular OutcoMes for People using Anticoagulation StrategieS)  
Study ID: [REMOVED] 
Document Date:  12-SEP-2017 
 
 
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 1of 205
Cover page of the integrated protocol
A randomized controlled trial of rivaroxaban for the prevention of major cardiovascular events in patients with coronary or peripheral artery disease(COMPASS - Cardiovascular OutcoMes for People using Anticoagulation StrategieS)
This protocol version is an integration of the following documents / sections:
Revised protocol, Version 1.1, dated 28 NOV 2012
Amendment no. 6 (global) (described in Section 13.1) forming integrated protocol 
Version 2.0, dated 03 JUL 2014
Amendment no. 8 (global) (described in Section 13.2) forming integrated protocol 
Version 3.0, dated 19AUG 2015
Amendment no. 11 (global) (described in Section 13.3) forming integrated protocol 
Version 4.0, dated 12SEPT 2017
Amendments not included in the consecutive numbering of amendments are local amendments not forming part of this integrated glo bal protocol . Local amendments 
were as filed in Japan (Amendments 1, 2, 7, 9 and 10), Sweden (Amendment 3), German y 
(Amendment 4), and [LOCATION_008] (Amendment 5).
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 2of 205
Title page  - amended
A randomized controlled trial of rivaroxaban for the prevention of major cardiovascular events in patients with coronary  or peripheral artery  disease (COMPASS - Cardiovascular 
OutcoMes for People using Anticoagulation StrategieS)
Rivaroxaban for the preve ntion of major cardiovascular events in CAD or PAD
(COMPASS)Test drug: BAY 59 -7939 / Rivaroxaban / Xarelto®
Study  purpose: Comparative combination drug stud y for new indication
Clinical study  phase: III Date: 12SEPT [ADDRESS_1158390] no.: 2012-004180-43 Version no.: 4.0
Study  no.: BAY 59 -7939/[ZIP_CODE] 
Coordinating center  Canada
Sponsor Non-USterritory : Bay er AG, D -[ZIP_CODE] Leverkusen, German y
US territory : Bay er HealthCare Pharmaceuticals Inc., [ADDRESS_1158391], [PO_BOX], Whippany NJ [ZIP_CODE] -0915, [LOCATION_003]
Coordinating center:
 Canada
Tel: Sponsor Clinical L eader
1:
Bayer U.S. LLC
Development, PharmaceuticalsThrombosis & Hematology  Therapeutic Area
[ADDRESS_1158392]., Location 2095BParsippany , New Jersey  [ZIP_CODE] [LOCATION_003]
Tel:
The study  will be co nducted in compliance with the protocol, International Conference on 
Harmonization –Good Clinical Practice (I CH-GCP) and any  applicable regulatory  
requirements.
Confidential
The information provided in this document is strictly confidential and is intended solely for the 
guidance of the clinical investigation.  Reproduction or disclosure of this document -whether in 
part or in full -to parties not associated with the clinica l investigation, or its use for any other 
purpose, without the prior written consent of the sponsor is not permitted.
Throughout this document, symbols indicating proprietary names ( , TM) may not be displayed.  Hence, 
the appearance of product names without these symbols does not imply that these names are not protected.
                                                
changed as per Amendment 11. (See Section 13.3.1 )
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
12 SEPT 2017 Integrated Clinical Study Protocol 
BAY 59-7939/ [ZIP_CODE] 
Version 4.0 
Signature [CONTACT_834393]. 
Name: [CONTACT_1221] : 
Date: 
Name : [CONTACT_1221]: 
Date Signatur e: 
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 4of 205
Signature [CONTACT_834394].
Name: [CONTACT_1221]:  Site investigator
Date: Signature:
[CONTACT_5627]: Role:  Site investigator  
Date: Signature:
[CONTACT_9001][INVESTIGATOR_834103]’s study  files and in the respective center’s investigator site file.
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
12 SEPT20l7 Integrated Clinical Study Protoco l 
BAY 59-7939 /[ZIP_CODE] 
Version 4.0 Page: 5 of205 
Signature [CONTACT_8152]'s medically responsible person -amended 
The signatory agrees to the content of the final clinical study protocol as presented. 
Name: [CONTACT_1221]: 
changed as per Amendment I l. (See Section 13.3 .2) 
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 6of 205
Synopsis  - amended
TitleA randomized controlled trial of rivaroxaban for the prevention of major 
cardiovascular events in patients with coronary or peripheral artery disease
(COMPASS -Cardiovascular OutcoMes for People using Anticoagulation 
StrategieS)
Short titleRivaroxaban for the prevention of major cardiovascular events in CAD or PAD (COMPASS)
Clinical study phaseIII
Study objectivesPrim ary objectives for rivaroxaban randomization
To determine whether rivaroxaban 2.5 mg twice daily (bid) + 
aspi[INVESTIGATOR_248] 100 mg once daily (od) compared w ith aspi[INVESTIGATOR_248] 100 mg od 
reduces the risk of a composite of myocardial infarction, stroke, or cardiovascular death in subjects with CAD or PAD
To determine whether rivaroxaban 5 mg bid compared w ith 
aspi[INVESTIGATOR_248] 100 mg od reduces the risk of a composite of myocardial 
infarction, stroke or cardiovascular death in subjects with CAD or 
PAD
Secondary objectives for rivaroxaban random ization
To determine whether each of rivaroxaban 2.5 mg bid + aspi[INVESTIGATOR_248] 
100mg od and rivaroxaban 5 mg bid alone reduces the risk of the 
composite of major thrombotic events : (1) coronary heart disease 
death, myocardial infarction, ischemic stroke, acute limb ischemia;(2) cardiovascular death, myocardial infarction, ischemic stroke, 
acute limb ischemia compared w ith aspi[INVESTIGATOR_248] 100 mg od in subjects 
with CAD or PAD
3
To determine whether each of rivaroxaban 2.5 mg bid + aspi[INVESTIGATOR_248] 
100mg od and rivaroxaban 5 mg bid alone redu ces the risk of 
mortality in subjects with CAD or PAD
Objective for pantoprazole randomization
To determine whether pantoprazole 40 mg od compared w ith 
placebo reduces the risk of upper gastrointestinal bleeding, ulceration, and gastrointestinal obstructio n or perforation in 
subjects with CAD or PAD receiving antithrombotic medications
Objective for Long -Term  Open -Label Extension (LTOLE)
To make rivaroxaban 2.5 mgtwice daily (bid) + aspi[INVESTIGATOR_248] 100 mg 
once daily (od) available to COMPASS trialsubjects until the 
rivaroxaban treatment is commercially available for this indication
or for approximately [ADDRESS_1158393].5
                                                
3Text r evised as per Amendments 6 and 8. (See Sections 13.1.2 and 13.2.2 )
4The protocol amendment with the LTOLE addition.
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 7of [ADDRESS_1158394] drugsRivaroxaban, aspi[INVESTIGATOR_248], and pantoprazole
Nam e of active ingredientRivaroxaban, aspi[INVESTIGATOR_248], and pantoprazole
Dose(s)Rivaroxaban 2.5 mg, bid
Rivaroxaban 5.0 mg, bid
Aspi[INVESTIGATOR_248] 100 mg, od
Pantoprazole 40 mg, od
LTOLE
Rivaroxaban 2.5 mg bid + aspi[INVESTIGATOR_248] 100 mg od6
Route of administrationPer oral
Duration of treatm entEstimated average of 3 -4 years
LTOLE: approximately 3 years7
Reference drugsRivaroxaban placebo, aspi[INVESTIGATOR_397629], and pantoprazole placebo
LTOLE: no reference drug8
Nam e of active ingredientNot applicable
Dose(s)Not applicable
Route of administrationPer oral
Duration of treatm entEstimated average of 3 -4 years
IndicationCoronary or peripheral artery disease
Diagnosis and main criteria for 
inclusionSubjects are eligible for  inclusion if they:
Meet criteria for CAD* and/or PAD9
*Subjects w ith CAD must also meet at least one of the following criteria:
Age 65 years, or
Age [ADDRESS_1158395] 2 vascular beds§, or at least 2
additional cardiovascular risk factors:
1)Curren t smoker (within 1 year ofrandomization)
                                                                                                                                                        
5Text added as per Amendment 11. (See Section 13.3.1 ) 
6Text added as per Amendment 11. (See Section 13.3.1 )
7Text added as per Amendment 11. (See Sec tion 13.3.1 )
8Text added as per Amendment 11. (See Section 13.3.1 )
9Text added/deleted as per Amendment 6. (See Section 13.1.2 )
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 8of 205
2)Diabetes mellitus
3)Renal dysfunction with estimated glomerular filtration rate 
60ml/min
4)Heart failure
5)Non-lacunar ischemic stroke 1 month ago
§ Because CAD involves disease in the coronary vasculature, only one 
additional vascular bed is required: e.g. the aorta and arterial supply to the brain, gastro -intestinal tract, low er limbs, upper limbs, or kidneys.
LTOLE: all subjects randomized to the COMPASS trial willing to consent 
to LTOLE are eligible unless the su bjects develop eda condition c onsidered 
by [CONTACT_834321].
10
Study designRandomized, double- blind, controlled trial w ith a 3 x 2 partial factorial 
design
LTOLE: open label uncontrolled study11
MethodologyThe study will comprise 4 periods:  screening, run -in, follow -up, and 
washout.
During the screening period, informed consent will be obtained and 
evaluations of subject eligibility will be performed.  The run -in period w ill 
occur during the 28 days12prior to initiation of study tr eatment, w ith the 
exception of subjects randomized Day 4 -712after coronary artery by[CONTACT_834322] a run -in.  During run -in, subjects will 
discontinue any current anticoagulant therapy and w ill begin rivaroxaban 
placebo and 100 mg aspi[INVESTIGATOR_248].  Treatment of subjects who comply with the 
run-in treatment and who remain committed to the study, as well as those 
who are randomized Day 4-712after coronary artery by[CONTACT_834323] 0, which will also signal the initiation of the follow -up 
period.  Subjects w illbe randomized 1:1 to pantoprazole or pantoprazole 
placebo and then will be randomized 1:1:1 to rivaroxaban and aspi[INVESTIGATOR_834104]:
Randomized study treatments* 
Rivaroxaban 2.5 mg bid +
Aspi[INVESTIGATOR_27969] n 100 mg od +
Pantoprazole 40 mg odRivaroxaban 2.5 mg bid +
Aspi[INVESTIGATOR_248] 100 mg od +
Pantoprazole placebo
Rivaroxaban 5 mg bid + 
Aspi[INVESTIGATOR_397629] + 
Pantoprazole 40 mg odRivaroxaban 5 mg bid + 
Aspi[INVESTIGATOR_397629] +
Pantoprazole placebo
Rivaroxaban placebo + 
Aspi[INVESTIGATOR_248] 100 mg od +
Pantoprazole 40 mg odRivaroxaban placebo + 
Aspi[INVESTIGATOR_248] 100 mg od + 
Pantoprazole placebo
*Subjects who have a continuous need for use of a proton pump inhibitor at 
                                                
10Text added as per Amendment 11. (See Section 13.3.1 )
11Text added as per Amendment 11. (See Section 13.3.1 )
12Text modified as per Amendments 6 and 8. (See Sections 13.1.2 and 13.2.2 )
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 9of 205
baseline will undergo only a single randomization (to rivaroxaban 2.5 mg 
bid + aspi[INVESTIGATOR_248] 100 mg od, rivaroxaban 5 mg bid + aspi[INVESTIGATOR_834105] + aspi[INVESTIGATOR_248] 100 mg od)
Subjects will be followed for the duration of the study irrespective of 
whether they are receiving study treatment or whether they experience an 
outcome event.  A final visit (Final Follow -up Visit) will mark the end of 
the follow -up period and w ill occur when a minimum of 2,200 subjects 
experience an event for the primary efficacy outcome. A final w ashout 
period visit (End of Washout Telephone Visit) will be conducted by 
[CONTACT_756] ( performed 30 days after the Final Follow -up Visit).
LTOLE: initiation visit and a follow -up period13
Type of controlFor rivaroxaban: active control (aspi[INVESTIGATOR_248]).  For pantoprazole: placebo
LTOLE: none14
Number of subjects12Enrolled = approximately 29,940 ; randomized = approximately 27,400 in 
approximately 33 countries worldwideApproximately 29,940 subjects will be enrolled; approximately 28,300 will 
be admitted to the run -in period and 2000 subjects w ill undergo coronary 
artery by[CONTACT_834324] -in.  A non -compliance rate of 10% is 
anticipated for those subjects in the run -in period; thus, ap proximately 
27,400 subjects w ill be randomized (of which approximately 2000 subjects 
who underw ent coronary artery by[CONTACT_9292] w ould be randomized without 
run-in) in approximately 33 countries worldw ide.
LTOLE: COMPASS trialsubjects are potentially eligi ble.
[ADDRESS_1158396] 
occurrence of the primary safety outcome, a modified International Society 
on Thrombosis and Haemostasis major bleeding.
LTOLE: the same primary safety and efficacy variables will be collected in 
LTOLE .
16
Plan for statistical analysisAnalysis of the primary efficacy variable for rivaroxaban or aspi[INVESTIGATOR_834106] -to-treat principle. Primary 
hypotheses will be tested using stratified log -rank tests.  Relative risk 
reduction will be estimated with stratified Cox proportional hazards 
models.
LTOLE: all statistical analyses will be descriptive.17
                                                
13Text added as per Amendment 11. (See Section 13.3.1 )
14Text added as per Amendment 11. (See Section 13.3.1 )
15Text added as per Amendment 11. (See Section 13.3.1 )
16Text added as per Amendment 11. (See Sec tion 13.3.1 )
17Text added as per Amendment 11. (See Section 13.3.1 )
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 10of 205
Table of contents
Cover page of the integrated protocol .................................................................................... 1
Title page - amended ................................................................................................................ 2
Signature [CONTACT_834395] ........................................................................................ 3
Signature [CONTACT_834396] ................................................................................................. 4
Signature [CONTACT_8152]’s medically responsible person – amended.................................. [ADDRESS_1158397] of abbreviations -amended ............................................................................................ 14
1.Introduction ..................................................................................................................... 16
1.1 Background – amended .................................................................................................. 16
1.2 Study  rationale ............................................................................................................... 17
1.2.1 Rivaroxaban - amended .............................................................................................. 17
1.2.2 Aspi[INVESTIGATOR_834107] - amended ........................................................................ 18
1.2.3 Proposed rivaroxaban evaluation - amended .............................................................. 21
1.2.4 Long -Term Open -Label Extension -amended ........................................................... 21
1.3 Benefit -risk assessment –amended ............................................................................... 22
2.Study objectives – amended ........................................................................................... 23
3.Investigators and other study participants ................................................................... 24
3.1 Study  committees -amended ......................................................................................... 24
3.2 Study  coordination ......................................................................................................... 25
3.3 Other study  personnel and administrative functions ...................................................... 26
4.Study design ..................................................................................................................... 26
4.1 Design overview – amended .......................................................................................... 26
4.1.1 Subjects randomized after CABG surgery  -amended ................................................ 28
4.2 Primary  efficacy  and safety  variables − amended ......................................................... 29
4.3 Justification of the design .............................................................................................. 29
4.3.1 Overall design rationale –amended ........................................................................... 29
4.3.2 Design rationale for Long -Term Open -Label Extension − amended ......................... 30
4.4 Final follow -up visit and end of study -amended ........................................................... 30
5.Study population -amended ........................................................................................... 31
5.1 Eligibility  − amended ..................................................................................................... 32
5.1.1 Inclusion criteria -amended ....................................................................................... 32
5.1.2 Exclusion criteria - amended ...................................................................................... 33
5.1.3 Long -Term Open -Label Extension − amended .......................................................... 34
[IP_ADDRESS] Inclusion criteria ...................................................................................................... 34
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 11of 205
[IP_ADDRESS] Exclusion criteria ..................................................................................................... 34
5.2 Discontinuation of subjects from study  treatment -amended ........................................ 34
5.2.1 Replacement ............................................................................................................... 35
5.2.2 Long -Term Open -Label Extension − amended .......................................................... [ADDRESS_1158398] identification ..................................................................................................... 35
6.Treatments ....................................................................................................................... 35
6.1 Treatments to be administered -amended ..................................................................... 35
6.1.1 Run-in -amended ....................................................................................................... 35
6.1.2 Randomization -amended .......................................................................................... 35
6.1.3 Treatment in Long -Term Open -Label Extension − amended .................................... 36
6.2 Identity of study  treatment -amended ........................................................................... 36
6.3 Treatment assignment -amended .................................................................................. 36
6.4 Dosage and administration - amended ........................................................................... 37
6.4.1 Dose modifications -amended ................................................................................... 37
6.4.2 Dose modifications and treatment guidance - amended ............................................. 37
[IP_ADDRESS] Guidance for the treatment of subjects who require an invasive procedure -
amended ................................................................................................................... 38
[IP_ADDRESS] Guidance for the treatment of subjects who require coronary  artery  by[CONTACT_15803]  –amended ................................................................................................... 38
[IP_ADDRESS] Guidance for the treatment of subjects who develop an acute coronary  syndrome 
and those who require percutaneous coronary  intervention with stenting –
amended ................................................................................................................... 39
[IP_ADDRESS] Guidance for the treatment of subjects who overdose on study  
rivaroxaban/rivaroxaban placebo –amended .......................................................... 40
[IP_ADDRESS] Guidance for the treatment of subjects who experience a major bleed –amended . 40
[IP_ADDRESS] Guidance for the treatment of subjects who develop a stroke and who are being 
considered for reperfusion therap y –amended ....................................................... [ADDRESS_1158399]-study  therapy  -amended ........................................................................................ 43
6.9 Prior and concomitant therap y -amended ..................................................................... 43
6.9.1 Combined CYP 3A4 and p- glycoprotein inhibitors and CYP 3A4 inducers -
amended ...................................................................................................................... 44
6.9.2 Clopi[INVESTIGATOR_7745] (or an y other non- study  antiplatelet treatment) - amended ..................... 44
6.9.3 Anti coagulant treatment -amended ............................................................................ 45
6.9.4 Proton pump inhibitor treatment -amended ............................................................... 46
7.Procedures and variables ................................................................................................ 46
7.1 Schedule of procedures − amended ............................................................................... 46
7.1.1 Tabulated overview -amended ................................................................................... 48
7.1.2 Timing of assessments ................................................................................................ 55
[IP_ADDRESS] Pre-screening visit ................................................................................................... 55
[IP_ADDRESS] Screening and run -in visit(s) - amended .................................................................. 55
[IP_ADDRESS] Randomization visit (Day 0 ± 5 day s) -amended ................................................... 56
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 12of 205
[IP_ADDRESS] Follow -up visits ....................................................................................................... 57
[IP_ADDRESS].1 Routine follow -up visits (Visits 3, 5, and 7- 15+) -amended ............................... 57
[IP_ADDRESS].2 Non-clinic assessments (Months 3 and 9 ± 4 weeks) .......................................... 58
[IP_ADDRESS].3 Final Follow -up Visit (± 4 weeks) ....................................................................... 58
[IP_ADDRESS] End of washout telephone visit ([ADDRESS_1158400] Final Follow -up Visit ± 5 days) ...... 59
[IP_ADDRESS] Long -Term Open -Label Extension − amended ....................................................... 59
[IP_ADDRESS].1 Initiation of Long- Term Open -Label Extension − amended ............................... 59
[IP_ADDRESS].2 Follow -up of Long -Term Open- Label Extension − amended ............................. 60
[IP_ADDRESS].3 Final visit of L ong-Term Open- Label Extension ................................................. 60
7.2 Population characteristics .............................................................................................. 60
7.2.1 Demographics ............................................................................................................. 60
7.2.2 Medical history ........................................................................................................... 61
7.2.3 Other baseline characteristics - amended ................................................................... 61
7.3 Efficacy  -amended ........................................................................................................ 61
7.4 Pharmacokinetics / pharmacod ynamics ......................................................................... 62
7.5 Safety  − amended ........................................................................................................... 62
7.5.1 E6 Definition of (serious) adverse event -amended .................................................. 63
7.5.2 Causal relationship -amended .................................................................................... 63
7.5.3 Protocol -specific adverse event definitions ................................................................ 63
[IP_ADDRESS] Protocol -specific exceptions to SAE reporting -amended ..................................... 63
[IP_ADDRESS] Reporting of (S)AEs - amended .............................................................................. 65
[IP_ADDRESS] Adverse events of special safet y interest - amended ............................................... 65
[IP_ADDRESS] Non-serious adverse events ..................................................................................... 67
[IP_ADDRESS] Pregnancies - amended ............................................................................................ 67
7.5.4 Reporting of events to Bay er by   [CONTACT_834325]’ 
reporting requirements -amended .............................................................................. 67
7.6 Other procedures and variables ...................................................................................... 67
7.7 Appropriateness of procedures / measurements............................................................. 68
8. Statistical methods and determination of sample size ................................................. 68
8.1 General considerations ................................................................................................... 68
8.2 Analy sis sets and data scopes......................................................................................... 68
8.2.1 Analy sis sets ............................................................................................................... 68
8.2.2 Data scopes ................................................................................................................. 68
8.3 Variables –amended ...................................................................................................... 69
8.3.1 Primary  efficacy outcome ........................................................................................... 69
8.3.2 Secondary  efficacy  outcomes -amended ................................................................... 69
8.3.3 Tertiary  and other efficacy  outcomes -amended ....................................................... 70
8.3.4 Primary  safet y outcome .............................................................................................. 70
8.3.5 Outcome for pantoprazole randomization - amended ................................................ 70
8.3.6 Subgroup variables -amended .................................................................................... 71
8.4 Statistical and analy tical plans -amended ..................................................................... 71
8.4.1 Analy sis of the primary  efficacy  outcome -amended ................................................ 72
8.4.2 Analy sis of the secondary  efficacy  outcomes -amended ........................................... 74
8.4.3 Analy sis of the tertiary  efficacy  outcomes ................................................................. 74
8.4.4 Analy sis of the primary  safet y outcome ..................................................................... 74
[COMPANY_003]
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 13of 205
8.4.5 Analy sis of the outcome for pantoprazole randomization -amended ........................ 74
8.4.6 Subgroup analyses -amended .................................................................................... 75
8.4.7 Handling of missing data ............................................................................................ 76
8.4.8 Long -Term Open -Label Extension –amended .......................................................... 76
8.5 Planned interim anal yses -amended .............................................................................. 77
8.6 Determination of sample size -amended ....................................................................... 78
9.Data handling and quality assurance ............................................................................ 80
9.1 Data recording................................................................................................................ 809.2 Monitoring ..................................................................................................................... 80
9.3 Data processing –amended ............................................................................................ [ADDRESS_1158401] information and consent.................................................................................... 8411.3 Publication policy -amended .......................................................................................... 85
11.4 Compensation for health damage of subjects / insurance .............................................. [ADDRESS_1158402] -amended ................................................................................................. 87
13.Protocol amendments ...................................................................................................... 91
13.1 Amendment 6 ................................................................................................................. 91
13.1.1 Overview changes to the study ................................................................................... 91
13.1.2 Changes to protocol text ........................................................................................... 102
13.2 Amendment 8 ............................................................................................................... 145
13.2.1 Overview changes to the study ................................................................................. 145
13.2.2 Changes to protocol text ........................................................................................... 151
13.3 A mendment 11 ............................................................................................................. 180
13.3.1 Overview changes to the study ................................................................................. 180
13.3.2 Changes to protocol text ........................................................................................... 182
14.Appendices ..................................................................................................................... 202
14.1 COMPASS MI ND substudy  -amended ...................................................................... 202
Table of Tables
Table 4–1.  Randomized study  treatments* ............................................................................. 27
Table 7–1.  Schedule of evaluations ......................................................................................... 48
Table 7–2 Schedule of evaluations after DSMB recommendation in Feb 2017 ...................... 52
Table 7–3 Schedule of LTOL E Procedures ............................................................................. 54
Table 7–4.  Adverse events of special interest ......................................................................... 66Table 8–1.  Events calculations ................................................................................................ 79
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 14of 205
Table of Figures
Figure 8 –1:Hypothesis testing problem .................................................................................. 72
Figure 14 –1: Covert brain infarct (arrow) on MR imaging (T- 1 sequence) .......................... [ADDRESS_1158403] of abbreviations  - amended
ACE Angiotensin converting enzy me
AE Adverse event
bid Twice dail y
BP Blood pressure
bpm Beats per minute
CABG Coronary  artery  by[CONTACT_834326] (either paper or electronic)
CT Computed tomograph y
CV Cardiovascular
dL Deciliter
DNA Deox yribonucleic acid
DSMB Data Safet y Monitoring Board 
DSS Digit Sy mbol Substitution
DVT Deep vein thrombosis
e.g. Exempli gratia , for example
eGFR Estimated glomerular filtration rate
EQ-5D European Quality  of Life-5 Dimensions
EU European Union
FLAIR Fluid Attenuated Inversion Recovery
GCP Good Clinical Practice
GI Gastrointestinal
GMP Good Manufacturing Practice
GPV Global Pharmacovigilance
IB Investigator’s Brochure
ICH International Conference on Harmonization
i.e. Id est, that is
IEC Independent ethics committee
in Inch
INR International normalized ratio
IRB Institutional review board
IT Information technology
Hb Hemoglobin
HIV Human immunodeficiency  virus
HR Hazard ratio
ISTH International Societ y on Thrombosis and Haemostasis
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 15of 205
kg Kilogram
LbLTOLEPoundLong -term open -label extension
18
MACE Major adverse cardiac event19
MD Medical director/doctor
MI Myocardial infarction
min Minute
mg Milligram
mL Milliliter
mmHg Millimeter of mercury
MRI Magnetic resonance imaging
MoCA Montreal Cognitive Assessment
MRU Medical resource utilization
NL National Leaders
NYHA [LOCATION_001] Heart Association
od Once dail y
PAD Peripheral artery  disease
PASS Power Anal ysis and Sample Size software
PCI Percutaneous coronary  intervention
PE Pulmonary  embolism
P-gp P-glycoprotein
PPI [INVESTIGATOR_834108]20
OR Odds ratio
QA Quality  assurance
RRR Relative risk reduction
SAE Serious adverse event
SAGE Standard Assessment of Global -Activities in the Elderly
SAP Statistical analy sis plan
SAS Statistical Analy sis System
S[LOCATION_003]R Serious unexpected suspected adverse reaction 
[LOCATION_003] [LOCATION_002] of America
US FDA [LOCATION_002] Food and Drug Administration
Xa Activated coagulation factor X
                                                
18Text added as per Amendment 11. (See Section 13.3.1 )
19Text added as per Amendment 11. (See Section 13.3.1 )
20Text added as per Amendment 11. (See Section 13.3.2 )
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 16of 205
1. Introduction
1.1 Background –amended
Globally  an estimated 17.5 million people died from cardiovascular disease in 2005 (30% of 
all deaths) and this number is projected to increase to 20 million by  2015.( 1)
Coronary  artery  disease (CAD) is the most common cause of cardiovascular disease.  One-
third to one -half of middle -aged males and females in high income countries are expected to 
develop ma nifestations of CAD during their lifetime and the number of patients with chronic 
CAD is rising globally .  Although CAD mortalit y rates have declined in high income 
countries over the past few y ears they  have risen sharply  in Asia, Latin America, the Middl e 
East, and in India and China. Coronary  heart disease remains responsible for about one -third 
of deaths in persons over the age of 35. (1,2)  
Peripheral artery  disease (PAD) of the lower extremities while often undiagnosed is a 
powerful risk marker of cardiovascular disease. (3)  The global prevalence of PAD is less well 
studied than that of CAD but screening studies suggest that approximately  20% of adults older 
than [ADDRESS_1158404] ive evidence of PAD .(4)  The disease prevalence is strongl y age -
related and like CAD the numbers of affected patients is rising because of the aging of the 
population.  Best available estimates suggest that [ADDRESS_1158405] 3 -to 6-fold to 
estimate the global burden of disease. (5)The severity  of PAD is a major determinant of 
subsequent risk of cardiovascular events and mortality .  
Aspi[INVESTIGATOR_248], statins ,and angiotensin converting enzyme (ACE) inhibitors are effective and widely 
used for the prevention of cardiovascular events in patients with CAD and PAD but the risk of vascular events remains high despi[INVESTIGATOR_98356].
   A new , safe ,and convenient 
antithrombotic therap y that further improves efficacy when it is added to or replaces aspi[INVESTIGATOR_834109] a major impact in reducing the individual, community , and global burden of 
disability  and death due to cardiovascular disease.  
Rivaroxaban is an orally  active anticoagulant that selectivel y targets activated coagulation 
factor X (Xa), thereb y inhibiting thrombin generation and thrombus formation.  Rivaroxaban 
has been demonstrated in large phase 3 randomized controlled trials to be a highl y effective 
antithrombotic treatment for the prevention and treatment of venous thromboembolism, the prevention of stroke and sy stemic embolism in patients with atrial fibrillation, and the 
prevention of major cardiovascular events in patients wi th a recent acute coronary  syndrome. 
The evidence of efficacy  of rivaroxaban for the prevention of atherothrombotic events on a 
background of dual antiplatelet therap y in patients with recent acute coronary s yndrome 
supports the hy pothesis that it may  also be effective for prevention of atherothrombotic events 
in patients with established CAD or PAD, receiving usual care.
21  
                                                
21Text modified as per Amendment 6. (See Section 13.1.2 )
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 17of 205
Further information concerning the results of the rivaroxaban trials is provided in Section 1.2.1.  Details concerning the pharmacology  of rivaroxaban are provided in the 
investigator's brochure, located in the Manual of Operations. 
The trial described herein, Cardiovascular Outc oMes for People using Anticoagulation 
StrategieS (COMPASS), is a randomized double -blind trial utilizing a 3 x 2 partial factorial 
design that will evaluate the efficacy  and safety  of rivaroxaban 2.5 mg twice daily  (bid) + 
aspi[INVESTIGATOR_248] 100 mg once daily  (od) ve rsus aspi[INVESTIGATOR_248] 100 mg od and rivaroxaban 5 mg bid versus 
aspi[INVESTIGATOR_248] 100 mg od for the prevention of myocardial infarction, stroke, and cardiovascular 
death in patients with established CAD or PAD, who are receiving usual care.  In the (partial 
factorial) random ization, patients who do not have a continuous need for use of a proton pump 
inhibitor (PPI) will be randomized to receive pantoprazole 40 mg od or placebo for the 
prevention of major upper gastrointestinal complications, and then randomized to receive 
rivaroxaban in combination with aspi[INVESTIGATOR_248], rivaroxaban alone ,or aspi[INVESTIGATOR_264086].
22
Long -Term Open -Label Extension –amended
On February  6, 2017, the COMPASS Data Safety  Monitoring Board (DSMB) recommended 
discontinuation of the rivaroxaban/aspi[INVESTIGATOR_834110] a clear benefit of one of the two rivaroxaban -containing arms. The DSMB recommendation was 
made because for rivaroxaban 2.5 mg bid + aspi[INVESTIGATOR_248] 100 mg od , the z -value (test statistic of the 
log-rank test) for efficacy  had crossed the critical value for earl y efficacy  as outlined in the 
DSMB charter consistently  over a 3- month period, and the z -value for rivaroxaban 5 mg bid 
had reached conventional significance for efficacy . The Steering Committee concurred with 
the recommendation of the DSMB, and the sponsor decided to stop the rivaroxaban/aspi[INVESTIGATOR_834111] y based on the recommendation of the DSMB and the Steering Committee. 
The sponsor is making rivaroxaban 2.5 mg bid + aspi[INVESTIGATOR_248] 100 mg od available earlyfor 
COMPASS trial subjects as part of a long -term open -label extension (LTOLE) protocol 
amendment. The dedicated LTOLE sections in this document describe LTOL E activities only; 
activities related to the pantoprazole/placebo arm remain unchanged with the exception of the 
removal of the washout visit. LTOLE activities will be coordinated with those of the ongoing 
pantoprazole/placebo arms of the trial where possible until pantoprazole/placebo part of the 
trialis completed.
[ADDRESS_1158406] program involving 12,729 patients 
undergoing hip or knee arthroplasty  demonstrated that rivaroxaban given at a dose of 10 mg 
                                                
22Text modified as per Amendment  6. (See Section 13.1.2 )
23Text added as per Amendment 11. (See Section 13.3.1 )
24Text modified as per Amendments 6 and 8.  (See Sections 13.1.2 and 13.2.2 )
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 18of 205
od compared with enoxaparin given at a dose of 30 mg bid or 40 mg od,significantly  reduced 
the risk of sy mptomatic venous thromboembolism and mortality  (odds ratio [OR] 0.48; 95% 
confidence interval [CI]: 0.30 to 0.76), without increasing the risk of major or clinically  
relevant non- major bleeding (OR 1.17; 95% CI: 0.93 to 1.46).( 6)  
The EINSTEIN venous thromboembolism treatment trials involving 9,447 patients with venous thromboembolism demonstrated that rivaroxaban 15 mg bid for 3 weeks followed b y 
20mg od compared with initial low -molecular -weight heparin followed b y warfarin 
(International Normalized Ratio [INR] 2.0 to 3.0) was associated with a similar or reduced risk of recurrent venous thromboembolism (deep venous thrombosis [DVT] trial, hazard ratio[HR] 0.68; 95% CI : 0.44 to 1.04; pulmonary  embolism [PE] trial, HR 1.12; 95% CI: 0.75 to 
1.68) with a similar or reduced rate of major bleeding during up to 12 months (DVT trial, HR 0.65; 95% CI : 0.33 to 1.30; PE trial, HR 0.49; 95% CI : 0.31 to 0.79). (7,8)
  In the EINSTEIN 
extension study , rivaroxaban compared with placebo reduced the risk of recurrent venous 
thromboembolism by  [CONTACT_726] 80% (HR 0.18; 95% CI  0.09- 0.39) at the expected cost of an 
increase in major bleeding (4 versus 0 events). (8)
The ROCKET AF trial involving 14,264 patients with atrial fibrillation at high risk of stroke demonstrated that rivaroxaban 20 mg od (15 mg od in patients with an estimated glomerular 
filtration rate of 30 to 49 ml/min) compared with warfarin (INR 2.0 to 3.0) was non -inferior 
for the prevention of stroke or s ystemic embolism (HR 0.79; 95% CI: 0.66- 0.96), with a 
significant reduction in life -threatening, intracranial , and fatal bleeding and a favorable effect 
on mortality .(9)
The ATLAS TIMI-51 study  demonstrated that rivaroxaban 2.5 mg or 5 mg bid compared with 
placebo reduced the risk of myocardial infarction, stroke ,or cardiovascular death by  16% (HR 
0.84, 95% CI  0.74- 0.96, p=0.008) in patients with a recent my ocardial infarction, most of 
whom (92%) were also receiving dual antiplatelet therap y.  The reduction in the primary  
efficacy  outcome was driven by  a reduction in both cardiovascular death and my ocardial 
infarction , and rivaroxaban was also associated with 31% reduction in stent thrombosis (HR 
0.69; 95% CI : 0.61- 0.93).  Rivaroxaban increased major and intracranial bleeding, but not 
fatal bleeding. (10)  On a background of aspi[INVESTIGATOR_264086], rivaroxaban compared with placebo 
produced consistent benefits and appeared to be associated with no excess of major bleeding, although this was based on modest numbers of patients.
1.2.2 Aspi[INVESTIGATOR_834107] -amended
A large bod y of evidence from randomized controlled trials has established the efficacy  of 
antithrombotic therapi[INVESTIGATOR_834112]. 
Data from the Antithrombotic Trialists Collaboration meta -analysis demonstrate the efficacy  
of antiplatelet therap y for prevention of cardiovascular events.( 11) Aspi[INVESTIGATOR_834113], stroke ,or cardiovascular death by  [CONTACT_452119] -quarter in patients with 
established coronary , cerebral ,and PAD .  A similar magnitude of benefit was evident across 
the different vascular beds. Aspi[INVESTIGATOR_834114] o f graft failure following 
coronary  artery  by[CONTACT_9292] (CABG) surgery .(11)Despi[INVESTIGATOR_166821], however [ADDRESS_1158407] one 
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 19of 205
blocked graft at 1 year of follow -up.( 12)  Graft failure is an independent predictor of 
myocardial infarction and death following CABG surgery .  
The CAPRI E trial demonstrated that clopi[INVESTIGATOR_834115], stroke ,or cardiovascular death by  [CONTACT_168984] 10% in patients with 
coronary , cerebral , or PAD .(13)  Increasing the intensity  of antiplatelet therapy  by [CONTACT_834327][INVESTIGATOR_8258] (dual antiplatelet therap y) compar ed with aspi[INVESTIGATOR_834116]  20% to 30% in patients with a 
recent acute coronary  syndrome and in those undergoing percutaneous coronary  intervention 
with stent insertion.( 14)  The replacement of clopi[INVESTIGATOR_834117] P2Y (12)receptor 
antagonists such as prasugrel and ticagrelor has provided even greater benefit during the first 12 to 18 months after an acute coronary  event. (15,16)
  However, a benefit of long term dual 
antiplatelet therap y (bey ond the first 12 -18 months) has not been demonstrated. The 
CHARI SMA tri al did not demonstrate a benefit of long -term aspi[INVESTIGATOR_834118]  
(median 28 months) in patients with stable coronary , cerebral ,or PAD or in those at high risk 
of atherothrombotic vascular events, although a benefit was suggested in the subgro up of 
patients with sy mptomatic cardiovascular disease. (17)
Other studies have investigated the potential benefits of combined antiplatelet therap yfor 
long-term prevention of cardiovascular disease. The TRA [ADDRESS_1158408] therap y alone reduced the risk 
of my ocardial infarction, stroke, or cardiovascular death by  13% at [ADDRESS_1158409] of an increase in 
major and intracranial bleeding.( 18)  The PEGASUS trial demonstrated that 33 months of 
treatment with ticagrelor (90 mg twice -daily or 60 mg twice -daily) compared with placebo 
reduced the r isk of cardiovascular death, m yocardial infarction, or stroke by 15 -16% 
(ticagrelor 90 mg: 7.85%, ticagrelor 60 mg: 7.77%, placebo 9.04%; p=0.008 and p=0.004, respectivel y) in patients with a history of m yocardial infarction [ADDRESS_1158410] of a 2 -3 fold increase in major bleeding (ticagrelor 90 mg: 2.60%, ticagrelor 60 mg: 
2.30%, placebo 1.06%; p<0.01 for each dose vs. placebo), and there was no reduction in total mortality  (ticagrelor 90 mg: 5.15%, ticagrelor 60 mg: 4.69%, placebo 5.16%; p=0.99 and 
p=0.14, respectivel y).(43)
26
The DAPT trial randomized 9,961 patients with a history  of coronary  stenting with a drug 
eluting stent who had completed 12 months of dual antipla telet therap y with a thienopy ridine 
and aspi[INVESTIGATOR_834119] 75 mg once dail y or prasugrel 10 mg once dail y 
or placebo for another 18 months. All patients continued receiving aspi[INVESTIGATOR_248]. Continuing treatment with a thienopy ridine as compa red with placebo reduced the rates of stent 
thrombosis by  71% (0.4% vs. 1.4%, p<0.001) and the composite, death, MI  or stroke by  29% 
(4.3% vs. 5.9%, p<0.001) but at the cost of excess moderate or severe bleeding (2.5% vs. 
                                                
25Text modified as per Amendment 6. (See Section 13.1.2 )
26PEGASUS trial data added as per Amendment 8. (See Section 13.2.2 )
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 20of 205
1.6%, p=0.001) and a borderline si gnificant 36% increase in all- cause death from an y cause 
(2.0% vs. 1.5%, p=0.05). ( 44)27
Excess mortality  seen with extended dual antiplatelet ther apy in the DAPT trial was 
confirmed in a subsequent meta -analysis of 10 randomized trials including 31,666 patients 
who had undergone coronary  artery  stenting comparing different durations of dual antiplatelet 
therap y. Shorter duration dual antiplatelet th erapy was associated with an 18% reduction in 
all-cause mortality  (HR 0.82, 95% CI  0.69- 0.98; p=0.02), predominantl y due lower non-
cardiac mortality  (HR 0.67, 0.51 -0.89; p=0.006), with similar cardiac mortality  (HR 0.93, 
0.73-1.17; p=0.52). Shorter duratio n dual antiplatelet therap y was also associated with a lower 
risk of major bleeding (HR 0.58, 0.47- 0.72; p<0.001), but a higher risk of my ocardial 
infarction (HR 1.51, 1.28 -1.77; p<0.001) and stent thrombosis (HR 2.04, 1.48- 2.80; 
p<0.001).( 45)27
Anticoagulation with warfarin and the combina tion of warfarin and single agent antiplatelet 
therap y are also effective for the secondary prevention of cardiovascular events. A 
meta -analysis of randomized controlled trials involving more than 20,000 patients with CAD
demonstrated that moderate intensi ty (INR 2.0 to 3.0) and high intensity  (INR >2.8) warfarin 
compared with control reduced the risk of major cardiovascular events b y 16%to 42%, 
establishing the efficacy  of anticoagulant therapy  for this indication. (19)
Direct randomized comparisons between anticoagulant and antiplatelet therapy  have
established the superior efficacy  of warfarin for the prevention of major cardiovascular events 
in patients with established CAD but at the cost of increased bleeding.  Thus, moderate 
intensity  (INR 2.0 to 3.0) or moderate to high intensity  (INR 2.5 to 3.5) warfarin compared 
with aspi[INVESTIGATOR_834120] l infarction, stroke or cardiovascular death by  21% 
compared with aspi[INVESTIGATOR_248] (OR 0.79; 95% CI : 0.67 to 0.94), but this was at the cost of a more than 
2-fold increase in major bleeding (OR 2.1; 95% CI 1.7 to 2.7). (19)A subsequent meta -
analysis of randomized controlled trials involving 25,307 patients with established CAD
demonstrated that the combination of warfarin (INR 2.0 to 3.0) and aspi[INVESTIGATOR_834121], ischemic stroke ,and all -cause 
mortality  by 27% (OR 0.73; 95% CI : 0.63 to 0.84).( 20)Once again the reduction in major 
cardiovascular events with warfarin -based therapy was accompanied by  a more than 2- fold 
excess of major bleeding (OR 2.32; 95% CI : 1.63 to 3.29). 
Warfarin has not been as extensively evaluated in patients with PAD but li mited data suggest 
that it also offers benefits in this setting.  The WAVE trial did not find a benefit of warfarin (INR 2.0 to 3.0) plus aspi[INVESTIGATOR_834122], stroke ,or cardiovascular death in pa tients (n=2,161) with PAD (HR 0.92; 95% CI : 
0.73- 1.16).( 21)  However, the combination was associated with a more than 3- fold excess of 
life-threaten ing bleeding ,and an exploratory  post -hoc anal ysis excluding patients with major 
bleeding suggested an 18% relative risk reduction (HR 0.82; 95% CI : 0.62 to 1.05). 
data on file)  
                                                
27Paragraphs added as per Amendment 8. (See Section 13.2.2 )
[COMPANY_003]
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 21of 205
Additional25evidence for the efficacy and safety of oral factor Xa inhibitors for the prevention 
of major cardiovascular events comes from the recently  completed AVERROES trial which 
demonstrated that th e oral factor Xa inhibitor, api[INVESTIGATOR_3822], compared with aspi[INVESTIGATOR_834123].( 22)  
In summary , the randomized trials of antithrombotic therapy in patients with established 
atherothrombotic vascular disease have demonstrated the efficacy  of single agent antiplatelet 
therap y (with aspi[INVESTIGATOR_87494]), anticoagulant therap y (warfarin) ,and the combination of 
single agent antiplatelet and anticoagulant therap y (aspi[INVESTIGATOR_834124]) for the long term 
secondary  prevention of major cardiovascular events.  Warfarin alone is substantially  more 
effective than aspi[INVESTIGATOR_264086], and the combination of warfarin and aspi[INVESTIGATOR_834125], but is limited by  [CONTACT_834328].  Furthermore, because of the challenges of 
adjusting the dose of warfarin based on the re sults of routine laboratory  monitoring, it is 
uncommonly  used for long -term prevention of cardiovascular events. 
The data summarized above support the h ypothesis that when given in combination with, or 
instead of aspi[INVESTIGATOR_248], a new anticoagulant such as rivar oxaban has the potential to y ield 
substantial benefits for the prevention of cardiovascular events in patients with established CAD or PAD .  
1.2.[ADDRESS_1158411] of rivaroxaban 2.5 mg bid + aspi[INVESTIGATOR_248] 
100mg od over existing standard treatment with aspi[INVESTIGATOR_248] , the sponsor will offer the 
rivaroxaban 2.5 mg bid + aspi[INVESTIGATOR_248] 100 mg od to trial subjects in a long -term open -label 
extension (LTOLE) until the rivaroxaban treatment is commercially  available for this 
indication or for approximately  [ADDRESS_1158412] .
In COMPASS, t he combination rivaroxaban 2.5mg bid+ aspi[INVESTIGATOR_248] 100mg odcompared to 
aspi[INVESTIGATOR_248] 100mg alone:
                                                
28Text added as per Amendment 6. (See Section 13.1. 2)
29Text added as per Amendmen t 11. (See Sections 13.3.1 and13.3.2 )
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 22of 205
Reduced the relativ e risk for the primary  composite of stroke, myocardial infarction 
and cardiovascular death by  24% (p<0.0001)
Increased the risk of ISTH modified major bleeding significantl y(HR 1.70, 95% CI  
1.40- 2.05, p<0.[ZIP_CODE])
No significant increase was found in intrac ranial or fatal bleeds
Reduced the risk for pre -specified net clinical benefit, a composite of outcomes of 
irreversible harm, significantly  (HR 0. 80, 95% CI 0.70-0.91, p=0.[ZIP_CODE])
Rivaroxaban 5.0 mg BID alone compared to 100 mg aspi[INVESTIGATOR_264086]:
Did not signif icantl y reduce the hazard for the primary outcome (HR 0.90, 95% CI  
0.79- 1.03, p=0.11), but increased major bleeding
Finding s were consistent across the majorit y regions and subgroups.
1.3 Benefit-risk assessment –amended
Considering the use of a new treatment for the prevention of cardiovascular disease, potential 
benefits need to be balanced against the risk.  Bleeding is the most common complication of 
antithrombotic therapy and upper gastrointestinal bleeding accounts for the majority of 
bleeding complications.  The risk of gastrointestinal bleeding increases with increasing intensity  of antithrombotic therapy .  When used for the prevention of cardiovascular disease, 
aspi[INVESTIGATOR_834126]/no aspi[INVESTIGATOR_834127] a 50 to 60% relative excess and a 
0.5 to 1% absolute excess risk of major gastrointestinal bleeding. (23,24 )  In the ROCKET -AF 
trial, the 20 mg od dose was associated with an annualized rate of International Society  on 
Thrombosis and Haemostasis (I STH) major and non -major gastrointestinal (GI) combined 
bleeding rate of 3.2/10 0 patient y ears. ( 46)
30
Major bleeding is an independent predictor of risk of death and other major cardiovascular events.( 25,26)  This excess risk may  in part be explained by  [CONTACT_834329] ,because patients 
who are more ill are more likely  to experience adverse outcomes and are also more likely  to 
bleed.  However, even minor bleeding leads to discontinuation of effective antithrombotic therapi[INVESTIGATOR_014], thereb y potentially  compromising the efficacy of cardiovascular prevention and 
providing another possible explanation for the excess cardiovascular risk associated with bleeding.  Effective strategies for the prevention of gastrointestinal bleeding have the potential to reduce morbidit y and mortality directly  caused by  [CONTACT_79602] ,but more importantly  may  also 
reduce ischemic cardiovascular events resulting from temporary or permanent interruption in patients treated with rivaroxaban.  
Among patients taking aspi[INVESTIGATOR_834128], treatment with a 
PPI[INVESTIGATOR_834129]. (27)  The [LOCATION_002] 
Food and Drug Administr ation (US FDA) has issued a warning concerning the use of 
omeprazole but not pantoprazole in combination with clopi[INVESTIGATOR_7745].  In the COMPASS trial, the 
efficacy  of pantoprazole will be compared with placebo for the prevention of upper 
                                                
30The bleeding rate w as updated as per Amendment 8 (was 2.23/100 patient years) and the reference was added.
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 23of 205
gastrointestinal bleeding, ulceration, obstruction or perforation in subjects randomized to the combination of rivaroxaban and aspi[INVESTIGATOR_248], rivaroxaban alone, or aspi[INVESTIGATOR_264086] ,using a partial 
factorial design.
Long -Term Open -Label Extension –amended
Rivaroxaban 2.5mg bid + aspi[INVESTIGATOR_248] 100mg od has demonstrated superior efficacy  onreducing
major adverse cardiac event ( MACE )in patients with CAD/PAD as compared to aspi[INVESTIGATOR_834130]-specified net clinical benefit significantl y (refer to Section 1.2.4).
Therefore, the sponsor aims to make rivaroxaban 2.5 mg bid + aspi[INVESTIGATOR_248] 100 mg od available in 
a long -term open -label extension .
31
2. Study objectives  – amended
Primary objectives for rivaroxaban randomization
To determine whether rivaroxaban 2.5 mg bid + aspi[INVESTIGATOR_248] 100 mg od compared with 
aspi[INVESTIGATOR_248] 100 mg od reduces the risk of a composite of my ocardial infarction, stroke ,or 
cardiovascular death in subjects with CAD or PAD
 To determine whether rivaroxaban 5 mg bid compared with aspi[INVESTIGATOR_248] 100 mg od reduces 
the risk of a composite of my ocardial infarction, stroke ,or cardiovascular death in 
subjects with CAD or PAD
Secondary objectives for rivaroxaban randomization
To determine whether each of rivaroxaban 2.5 mg bid + aspi[INVESTIGATOR_248] 100 mg od and 
rivaroxaban 5 mg bid alone reduces the risk of the composite of major thrombotic 
events (coronary  heart disease death, my ocardial infarction, ischemic stroke, acute 
limb ischemia; cardiovascular death, my ocardial infarction, ischemic stroke, acute 
limb ischemia ) compared with aspi[INVESTIGATOR_248] 100 mg od in subjects with CAD or PAD32
To determine whether each of rivaroxaban 2.5 mg bid + aspi[INVESTIGATOR_248] 100 mg od and 
rivaroxaban 5 mg bid alone reduces the risk of mortality in subjects with CAD or PAD
Tertiary objective for rivaroxaban randomization
To determine whether each of rivaroxaban 2.5 mg bid + aspi[INVESTIGATOR_248] 100 mg od and 
rivaroxaban 5 mg bid alone preserves the ability  to perform every day activities 
independentl y in subjects with CAD or PAD
To determine whether each of rivaroxaban 2.5 mg bid + aspi [INVESTIGATOR_248] 100 mg od and 
rivaroxaban 5 mg bid alone reduces the incidence of hospi[INVESTIGATOR_834131]
To collect medical resource utilization data to be incorporated in economic modeling 
for subjects with CAD or PAD
                                                
31Text added as per Amendment 11. (See Section 13.3.1 )
32Text revised a s per Amendments 6 and 8. (See Sections 13.1.2 and 13.2.2 )
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 24of 205
Objective for pantoprazole randomization
To determine whether pantoprazole [ADDRESS_1158413]-CABG randomization
33
To determine whether each of rivaroxaban 2.5 mg bid + aspi[INVESTIGATOR_248] 100 mg od and 
rivaroxaban 5 mg bid alone reduces the risk of by[CONTACT_834330][INVESTIGATOR_248] 100 mg od33
To determine the association between post CABG graft failure and risk of a composite of my ocardial infarction, stroke, or cardiovascular death in subjects with CAD or 
PAD
[ADDRESS_1158414] of the antithrombotic therapi[INVESTIGATOR_834132], thereb y providing additional information 
about mechanisms of disease and treatment benefits.34  COMPASS -MIND will be conducted 
concurrently  with the main study  in a subset of subjects at selected centers.  A detailed 
description is inc luded in Section 14.1.
Objective for Long -Term Open -Label Extension –amended
The objective of LTOLE is to make rivaroxaban 2.5 mg bid + aspi[INVESTIGATOR_248] [ADDRESS_1158415].
Primary , secondary  and tertiary  efficacy  and safety  outcomes as described above will be 
collected in theLTOLE.35
3. Investigators  and other study participants
The global sponsor of this study is identified on the title page of this protocol.  I f required by  
[CONTACT_1769], local co -sponsors will be nominated and will be identified on the respective 
country -specific signature [CONTACT_1787].
The COMPASS trial will be carried out in accordance with Good Clinical Practice (GCP) in 
close collaboration between Bay er and 
3.[ADDRESS_1158416] of the study  chair and principal 
                                                
33Text added as per Amendment 6. (See Section 13.1.2 )
34Sentence was revised as per Amendment 8.  (See Section 13.2.2 )
35Text added as per Amendment 11. (See Section 13.3.1 )
[COMPANY_003]
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 25of [ADDRESS_1158417] leader, senior stud y coordinator, 2- 3 sponsor representatives, and 3 -4 
National Leaders (NL). 
A Steering Committee comprising members of the Operations Committee, university -based 
and sponsor -based scientists with clinical and methodological expertise, and NLfrom each 
country , has overall responsibility  for the study . The Steering Committee will be responsible 
for pr oducing and conducting a scientificall y sound study  design and ensuring accurate 
reporting of the stud y.  The Steering C ommittee will meet periodically  to address and resolve 
scientific and practical issues encountered during the study . 
An Events Committe e consisting of members with clinical and methodological expertise will 
oversee the process of event adjudication. The process of event adjudication is detailed in the 
Event Adjudication Plan.[ADDRESS_1158418] (DSMB) will be formed, comprising a chair, 
co-chair, and members who have recognized expertise in clinical trials, cardiovascular 
disease , and biostatistics, and who are not members of the Steering Committee or involved in 
the routine conduct of the COMPASS trial.  The DSMB will be responsible for:
monitoring efficacy  and safet y of the studied medications based on periodic updates 
throughout the stud y 
giving recommendations to the Steering Committee as to whether to continue, modify ,
or stop the study
The DSMB play s a key  role in monitoring all aspects of the study .  This committee will 
review aggregate data b y treatment group in an unblinded fashion and thus are tasked with 
assessing risk and benefit for the stud y subjects. 
At the first meeting of the DSMB, the DSMB charte r and the frequency  of meetings will be 
agreed upon. The DSMB will be supported at meetings by [CONTACT_834331] 
(unblinded for the purpose of preparing reports for the DSMB).  The stud y chair and/or the 
principal investigators will atten d the open portion of the meeting to provide reports and 
respond to questions concerning the stud y.
Long-Term Open-L abel Extension − amended
Outcome events for LTO LE will be collected in a descriptive way , and no adjudication will be 
performed. 
The DSMB will not monitor the L TOLE and will conclude responsibilities when the 
pantoprazole/placebo treatment is completed.[ADDRESS_1158419] 3 paragraphs o f this section were revised as per Amendment 8. (See Section 13.2.2 )
37Text added as per Amendment 11. (See Section 13.3.1 )
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 26of [ADDRESS_1158420] of the study  and will provide ongoing methodological and 
administrative support to the DSMB and will make available appropriate study  data and/or 
documentation for these committees. 
The NL are responsible for the conduct of the study  within their respective countries.  The NL 
are ph ysicians with experience in both clinical management of cardiovascular disease and 
conduct of clinical studies in this field.  Additional information is provided in the Manual of 
Operations.The Site I nvestigators are responsible for the conduct of the study  within their respective 
centers.  Additional information is provided in the Manual of Operations.
Whenever the term ‘investigator’ is noted in the protocol text, it may  refer to either the 
principal investigator [INVESTIGATOR_8921], or an appropriately  qualified, trained ,and delegated 
individual of the investigational site.The principal investigator [INVESTIGATOR_8922].  Likewise, all protocol amendments/integrated 
protocols must be signed and dated b y the principal investigator [INVESTIGATOR_382281].
3.[ADDRESS_1158421] will be updated as needed; an abbreviated version with personnel relevant for the centers will be available in each center’s investigator site file.
Acomplete list of all participating centers and their investigators, as well as all required 
signature [CONTACT_834397], will be maintained in the trial master file.
4. Study design
4.1 Design overview – amended
This Phase 3, event- driven (at least 2,200 primary  efficacy  outcome events), randomized 
controlled trial will have a [ADDRESS_1158422] 27,[ZIP_CODE]
subjects who will receive treatment for an expected average duration of 3 to 4 y ears.  The 
COMPASS trial will involve 4 periods: screening, run -in, follow -up, and washout.
Prescreening procedures may require informed consent in some countries.  In all other study  
sites, informed consent will be obtained prior to the initiation of any  screening proce dures 
(Section [IP_ADDRESS]).[ADDRESS_1158423] eligibility  and will 
include the review of inclusion and exclusion criteria, phy sical measurements, laboratory  
evaluations, etc. (Section [IP_ADDRESS]).39
The run -in period will occur during the 2839daysprior to initiation of randomized study  
treatment, with the exception of subjects who are randomized after CABG surgery , who will 
                                                
38Text modified as per Amendments 6 and 8. (See Sections 13.1.2 and 13.2.2 )
39Text modified/added as per Amendment 6. (See Section 13.1.2 )
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 27of 205
not undergo a run -in phase (Section 4.1.1).  During run -in, subjects will discontinue any  
antithrombotic39therapy  and will begin study  rivaroxaban placebo and study  aspi[INVESTIGATOR_248] 100 mg.  
Subjects who successfully complete the run -in period and who remain committed to the study  
as well as those who are being randomized after CABG will be randomized and begin study  
treatments on Day  0, which will also signal the initiation of the follow -up period.  Subjects 
without a continous39need for treatment with a PPI[INVESTIGATOR_834133] 1:1 to the 
pantoprazole or pantoprazole placebo and all subjec ts (including those subjects who entered 
the study  while alread y receiving a PPI) will then be randomized 1:1:1 to rivaroxaban alone, 
the combination of rivaroxaban and aspi[INVESTIGATOR_834134], and their matching placebos as shown in Table 4–1:
Table 4–1.  Randomized study treatments* 
Study Arm Treatm ent Assignments
ARivaroxaban 2.5 mg bid +
Aspi[INVESTIGATOR_248] 100 mg od +
Pantoprazole 40 mg odRivaroxaban 2.5 mg bid +Aspi[INVESTIGATOR_248] 100 mg od +Pantoprazole placebo od
BRivaroxaban 5 mg bid + Aspi[INVESTIGATOR_834135] + 
Pantoprazole 40 mg odRivaroxaban 5 mg bid + 
Aspi[INVESTIGATOR_834135] +
Pantoprazole placebo od
CRivaroxaban placebo + 
Aspi[INVESTIGATOR_248] 100 mg od +Pantoprazole 40 mg odRivaroxaban placebo + Aspi[INVESTIGATOR_248] 100 mg od + Pantoprazole placebo od
*Subjects who have acontinuous need for use of39a proton pump inhibitor at baseline will undergo only a single 
randomization (to rivaroxaban 2.5 mg bid + aspi[INVESTIGATOR_248] 100 mg od, rivaroxaban 5 mg bid + aspi[INVESTIGATOR_834105] + aspi[INVESTIGATOR_248] 100 mg od)
Subjects will be seen in the clinic at [ADDRESS_1158424] information on treatment adherence, treatment interruption, outcomes, and adverse events (AEs).  Validated questionnaires (Standard 
Assessment of Global -Activities in the Elderly  [SAGE], Montreal Cognitive Assessment 
[MoCA], Digital Sy mbol Substitution [DSS], European Qualit y of Life -5 Dimensions [EQ -
5D])will be administered at screening/run -inor randomization , or as soon as po ssible 
thereafter, as well as at Month [ADDRESS_1158425] 
health and qualit y of life .  The SAGE, MoCA, DSS, and EQ-5D will also be administered at 
the next study  clinic visit after each outcome event. The Interheart Diet Questionnaire and the 
International Ph ysical Activity  Questionnaire will be administered at screening/run- in or
randomization, or as soon as possible thereafter, and at Month 24.   All subjects will be 
followed for the duration of the study , irrespective of whether they  are receiving study  
treatments or whether an event has occurred. Additional follow -up visits will be conducted b y 
telephone at Months 3 and 9.  The Final Follow- up Visit will occur as soon as possible after 
the required p re-specified number of subjects experience a primary  efficacy  outcome event for 
the antithrombotic randomization (close out is expected to occur over a period of about 3 months).  A final washout period visit (End of Washout Telephone Visit) will be conduc ted 
by [CONTACT_756] (performed 30daysafter the Final Follow -up Visit) to collect information on 
outcomes and protocol specific AEs.  Adverse events will continue to be collected up to 
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 28of [ADDRESS_1158426] study  drug treatment.  Bay er Global Pharmacovigilance will c ontinue to follow 
the reported AEs until stabilized or resolved.40
Amended after early termination of rivaroxaban/aspi[INVESTIGATOR_834136]/placebo follow -up visit, due to the short half -life of pantoprazole.
[ADDRESS_1158427] administratio n of an y 
anticoagulant (including DVT proph ylaxis) (Section 7.1.1 Tabulated overview).
Subjects randomized Day  4-7 after CABG surgery  will undergo computed tomograph y (CT)  
angiograph y at [ADDRESS_1158428] angiography  (e.g., contrast allergy , estimated 
glomerular filtration rate <30 ml/min). In the event the subject undergoes an invasive 
coronary  angiography  at approximately  [ADDRESS_1158429] 
angiogram may  not be required.
Long -Term Open -Label Extension −amended
Thelong-term open -label extension (L TOLE) will provide open- label rivaroxaban 2.5mg bid
+aspi[INVESTIGATOR_248] 100mg od to COMPASS subjects until itis commercially  available or for 
approximately [ADDRESS_1158430]. The implementation of LTOLE is an amendment to the COMPASS trial. 
For inclusion and exclusion criteria, see Section 5.1.3 ; for treatment relate d details, see 
Section 6.1.3 (Treatment to be administered) , Section 6.6(Drug logistics and accountabilit y), 
and Section 6.8(Post-study  therapy ). 
The LTOLE will involve an initiation visit and a follow -up period. 
Treatment initiation visits can be scheduled as soon as the LTOLE has received regulatory  
and ethics approvals, the site has signed a contract amendment, and the drug is available at the site. Before entering LTOL E, informed consent is needed. 
For detaile d procedures and variables, see Section 7.1.1 (Tabulated overview of LTOLE) and 
Section [IP_ADDRESS] (Timing of assessments in LTOLE) .The same efficacy and safet y outcomes as 
in the COMPASS trial will be collected in the LTOL E. All statistical analyses will be 
descriptive.
43
                                                
40Paragraph revised as per Amendments 6 and 8. (See Sections 13.1.2 and 13.2.2 )
41Text added as per Amendment 11. (See Sections 13.3.1 and13.3.2 )
42This section was revised as per Amendments 6 and 8.  (See Sections 13.1.2 and 13.2.2 )
43Text added as per Amendment 11. (S ee Section 13.3.1 )
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 29of 205
4.2 Primary efficacy and sa fety variables − amended
The primary  efficacy  outcome for the rivaroxaban randomization is a composite of myocardial 
infarction, stroke, or cardiovascular death.
The primary  safet y outcome for the rivaroxaban randomization is a composite of: 
fatal bleeding, and/or 
symptomatic bleeding in a critical area or organ, such as intracranial, intraspi[INVESTIGATOR_1304], 
intraocular, retroperitoneal, intraarticular or pericardial, or intramuscular with 
compartment s yndrome, or bleeding into the surgical site requiri ng re -operation, 
and/or 
bleeding leading to hospi[INVESTIGATOR_834137] -Term Open -Label Exten sion−amended
The same primary  efficacy  and safet y outcomes collected in the COMPASS trial will be 
collected during the LTOLE visits.44
4.3 Justification of the design
4.3.1 Overall design rationale –amended
The primary  objective of the COMPASS trial is to determine whether rivaroxaban 2.5 mg bid 
+ aspi[INVESTIGATOR_248] 100 mg od (Arm A) compared with aspi[INVESTIGATOR_248] 100 mg od (Arm C) reduces the risk of 
the composite of my ocardial infarction, str oke, or cardiovascular death in subjects with CAD 
or PAD and, similarly , to determine whether rivaroxaban 5.0 mg bid + aspi[INVESTIGATOR_834135] 
(Arm B) compared with aspi[INVESTIGATOR_248] 100 mg od (Arm C) reduces the risk of the composite of myocardial infarction, stroke ,or cardiovascular death in subjects with CAD or PAD .  The 
event -driven, double -blinded, 3 x 2 partial factorial design was selected for this study  to 
support a rigorousl y controlled approach that would minimize study  bias while focusing on 
the effects of treatment on the composite of the expected outcomes (my ocardial infarction, 
stroke, or cardiovascular death) in this study  population. 
The benefit of increased
45intensity  of antithrombotic therap y for the prevention of recurrent 
thrombotic cardiovascular events b y adding a second agent to aspi[INVESTIGATOR_834138] y after an acute coronary s yndrome when compared with 
aspi[INVESTIGATOR_264086].  Additionally , a benefit has been shown in trials of combined warfarin and 
aspi[INVESTIGATOR_834139]. 
The potential for the combination of rivaroxaban and aspi[INVESTIGATOR_834140] r ivaroxaban trials.  A pooled post hoc anal ysis of the data from 
patients with an acute coronary  syndrome in the Phase 2 and Phase 3 trials (ATLAS TIMI 46 
and A TLAS TIMI 51) suggests  that the effect size of rivaroxaban plus aspi[INVESTIGATOR_834141] e for the composite outcome of CV death, my ocardial infarction, and stroke (HR 
                                                
44Text added as per Amendment 11. (See Section 13.3.1 )
45Text modified as per Amendment 6. (See Section 13.1.2 )
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 30of 205
0.66, 95% CI  0.46- 0.96,  p=0.026) (data on file) is at least double the effect size seen in the 
primary  anal ysis of the ATL AS 51 trial (HR 0.84, 95% CI  (0.74 -0.96, p=0.008).  For patients 
who do not have an ongoing indication for dual antiplatelet therap y but have a residual risk of 
cardiovascular events, it is expected that the addition of rivaroxaban 2.[ADDRESS_1158431] shown a benefit, but where there was a 
lack of benefit it could be explained either by [CONTACT_834332] (e.g., in the CHARISMA trial, clopi[INVESTIGATOR_834142] a history  of symptomatic vascular disease) or b y an excess of bleeding of the 
experimental treatment (e.g., in the WAVE trial, warfarin plus aspi[INVESTIGATOR_34221] a substantial excess of bleeding compared with aspi[INVESTIGATOR_834143]).
To date, no trials have directl y compared a new anticoagulant with aspi[INVESTIGATOR_834144] -term 
secondary  prevention of cardiovascular disease .  Prior efforts to identify  more effective 
antithrombotic treatments than aspi[INVESTIGATOR_834145] (terutroban, 
a platelet thromboxane receptor antagonist; clopi[INVESTIGATOR_7745], prasugrel ,and t icagrelor , P2Y12
45
antagonists; and vorapaxar, a PAR -[ADDRESS_1158432]) and warfarin.  In most cases, the 
benefit of the experimental treatmen t has either been of insufficient magnitude to warrant a 
switch in treatment (e.g., clopi[INVESTIGATOR_7745], prasugrel) or has been accompanied by a substantial excess of bleeding (e.g., vorapaxar, ticagrelor
46, warfarin).  The promise of a new 
anticoagulant such as rivaroxaban (rivaroxaban 5.0 mg as explored in Arm B) is highlighted 
by [CONTACT_834333][INVESTIGATOR_834146] m yocardial infarctions and no significant excess in bleeding. (22)
The use of aspi[INVESTIGATOR_248] -alone antiplatelet therap y for atherosclerotic CAD a nd PAD is widely  
accepted .
47As such, most patients will be candidates for aspi[INVESTIGATOR_512998].  This is in line 
with current practice guidelines and the current prescribing information for secondary prevention.   The dose of aspi[INVESTIGATOR_834147] 100mg/d.  
4.3.2 Design rationale for Long -Term Open -Label Extension −amended48
Due to the clinical efficacy  of rivaroxaban 2.5mg bid + a spi[INVESTIGATOR_248] 100mg od (see Section 1.2.4), 
participation in the LTOLE will be offered to all subjects who meet the LTOL E 
Inclusion/Exclusion criteria defined in Section 5.1.3.
4.[ADDRESS_1158433] 2,200 subjects experience an event 
                                                
46“ticagrelor” added as per Amendment 8 based upon the recently published PEGASUS trial.
47Sentence revised as per Amendment 8.  (See Section 13.2.2 .)
48Text added as per Amendment 11. (See Section 13.3.1 )
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 31of [ADDRESS_1158434] experienced an outcome.  The Final Follow -up 
Visit and the subsequent 30 -daywashout period will occur nearly  simultaneously  (as 
scheduling permits) for all stu dy subjects.  
For each participating European Union (EU) country , the end of the study  according to the EU 
Clinical Trial Directive will be reached when the telephone call at the end of the [ADDRESS_1158435] for all centers in the respective country  has occurred.  The 
end of the study as a whole will be reached as soon as the end of the stud y according to the 
above definition has been reached in all participating countries (EU and non -EU).
Long -Term Open -Label Extension − amended
The final visits of LTOLE will begin, per country , when the duration reaches [ADDRESS_1158436] the final visit may  be conducted at 
the next scheduled visit.49  
5. Study population - amended
Multiple strategies will be employ ed to identify  subjects potentially  eligibl e for this study .  
These will include (but are not restricted to) database screening, chart screening ,and patient 
screening at phy sician offices and at internal medicine, cardiology ,and vascular 
disease/imaging clinics.  The approach at individual center s will vary  according to phy sician, 
office, or hospi[INVESTIGATOR_84365], and ethical considerations. 
Approximately  28,[ADDRESS_1158437] CABG and without run- in.  Approximately  10% of run -in subjects 
are expected to either be non- compliant with treatment or to decline further interest in 
participating; thus, the study  will randomize approximately  27,[ADDRESS_1158438] one or more of the following:51
Myocardial infarction within the last 20 y ears51, or
                                                
49Text added as per Amen dment 11. (See Section 13.3.1 )
50Text modified/added as per Amendments 6 and 8. (See Sections 13.1.2 and 13.2.2 .)
51Text modified as per Amendment 6. (See Section 13.1.2 )
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 32of 205
Multi- vessel coronary disease* with s ymptoms or history  of stable or unstable angina, 
or51
Multi- vessel percutaneous coronary  intervention (PCI ), or
Multi- vessel CABG surgery  
*Refers to stenosi s of greater than or equal to 50% in 2 or more coronary  arteries, 
confirmed b y invasive coronary  angiography , or non-invasive imaging or stress studies 
(e.g. exercise or pharmacologic) suggestive of significant ischemia in 2 or more coronary  
territories; or in [ADDRESS_1158439] one or more of the following:51
Previous aorto- femoral by [CONTACT_4897] , limb by [CONTACT_4897] , or percutaneo us 
transluminal angioplast y revascularization51of the iliac, or infrainguinal arteries, or
Previous limb or foot amputation for arterial vascular disease (i.e., excludes trauma), 
or
History  of intermittent claudication and one or more of the following: 1)51an 
ankle/arm blood pressure (BP) ratio < 0.90, or 2)51significant peripheral artery  
stenosis ( ≥50%)51documented b y angiograph y, or by  [CONTACT_136665], or
Previous carotid revascularization (e.g., endarterectomy, stenting) or51asymptomatic 
(i.e., no ipsilateral stroke or transient ischemic attack within 6 months) carotid artery  
stenosis ≥50%51as diagnosed by  [CONTACT_834334] .
5.1 Eligibility − amended
In order to be eligible for study  entry , potential subjects must meet all of the inclusion criteria 
and none of the exclusion criteria listed below.
5.1.1 Inclusion criteria -amended
Willing and able to provide written informed consent
Meet criteria for CAD* and/52or PAD
*Subjects with CAD must also meet at least one of the following criteria52:
Age ≥65, or 
Age <[ADDRESS_1158440] 2
vascular beds§,52or at least 2 additional risk factors:
1) Current smoker (within 1 year of randomization)52
2) Diabetes mellitus
3) Renal dy sfunction with estimated glomerular filtration rate 
<60ml/min 
                                                
52Text modified/added as per Amendment 6. (See Section 13.1.2 )
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 33of 205
4) Heart failure 
5) Non-lacunar ischemic stroke ≥1 month ago
§ Because CAD involves disease in the coronar y vasculature, onl y one additional vascular bed 
is required: e.g. the aorta and arterial supply  to the brain, gastro -intestinal tract, lower limbs, 
upper limbs, or kidney s.52
5.1.2 Exclusion criteria -amended
High risk of bleeding
Stroke within 1 month or any  history  of hemorrhagic or lacunar stroke 
Severe heart failure with known ejection fraction <30% or [LOCATION_001] Heart 
Association (NYHA) class III o r IV s ymptoms 
Estimated glomerular filtration rate (eGFR)<15 mL/min
Need for dual antiplatelet therap y, other non -aspi[INVESTIGATOR_834148] y,or oral 
anticoagulant therap y
Known non-cardiovascular disease that is associated with poor prognosis (e.g., metastatic cancer) or that increases the risk of an adverse reaction to study  
interventions.
History  of hypersensitivity  or known contraindication for rivaroxaban, aspi[INVESTIGATOR_248], 
pantoprazole, or excipi[INVESTIGATOR_840], if applicable.
52
Systemic treatment with strong inhibitors of both CYP 3A4 and p- glycoprotein (P -gp) 
(e.g., s ystemic azole antimy cotics, such as ketoconazole, and human 
immunodeficiency  virus [HI V]-protease inhibitors, such as ritonavir), or strong 
inducers of CYP 3A4, i.e. rifampi[INVESTIGATOR_2513], rifabutin, phenobarbital, phen ytoin, and 
carbamazepi[INVESTIGATOR_050]53
Any known hepatic disease associated with coagulopathy
Subjects who are pregnant, breastfeeding ,or are of childbearing potential, and53
sexually  active and not practicing an effective method of birth control (e.g. surgically  
sterile53, prescription oral contraceptives, contraceptive injections, intrauterine device, 
double -barrier method, contraceptive pa tch, male partner sterilization) 
Previous assignment to treatment during this study
Concomitant participation in another study  with investigational drug53
Known contraindication to any  study  related procedures53
An additional exclusi on for the pantoprazole randomization is:
Need for continuous53treatment with a PPI
                                                
53Text modified as per Amendment 6. (See Section 13.1.2 )
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 34of 205
5.1.3 Long-Term Open -Label Extension −amended54
Allsubject sfrom COMPASS trial will be invited to join LTOLE as long as they  continue to 
meet the COMPASS eligibility  criteria (refer to sections 5.1.1 and 5.1.2) plus the specific 
ones for LTOLE (refer to sections [IP_ADDRESS] and [IP_ADDRESS] ). All L TOLE subjects must provide 
written informed consent to participate in LTOLE .
[IP_ADDRESS] Inclusion criteria
All subject s randomized to the COMPASS trial willing to consent to L TOLE are 
eligible u nless the subjects developed a condition considered by  [CONTACT_834335] .
Subject s who have given their written informed consent to participate in the L TOLE 
after having received adequate information prior to any  LTOLE specific procedures.
[IP_ADDRESS] Exclusion criteria
Subjects should not be included if, in the judgement of the investigator, they  have 
developed a condition which should exclude them from receiving LTOLE study  
medication. For example if the subject has developed atrial fibrillation or h ad a severe 
allergic rash while in the study , which subsided when drug was stopped and returned 
when drug was reinitiated.
5.[ADDRESS_1158441] will not suffer any disadvantage as a result.  In all cases, the reason for permanent discontinuation of study treatments (including “at the subject’s request”) must be recorded in the case report fo rm (CRF) and in the subject's 
medical records.  
It is important to note that discontinuation of study  treatment is not the equivalent to 
withdrawal of informed consent.  Additionally , withdrawal of consent does not withdraw 
permission to collect vital sta tus.  Withdrawal of this consent must be made separatel y.  In 
cases where subjects indicate they  do not want to “continue”, investigators must determine 
whether this refers to discontinuation of study treatment (the most common expected 
scenario), unwillin gness to attend follow -up visits, unwillingness to have telephone contact, 
unwillingness to have any  contact [CONTACT_834336], or unwillingness to allow contact 
[CONTACT_4490] a third part y (e.g., family  member, doctor).  In all cases, including the subjects who
have had any of the primary study outcome events, every effort must be made to 
continue to follow the subject at regular study visits.
55Additionally, survival status and 
outcome information must be determined for all subjects.53
                                                
54Text added as per Amendment 11. (See S ection 13.3.1 )
55Sentence revised as per Amendment 8.  (See Section 13.2.2 )
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 35of [ADDRESS_1158442] replacements are permitted in this study.
5.2.2 Long-Term Open -Label Extension −amended56
In case of permanent discontinuation of LTOLE treatment, the subject should come for a final 
visit within appr oximately [ADDRESS_1158443] identification number 
will not be re- used. 
6. Treatments
6.1 Treatments to be administered -amended
The study  drugs to be administered in this trial i nclude the antithrombotic drugs, rivaroxaban 
and enteric -coated57aspi[INVESTIGATOR_248]; the PPI[INVESTIGATOR_834149]; and their matching placebos.  
6.1.1 Run-in - amended
During the run- in period, Day  -2857to Day  -158, eligible subjects (excluding those who are 
randomized58Day 4-757after CABG surgery ) who have signed informed consent and stopped 
non-study  anticoagulants and aspi[INVESTIGATOR_834150] [ADDRESS_1158444] 80% except for extenuating circumstanc es,57and 
who wish to continue in the study  will be randomized.  Subjects being randomized after run -
in57and those who are being randomized  Day  4-757  after CABG surgery (Section 7.1.1
Tabulated overview) and who do not have a continuous57need to take a PPI, will initially  be 
randomized 1:1 to receive pantoprazole 40 mg od or matching placebo od, stratified by  [CONTACT_384].  
All subjects will then be randomized 1:1:1 to anticoagulan t therapy  stratified by  [CONTACT_834337][CONTACT_3225] (randomized to pantoprazole, randomized to pantoprazole placebo, not randomized 
because subject is already  taking a PPI[INVESTIGATOR_834151]:
                                                
56Text added as per Amendment 11. (See Section 13.3.1 )
57Text modified/added  as per Amendment 6. (See Section 13.1.2 )
58Text deleted as per Amendment 6. (See Section 13.1.2 )
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 36of 205
Arm A:  rivaroxaban 2.5 mg bid + aspi[INVESTIGATOR_248] 100 mg od
Arm B:  rivaroxaban 5.0 mg bid + aspi[INVESTIGATOR_834152] C:  rivaroxaban placebo bid + aspi[INVESTIGATOR_248] [ADDRESS_1158445].   
6.1.3 Treatment in Long -Term Open -Label Extension −amended59
The LTOLE treatment will be open -label rivaroxaban 2.5 mg bid + aspi[INVESTIGATOR_248] [ADDRESS_1158446] except for the
medication number .  Label text will be approved according to the sponsor’s agreed 
procedures, and a copy of the labels will be made available to the stud y site upon request. For 
the purpose of this study , the term “aspi[INVESTIGATOR_248]” is used interchangeabl y with th e term “acet yl 
salicy lic acid”.60
For all stud y drugs, a s ystem of numbering in accordance with all requirements of Good 
Manufacturing Practice ( GMP )will be used, ensuring that each dose of study drug can be 
traced back to the respective bulk ware of the i ngredients.  L ists linking all numbering levels 
will be maintained by  [CONTACT_456]’s clinical supplies quality assurance (QA) group. 
Acomplete record of batch numbers and expi[INVESTIGATOR_577465].
6.[ADDRESS_1158447] a unique 
number for each medication that corresponds to one of the treatments listed in Table 4–1.
Long-Term Open-L abel Extension − amended
All subject sin the L TOLE will receive the same treatment of rivaroxaban 2.5 mg bid + 
aspi[INVESTIGATOR_248] 100 mg od.62
                                                
59Text added as per Amendment 11. (See Section 13.3.1 )
60Text added as per Amendment 6. (See Section 13.1.2 )
61Sentence revised as per Amendment 8. (See Section 13.2.2 )
62Text added as per Amendment 11. (See Section 13.3.1 )
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 37of 205
6.4 Dosage and administration -amended
Study  medication will be taken orall y.  Study rivaroxaban/rivaroxaban placebo is taken twice 
daily  (generally  morning and evening, approximately  12 hours apart) and study  aspi[INVESTIGATOR_248]/aspi[INVESTIGATOR_834153] y pantopra zole/pantoprazole placebo are taken once dail y, generall y in the 
morning.  The first doses of study drug should be administered on the day  of randomization ,
or at least [ADDRESS_1158448] -
CABG.63   
If a dose of study  rivaroxaban/rivaroxaban placebo is missed and less than [ADDRESS_1158449] elapsed since the missed dose was due, the dose sh ould be skipped and the 
next dose of study  rivaroxaban should be taken according to schedule.
If a dose of study  aspi[INVESTIGATOR_248]/aspi[INVESTIGATOR_834154]/pantoprazole placebo is 
missed it should be taken as soon as the subject becomes aware that the d ose has been missed. 
6.4.[ADDRESS_1158450]’s well -being.  All subjects who interrupt study  drug should 
resume treatment when possible.  If there is concern that the subject may be intolerant of 
study  treatments or if the subject is reluctant to take the full dose of study  treatments, a 
possible approach to restarting stud y medications is to reduce the frequency of dosing (eg, to 
once -daily or alternate -daily ).64Irrespective of whether or not treatment is resumed, all 
subjects must be followed according to the stud y protocol until the end of the study .  
Permanent study  drug interruption should be recorded on the corresponding follow -up case 
report form, giving the date and primary  reason for stoppi[INVESTIGATOR_49080].  If one of the 
study  treatments needs to be discontinued65, other study  treatments must be continued.  For 
example, if study  rivaroxaban/rivaroxaban placebo is interru pted, study  aspi[INVESTIGATOR_248]/aspi[INVESTIGATOR_834153] y pantoprazole/pantoprazole placebo should be continued.
Long-Term Open-L abel Extension − amended
No dose modifications will be conducted in the LTOL E.[ADDRESS_1158451] clinical judgment nor usual care
65in 
determining the appropriate management strategy  for individual subjects. For specific 
treatment guidance with study  pantoprazole/pantoprazole placebo see Section 6.9.465  
                                                
63Sentence revised as per Amendment 8.  (See Section 13.2.2 )
64Sentence revised as per Amendment 8.  (See Section 13.2.2 )
65Text modified/added as per Amendment 6. (See Section 13.1.2 )
66Text added as per Amendment 11. (See Section 13.3.1)
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 38of 205
[IP_ADDRESS] Guidance for the treatment of subjects who require an invasive 
procedure - amended
If the subject requires an invasive procedure that is associated with a standard or high risk of bleeding (i.e., an y procedure that is not considered “minor”), stud y rivaroxaban/rivaroxaban 
placebo must be interrupted.  Study  aspi[INVESTIGATOR_248]/aspi[INVESTIGATOR_834155], at the 
discretion of the investigator.  If stud y aspi[INVESTIGATOR_248]/aspi[INVESTIGATOR_834156], non-study  aspi[INVESTIGATOR_834157].
67
Dosing recommendations before and after invasive procedures and surgical intervention
If an invasive procedure or surgical intervention is required, rivaroxaban/rivaroxaban placebo 
should be stopped at least [ADDRESS_1158452] the urgency of the intervention.  Rivaroxaban/rivaroxaban placebo should be restarted after the invasive procedure or surgical intervention as soon as possible, provided the clinical situation allows and adequat e hemostasis has been established.
If surgery  is urgent or needed in an emergency  situation, the risk of bleeding must be weighed 
against the risk of delay ing surgery .  The total daily  dose of rivaroxaban in subjects 
randomized to receive [ADDRESS_1158453] who requires urgent or emergency  surgery , unblinding may  be 
considered but should only be performed if knowledge of randomized treatment allocation 
will influence clinical management (Section 6.5).  A two- unit single donor platelet transfusion 
in subjects treated with the combination of aspi[INVESTIGATOR_834158] y to 
generate thromboxane and thereby [CONTACT_834338][INVESTIGATOR_248]. (29)
Long-Term Open-L abel Extension − amended
The same guidance will apply  to LTOLE.68
[IP_ADDRESS] Guidance for the treatment of subjects who require coronary artery 
by[CONTACT_10956] –amended
CABG surgery can occur immediately  prior to randomization or it may  occur in randomized 
subjects who later develop a need for the surgery .   
Subjects who are scheduled to be randomized  Day  4-7 after CABG surgery  will not 
participate in the run -in phase ( Section 4.1.1).  Randomization should only  be performed 
between Day 4-[ADDRESS_1158454] tubes .  
                                                
67Text deleted as per Amendment 6. (See Section 13.1.2 )
68Text added as per Amendment 11. (See Section 13.3.1 )
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 39of [ADDRESS_1158455] administration of any  
anticoagulant (including DVT proph ylaxis).69
Subjects who are scheduled for CABG surgery  during the course of the trial ideally  should 
interrupt study  rivaroxaban/rivaroxaban plac ebo at least 24 hours before CABG surgery  in 
order to minimize the risk of bleeding.  Study  aspi[INVESTIGATOR_248]/aspi[INVESTIGATOR_834159]/or non- study  aspi[INVESTIGATOR_834160].  The timing of 
resumption of study  antithr ombotic therap y after surgery is at the discretion of the investigator 
but, in general, study rivaroxaban/rivaroxaban placebo or study aspi[INVESTIGATOR_248]/aspi[INVESTIGATOR_834161].  Study  
rivaroxaban/r ivaroxaban placebo should be interrupted if subjects require in- hospi[INVESTIGATOR_834162].  I n all cases, the goal should be to resume study  
antithrombotic drugs within 14
73days and prior to being discharged from hospi[INVESTIGATOR_307].70  
Long -Term Open -Label Extension − amended71
The same guidance will apply  to LTOLE. For subjects who are scheduled to undergo CABG, 
LTOLE treatment can be init iated four day s after CABG and at least [ADDRESS_1158456] administration of an y anticoagulant (including DVT proph ylaxis).72
[IP_ADDRESS] Guidance for the treatment of subjects who develop an acute coronary 
syndrome and those who require percutaneous coronary intervention 
with stenting –amended
Study  rivaroxaban/rivaroxaban placebo should be interrupted in subjects who require 
anticoagulant or dual antiplatelet therap y because of an acute coronary  syndrome or need for 
percutaneous coronary  intervention with stenting.  Standard antiplatelet therapy , including 
loading doses of aspi[INVESTIGATOR_8258] (or prasugrel or ticagrelor) can be administered 
according to usu al practice.   Study  aspi[INVESTIGATOR_248]/aspi[INVESTIGATOR_834163]. Standard 
anticoagulant therapy can be used without regard to the timing of the most recent dose of study  rivaroxaban/rivaroxaban placebo because the doses of rivaroxaban being tested in the 
COM PASS trial are lower than the 15
73or 20 mgdose given for stroke prevention in atrial 
fibrillation and the half -life is short, 5 -13 hours.  
Subjects who remain on long term dual antiplatelet therapy  may commence “interim study  
rivaroxaban/rivaroxaban plac ebo” once any non-study  anticoagulant therapy  is stopped. 
Study  aspi[INVESTIGATOR_248]/placebo may  be continued.74The difference between interim study  
rivaroxaban/rivaroxaban placebo and study rivaroxaban/rivaroxaban placebo is that during the period of dual antiplatel et therapy  all subjects will receive rivaroxaban at a dose of 2.5 mg bid 
(i.e., the dose of rivaroxaban in those previously  allocated 5 mg bid will be reduced to 2.5 mg 
bid). Subjects previously allocated 2.5 mg bid will continue on the same dose whereas those 
                                                
69Text modified as per Amendments 6 and 8. (See Sections 13.1.2 and 13.2.2 )
70Text deleted as per Amendment 6. (See Section 13.1.2 )
71Text added as per Amendment 11. (S ee Section 13.3.1 )
72Text modified as per Amendments 6 and 8. (See Sections 13.1.2 and 13.2.2 )
73Text modified/added as per Amendment 6. (See Section 13.1.2 )
74The first sentence was revised and the second sentence was added as per Amendment 8.  (See Section 13.2.2 )
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 40of 205
previously  allocated rivaroxaban placebo will remain on placebo.  Interim study  rivaroxaban 
will be allocated via the  randomization and drug management s ystem. All subjects 
should resume originally  allocated study  rivaroxaban/rivaroxaban placebo once non- study  
dual antiplatelet therap y is stopped and they  are not being treated with non- study  
anticoagulants.  When switching back to originally  allocated study  anticoagulant, interim 
study  anticoagulant therapy  should be stopped.70
Long -Term Open -Label Extension − amended
Study  rivaroxaban should be interrupted in subjects who require anticoagulant or dual 
antiplatelet therap y because of a n acute coronary  syndrome or need for percutaneous coronary  
intervention with stenting. Standard antiplatelet therapy, including loading doses of aspi[INVESTIGATOR_8258] (or prasugrel or ticagrelor) can be administered according to usual practice.  Study  aspi[INVESTIGATOR_834164]. All subjects should resume rivaroxaban 2.5 mg bid + aspi[INVESTIGATOR_834165] -study  dual antiplatelet therap y is stopped and they are not being treated with non -
study  anticoagulants.
75
[IP_ADDRESS] Guidance for the treatment of subjects who overdose on study 
rivaroxaban/rivaroxaban placebo –amended
If rivaroxaban overdose is suspected, the use of activated charcoal up to [ADDRESS_1158457] of an overdose of rivaroxaban is expected to be 
limited. If available, consideration may be given to the use of a specific reversal agent.76
Long -Term Open -Label Extension − amended
The same guidance will apply  to LTOLE.77
[IP_ADDRESS] Guidance for the treatment of subjects who experience a major bleed –
amended
Temporary  discontinuation of rivaroxaban is expected to be sufficient to control bleeding in 
most cases because the drug half -life is onl y 5-13 hours.  L ocal measures should be applied if 
needed to control bleedin g (e.g., local pressure, endoscopy  and injection of a bleeding vessel, 
embolization) and intravenous fluids and blood transfusion support should be provided as 
indicated.  In the rare case of life -threatening bleeding, the investigator may  consider 
obtaining advice from a hematologist.  Animal studies suggest that both prothrombin complex concentrates and recombinant factor VIIa partiall y restore hemostasis following treatment 
with factor Xa inhibitors such as rivaroxaban and a randomized trial involving he althy  
subjects treated with rivaroxaban has demonstrated that prothrombin concentrates reverse prolongation of the prothrombin time.( 30)  Rivaroxaban cannot be dial yzed as it is highly  
                                                
75Text added as per Amendment 11. (See Section 13.3.1 )
76This paragraph w as revis ed as per Amendment 8.  (See Section 13.2.2 )
77Text added as per Amendment 11. (See Section 13.3.1 )
[COMPANY_003]
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 41of 205
protein bound. If available, consideration may be given to the use of a specific reversal 
agent.78
Long -Term Open -Label Extension − amended
The same guidance will apply  to LTOLE.79
[IP_ADDRESS]   Guidance for the treatment of subjects who develop a stroke and who 
are being considered for reperfusion therapy – amended
The decision to use reperfusion therapi[INVESTIGATOR_014] (including intravenous, intra -arterial thromboly sis,
or mechanical endovascular approaches) in acute ischemic stroke should follow local practice, experience, and guidelines. At present there are limited data to guide treatment in this setting in subjects taking rivaroxaban. The following guidance is intended to aid clinical decision making in this setting. 
At or arou nd the time of the peak drug levels (we suggest in the first 6 hours after a dose), 
clinicians may  choose to unblind and to avoid thromboly sis if the subject is taking 
rivaroxaban. Alternatively, if it is possible to obtain a rivaroxaban anti-Xa level in t his time 
period, clinicians may  use this information to decide on the appropriateness of starting 
thromboly sis. Endovascular therap y with clot extraction can proceed whether or not the 
subject is receiving rivaroxaban without the need to unblind.
80
Long -Term Open -Label Extension − amended81
The decision to use reperfusion therapi[INVESTIGATOR_014] (including intravenous, intra -arterial thromboly sis, 
or mechanical endovascular approaches) in acute ischemic stroke should follow local practice, 
experience, and guidelines. At p resent there are limited data to guide treatment in this setting 
in subjects taking rivaroxaban. The following guidance is intended to aid clinical decision making in this setting. 
At or around the time of the peak drug levels (we suggest in the first 6 h ours after a dose), 
clinicians may  consider to avoid thromboly sis. I f it is possible to obtain a rivaroxaban anti -Xa 
level in this time period, clinicians may  use this information to decide on the appropriateness 
of starting thrombol ysis. 
6.5 Blinding
Subjects, site personnel, sponsor personnel,  staff (with the exceptions mentioned 
below), persons performing the assessments, and data anal ysts will remain blinded to the 
identity  of the treatment from the time of randomization until database lock.  R andomization 
data are to be kept strictly  confidential until the time of unblinding and will not be accessible 
by [CONTACT_37242]: (1)  information 
technology  (IT) computer programmers who work on the  randomization and drug 
management s ystem; and (2) the  unblinded biostatistician who prepares reports for the 
                                                
78This paragraph w as revised as per Amendment 8.  (See Section 13.2.2 )
79Text added a s per Amendment 11. (See Section 13.3.1 )
80Section was added w ith Amendment 8.  (See Section 13.2.2 )
81Text added as per Amendment 11. (See Section 13.3.1 )
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 42of 205
DSMB and provides unblinded information to Bayer for required regulatory  reporting 
(suspected unexpected serious adverse reactions [S[LOCATION_003]R] reporting).  These individuals will 
not be involved in the day -to-day running of the study .
In compliance with applicable regulations, in the event of a S[LOCATION_003]R that was believed to be related to study treatment, the subject’s treatment code will usually be unblinded before 
reporting to the health authorities, ethic committees and investigators.
Emergency unblinding by [CONTACT_834339] y and 
will only  be provided for the treatment that requires unblinding.  Most often, study  drug 
interruption and knowledge of the possible treatment assignments are sufficient to treat a 
study  subject who presents with an emergency  condition. Detailed information concerning 
unblinding procedure s isprovided in the Manual of Operations.  I n case of unblinding, only  
those individuals who are required to know treatment allocation may be given this information.  All others must remain blinded to treatment, including the subject.  All subjects should resume study  treatments after recovery  if it is medically  appropriate to do so and 
should be followed until the end of the stud y.
Long -Term Open -Label Extension –amended
The LTOLE is open label and no blinding procedures are applicable to the L TOLE.
[ADDRESS_1158458] ug logistics and accountability - amended
Each stud y site will be supplied with study  medication kits for the run- in (2 pi[INVESTIGATOR_182586]) and 
additional study  supply for the follow -up phase (and will be re -supplied throughout the study , 
as needed).  The stud y medication supply  will have appropriatel y labeled packaging according 
to national law and GMP ruling.  The stud y medication packaging has a 2 -part tear-off label.  
A unique medication number will be printed on each part of this label, which corresponds to one of the unique treatment arms for the blinded randomized treatment period.  I nvestigator 
staff will identify  the study  drug package(s) to dispense to the subject by  [CONTACT_834340] s ystem and obtaining the medication number(s).  At the 
time of dispensing, one part of the [ADDRESS_1158459]’s 
drug dispensing log and the other will remain on the study  medication package.  
All study  drugs will be stored at the investigational site in accordance with GCP and Good 
Manufacturing Practices (GMP) requirements and the instructions given b y the clinical 
supplies department of the sponsor (or its affiliate), and will be inaccessible to unauthorized personnel.  Special storage conditions and a complete record of batch numbers and expi[INVESTIGATOR_834166]; the site -relevant elements of this information will 
be available in the investigator site file.  The responsible site personnel will confirm the date
83
of receipt of study  drug and will use the study  drug only within the framework of this clinical 
study  and in accordance with this protocol.  Receipt, distribution, return and destruction (if 
any) of the study  drug must be properl y documented according to the agreed and specified 
                                                
82Text added as per Amendment 11. (See Section 13.3.1 )
83Text deleted as per Amen dment 6. (See Section 13.1.2 )
[COMPANY_003]
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 43of 205
procedures.  Specific instructions for the study  drug recordkeepi[INVESTIGATOR_834167].
Written instructions on medication destruction will be made available to affected parties as 
applicable.
Long -Term Open -Label Extensi on -amended
Investigator staff will continue to access the  randomization and drug management 
system to dispense study  medication . LTOLE treatment will be provided in appropriatel y 
labelled medication kits that identify  the treatment. All L TOLE treatment will be stored at the 
site in accordance with GCP and Good Manufacturing Practices (GMP) requirements and the 
instructions given b y the clinical supplies department of the sponsor or its affiliates. Receipt, 
distribution, return and destruction (if an y) of the study  drug must be properly  documented 
according to the agreed and specified procedures.[ADDRESS_1158460] to resume treatment with open -label aspi[INVESTIGATOR_834168].85
Long -Term Open -Label Extension − amended86
At the conclusion of LTOL E treatment, subject’s will be directed to their usual care physician
for appropriate treatment .  
6.9 Prior and concomitant therapy -amended
As described in Section 5.1.2, Exclusion criteria, the use of the following agents is not 
permitted at study  entry :  systemic treatment with strong inducers of CYP 3A4 (e.g. 
rifampi[INVESTIGATOR_2513]) and inhibitors of both87CYP 3A4 and P -gp (e.g., s ystemic azole antimy cotics, 
such as ketoconazole, and HIV- protease inhibitors, such as ritonavir) (see Section 6.9.1)88.  
Addit ionally , subjects with a need for dual antiplatelet therapy  or oral anticoagulant therap y 
are not eligible for inclusion in COMPASS.
                                                
84Text added as per Amendment 11. (See Section 13.3.1 )
85Text revised as per Amendment 8.  (See Section 13.2.2 )
86Text added as per Amendment 11. (See Section 13.3.1 )
87Text modified/added as per Amendment 6. (See Section 13.1.2 )
88The cross -reference to Section 6.9.1 was added as per Amendment 8.
[COMPANY_003]
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 44of [ADDRESS_1158461]’s own aspi[INVESTIGATOR_248], which must be discontinued at the time of commencing the run- in, and treatments that are contraindicated in combination 
with rivaroxaban.  Subjects may  receive all medications that their treating phy sicians believe 
are necessary .  If subjects develop a need for treatments that may  interfere with the efficacy  or 
safety of stud y drugs or for treatments that are taken in place of stud y drug, they must 
temporaril y discontinue the relevant study drug (study rivaroxaban/rivaroxaban placebo, 
aspi[INVESTIGATOR_248]/aspi[INVESTIGATOR_397629], or pantoprazole/pantoprazole placebo ) until such time that the 
interacting treatment is discontinued.  Study aspi[INVESTIGATOR_248]/aspi[INVESTIGATOR_834169] 
89
irrespective of the need for aspi[INVESTIGATOR_834170] y.  
Long-Term Open-Labe l Extension − amended
During the LTOLE, all subjects should continue to receive an y ongoing medications, with the 
exception of the subject’s own aspi[INVESTIGATOR_834171]. Subjects may  receive all medications that their trea ting phy sicians believe 
are necessary . If subjects develop a need for treatments that may  interfere with the efficacy  or 
safet y of LTO LE treatment or for treatments that are taken in place of LTOLE treatment, they  
must temporarily  discontinue the relevant study  drug ( rivaroxaban or a spi[INVESTIGATOR_834172]) until 
such time that the interacting treatment is discontinued.
90
6.9.1 Combined CYP 3A4 and p-glycoprotein inhibitors and CYP 3A4 inducers -
amended
Strong inhibitors of both CYP 3A4 and p- glycoprotein increase plasma concentrations of 
rivaroxaban and are contraindicated in subjects taking rivaroxaban. These include systemic azole antifungal drugs (e.g. ketoconazole, itraconazole, posaconazole , etc.), and HIV protease 
inhibitors.  Additionally , strong inducers of CYP 3A4 such as rifampi[INVESTIGATOR_2513], rifabutin, 
phenobarbital, phen ytoin, and carbamazepi[INVESTIGATOR_834173]. If any of these treatments are needed, randomized study 
rivaroxaban/rivaroxaban placebo must be temporarily  discontinued and open- label aspi[INVESTIGATOR_834174].
91  
Long -Term Open -Label Extension − amended
The same guidance applies to LTOLE .No placebo wil l be used.92
6.9.2 Clopi[INVESTIGATOR_7745] (or any other non -study antiplatelet treatment) - amended
Subjects who develop a need for treatment with non- study  dual antiplatelet therap y, such as 
aspi[INVESTIGATOR_259941] (e.g., subjects who experience an acute coronary  syndrom e, those 
who undergo percutaneous coronary intervention with stent insertion) must interrupt87study  
treatment of87rivaroxaban/rivaroxaban placebo.  Study rivaroxaban/rivaroxaban placebo must 
                                                
89Prior to Amendment 8, this sentence had read: “…should be continued…”  (See Section 13.2.2 )
90Text added as per Amendment 11. (See Section 13.3.1 )
91Section revised as per Amendments 6 and 8.  (See Sections 13.1.2 and 13.2.2 )
92Text added as per Amendm ent 11. (See Section 13.3.1 )
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 45of 205
be restarted once dual antiplatelet therap y is stopped (i.e., after completion of an adequat e 
duration of dual antiplatelet treatment).  Additional guidance is provided in Section [IP_ADDRESS].  
Long -Term Open -Label Extension − amended
The same guidance appli esto LTOLE. No placebo will be used.93
6.9.3 Anticoagulant treatment -amended
Subjects who develop a need for anticoagulant therap y (e.g., thromboprophylaxis in subjects 
undergoing major orthopedic surgery , acute venous thromboembolism, atrial fibrillation, 
mechanical aortic valve replacement) must interrupt study  rivaroxaban/rivaroxaban placebo.  
Study  rivaroxaban/rivaroxaban placebo must be restarted in subjects who no longer have a 
need for non -study  anticoagulant therapy  (e.g., after completion of anticoagulant 
thromboprophy laxis or anticoagulant treatment for venous thromboembolism).  I n subjects 
who develop a need for anticoagulant therap y, study  aspi[INVESTIGATOR_248]/aspi[INVESTIGATOR_834175], at the discretion of the investigator.[ADDRESS_1158462] dose of open 
prophy lactic anticoagulation at the time that the next dose of study  rivaroxaban/rivaroxaban 
placebo is due.  If study  drug is interrupted and the subject is transitioned to an anticoagu lant 
with a slow onset of action, bridging therap y ma y be needed.
If therapeutic anticoagulation is required, subjects should start therapeutic anticoagulation immediately , irrespective of the timing of the last dose of study  rivaroxaban.  
Long -Term Open -Label Extension − amended
95
Subjects who develop a need for anticoagulant therapy (e.g., thromboprophy laxis in 
subjects undergoing major orthopedic surgery , acute venous thromboembolism, atrial 
fibrillation, mechanical aortic valve replacement) must discontinue L TOLE medication. 
Guidance for converting see below:
Converting from rivaroxaban to oral anti -coagulants
Rivaroxaban affects INR, so INR measurements made during co -administration with oral 
anticoagulant may not be useful for determining the appropriate dose of oral anticoagulant. 
One approach is to discontinue rivaroxaban and begin both a parenteral anticoagulant and oral VKA at the time the next dose of rivaroxaban would have been taken.
Converting from rivaroxaban to parenteral anti -coagulants
Discontinue rivaroxaban and give the first dose of parenteral anticoagulant at the ti me that 
the next rivaroxaban dose would be taken.
Study rivaroxaban can be restarted at the discretion of the investigator in subjects who 
no longer have a need for non- study  anticoagulant therapy  (e.g., after completion of 
                                                
93Text added as per Amendment 11. (See Section 13.3.1 )
94Text deleted as per Amendment 6. (See Section 13.1.2 )
95Text added as per Amendment 11. (See Section 13.3.1 )
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 46of 205
anticoagulant thromboprophy laxis or anticoagulant treatment for venous thromboembolism). 
Guidance for restarting see below:
Converting patients from VKAs to rivaroxaban
When converting patients from VKAs to rivaroxaban, INR values will be falsely  elevated 
after the intake of rivaroxaban. The INR is not valid to measure the anticoagulant activity  
of rivaroxaban, and therefore should not be used. 
Converting patients from p arenteral antico agulant to rivaroxaban
For patients currentl y receiving a parenteral anticoagulant, start rivaroxaban 0 to 2 hours 
before the time of the next scheduled administration of the parenteral drug (e.g. LMWH) or at the time of discontinuation of a continuously administered parenteral drug (e.g. 
intravenous unfractionated heparin). 
6.9.4 Proton pump inhibitor treatment -amended
Subjects who develop a continuous96need for treatment with a PPI[CONTACT_61641]96(e.g., 
gastroduodenal ulcer) should discontinue study  pantoprazole/pantoprazole placebo while 
receiving non- study  PPI [CONTACT_3148].  Study  pantopr azole/pantoprazole placebo should96be 
restarted in all subjects who no longer have a continuous96need for PPI[CONTACT_48831] . 
7. Procedures and variables
7.1 Schedule of procedures − amended
The study  schedule comprises 4 periods:  screening, run- in, follow -up, and washout.  The trial 
will require clinic visits at screening (in most cases this visit is expected to coincide with the run in visit), run- in, randomization, [ADDRESS_1158463] s ubjects by  [CONTACT_834341] 3, Month 9 and at the End of Washout Telephone Visit ([ADDRESS_1158464] Final Follow -up 
Visit).  Some centers may  also perform pre -screening visits.  Further details are provided in 
the Manual of Operations.  
A tabulated overview ( Table 7–1) of the procedures conducted in each of these periods is 
provided in Section 7.1.1 and the procedures and their timing are described in more detail in 
Section 7.1.2. 
Early termination of rivaroxaban/aspi[INVESTIGATOR_834176] − amen ded
On February  6, 2017, the COMPASS Data Safety  Monitoring Board (DSMB) recommended 
discontinuation of the rivaroxaban/aspi[INVESTIGATOR_834177]. The PPI  [INVESTIGATOR_834178]. 
                                                
96Text modified/added as per Amendment 6. (See Section 13.1.2 )
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 47of 205
Another update has bee n added to the revised schedule of evaluation . Specifically , the 
pantoprazole/placeb o washout call previously  included in the table was removed as shown in 
Table 7–2.97
Long-Term Open- Label Extension − amended98
A tabulated overview of the procedures conducted during the LTOLE is provided in Table 7–
3,and the procedures and their timing are described in more detail in Section [IP_ADDRESS].
                                                
97Text added as per Amendment 11. (See Sections 13.3.1 and13.3.2 )
98Text added as per Amendment 11. (See Section 13.3.1 )
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 48of 205
7.1.1 Tabulated overview - amended
Table 7–1.  Schedule of evaluations
Pre-Screeninga
Screening/
Run-in
Randomizations,[ADDRESS_1158465] 
Finalm
Windowsq,99 ± 5d ± 7d ± 2w ± 4w ± 4w ± 4w ± 4w ± 4w ± 4w ± 4w ± 4w ± 4w ± 4w ± 4w ± 4w ± 5d
Informed consent (if required for 
pre-screening)X
Informed consent Xr,99
Inclusion/exclusion criteria X X X99
Demographics X
Medical histor y X
Physical measurementsbX X X
Concomitant medications X X X X
Pregnancy test if pre -
menopausalX
Laboratory testscXdXe
Blood/DNA collection and storageX
fXf
Diet and activity questionnaires XoXoXp100X
                                                
99Added as per Amendment 6. (See Section 13.1.2 )
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 49of 205
Pre-Screeninga
Screening/
Run-in
Randomizations,[ADDRESS_1158466] 
Finalm
Windowsq,99 ± 5d ± 7d ± 2w ± 4w ± 4w ± 4w ± 4w ± 4w ± 4w ± 4w ± 4w ± 4w ± 4w ± 4w ± 4w ± 5d
MoCA, DSS, and SAGE t, [ADDRESS_1158467] coronary angiographyhXh
MRI brainiX X
Outcomes X100X X X X X X X X X X X X X X X
Adverse eventsjX X X X X X X X X X X X X X X X X X
Study drug dispensed XkXlX X X X X X X X X X
Study drug adherence X X X X X X X X X X X X X X X
Study drug accountability X X X X X X X X X X X X X
Abbreviations:  w = week; m = month; y = year; d = day; DNA = d eoxyribonucleic acid; MoCA =Montreal Cognitive Assessment; DSS = Digit Symbol 
Substitution test; SAGE = Standard Assessment of Global -Activities in the Elderly; EQ-5D = European Quality of Life -5 Dimensions questionnaire; CT = 
computed tomography; MRI = magnetic resonance imaging; CABG = coronary artery by[CONTACT_9292]
                                                                                                                                                                                                                       
100Added as per Amendment 6. (See Section 13.1.2 )
101Footnote t added as per Amendment 8 (See Section 13.2.2 )
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 50of [ADDRESS_1158468] CABG surgery . For other, non -CABG subjects, the blood results of cr eatinine and total 
cholesterol should be available within 3 months of this visit. 102
f.Collection of blood & DNA samples for central evaluation in subjects participating in the COMPASS- MIND substudy is optional. If collected, obtain 
samples102at randomization, before starting the study drug102, and at [ADDRESS_1158469] the second blood 
sample at 1 month. If either the DNA sample or second blood sample is missed, it should be collected at the next visit.102
g.Using the European Quality of Life -5 Dimensions questionnaire and to be performed at screening/run -in or randomization (see “o”) , year [ADDRESS_1158470] angiography will be performed at 1 year or later in all subjects who are rando mized Day 4 -7102after CABG to evaluate graft patency  (except in subjects 
those with specific contraindications). In the event the subject undergoes an invasive coronary angiography at [ADDRESS_1158471] dose of study treatment
k.Stop treatment with non -study aspi[INVESTIGATOR_248].102  Dispense run -in medications. CABG surgery patients will be randomized Day 4 -7102after CABG surgery and will 
not be dispensed run -in study drug; however, the Screening/Run-In Visit CRFs are still required to be completed for these subjects.  
l.Stop run -in medication and begin randomized treatment assignment
m.Telephone visits
n.Visits will continue every 6 months until the required number of primary efficacy outcomes has been collected
o.It is optional to administer all or some of the questionnaires (SAGE, DSS, MoCA, EQ -5D, Diet, and Physical Activity) at Screening/Run-in instead of at the 
Randomization Visit, or as soon as possible thereafter (with the exception of patients randomized Day [ADDRESS_1158472] CABG; see “p”).[ADDRESS_1158473] CABG, questionnaires (SAGE, DSS, MoCA, EQ -5D, Diet, and Physical Activity) should be performed at the [ADDRESS_1158474] to 
return within the visit "window," especially due to unforeseen circumstance beyond the control of the subject or the study center, then the visit sho uld be 
scheduled as close to the interval as is convenient for the subject and study center.102
                                                
102Text modified/added as per Amendment 6. (See Section 13.1.2 )
103Text modified/added as per Amend ment 8. (See Section 13.2.2 )
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 51of [ADDRESS_1158475] -CABG.
t.Also to be administered at the next study clinic visit after each outcome event .
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 52of 205
Table 7–2Schedule of evaluations after DSMB recommendation in Feb 2017104
Follow -up Rivaroxaban/ Aspi[INVESTIGATOR_834179]/placeboPantoprazole/placeboj
VisitjFinal Rivaroxaban/ 
Aspi[INVESTIGATOR_834180] -upRivaroxaban/ Aspi[INVESTIGATOR_834181]/ Placebo Follow -up Final Pantoprazole/ 
Placebo Follow -up 
Timing [ADDRESS_1158476] Rivaroxaban/ 
Aspi[INVESTIGATOR_834182]6 m post Rivaroxaban/ Aspi[INVESTIGATOR_834183] -up and 6 monthly  thereafterExpected in  2018, 
endpoint dependent
WindowsgMar –15 May 2017 ± 5d ± 4w ± 4w
Complete outstanding re -consents X
Physical measurementsaX X
Concomitant medications X X
Diet and activity questionnaires
MoCA, DSS, and SAGEhX X X
EQ-5DbX X
CT coronary angiographycX if 1yr not done yet
MRI braindX
Outcomes X X X X
Adverse eventseX X X X
Study drug dispensediXiX
Study drug adherence X X X
Study drug accountability X X X
Abbreviations:  w = week; m = month; y = year; d = day; DNA = deoxyribonucleic acid; MoCA =Montreal Cognitive Assessment; DSS = Digit Symbol 
Substitution test; SAGE = Standard Assessment of Global -Activities in the Elderly; EQ-5D = European Quality of Lif e-5 Dimensions questionnaire; CT = 
computed tomography; MRI = magnetic resonance imaging; CABG = coronary artery by[CONTACT_9292]
a.Weight, height, waist and hip circumference, heart rate, ankle -brachial blood pressure index
b.Using the European Quality of Life -[ADDRESS_1158477] angiography will be performed at 1 year or later in all subjects who are randomized Day 4 -7 after CABG t o evaluate graft patency  (except in subjects 
those with specific contraindications). In the event the subject undergoes an invasive coronary angiography at [ADDRESS_1158478] dose of study treatment
f.Telephone visits
                                                
104Text added as per Amendment 11. (See Section 13.3.1 )
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 53of [ADDRESS_1158479] to 
return within the visit "window," especially due to unforeseen circumstance beyond the con trol of the subject or the study center, then the visit should be 
scheduled as close to the interval as is convenient for the subject and study center. 
h.Also to be administered at the next study clinic visit after each outcome event
i.Applicable only for sub jects ongoing with pantoprazole/placebo
j.For subjects from the PPI [CONTACT_14455], follow up visits will continue regardless of early stoppage of the rivaroxaban/aspi[INVESTIGATOR_834184], and there will be no 
washout visit.
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 54of 205
Table 7–3Schedule of LTOLE Procedures105
Visita1 2 3 4 5 6 Final LTOLE visite
Timingb06m 1y 1.5y 2y 2.5y 3y/
commercial availablef
Windows ± 4w± 4w± 4w± 4w± 4w± 4w
Informed consent X
Inclusion/exclusion criteria X
Concomitant medications X X
Pregnancy test if pre -menopausal X
Serum creatininecX
Outcomes X X X X X X
Adverse eventsdX X X X X X
Study drug dispensed X X X X X X
Study drug accountability X X X X X X
Study drug adherence X X X X X X
Questionnaires (MoCA, DSS, SAGE, EQ -5D) X
a.LTOLE visits may be combined with PPI [INVESTIGATOR_834185] , and the visit window may be adjusted accordingly .
b.Clinic visits should be scheduled as close to the specified interval as possible, and preferably within the defined window.  If it is not possible for the subject to 
return within the visit "window," especially due to unforeseen circumstance beyond the con trol of the subject or the study center, then the visit should be 
scheduled as close to the interval as is convenient for the subject and study center. 
c.If not available in the [ADDRESS_1158480] is on LTOLE treatment and will stop it at this visit and will be suggested to start non -study antithrombotic treatment at physician’s discretion.
f.If the commercial availability in a country is achieved earlier than [ADDRESS_1158481] at the next scheduled visit ; if a participant stops LTOLE treatment, a final visit should be scheduled immediately .
                                                
105Text added as per Amendment 11. (See Section 13.3.1 )
[COMPANY_003]
Integrated Clinic al Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 55of 205
7.1.2 Timing of assessments
[IP_ADDRESS] Pre-screening visit 
Pre-screening visits are optional but when performed will generall y be conducted during the 
1-[ADDRESS_1158482] eligibility .  Some centers may  be required by  [CONTACT_834342] -screening events.  If this is the case, pre -screening 
activities will include:
Obtain written informed consent for pre-screening (if required) 
Review inclusion and exclusion criteria and evaluate subject willingness to participate 
in the study
Record adverse events if informed consent was obtained
[IP_ADDRESS] Screening and r un-in visit(s) - amended
The aim of the screening visit is to confirm eligibility .  Laboratory  results of creatinine and 
total cholesterol performed within a y ear of this v isit can be used to assess eligibility . 
Otherwise, obtain relevant laboratory  tests.106  For subjects who are randomized Day 4-7106
after CABG surgery , the screening visit may  be performed prior to or after106surger y 
(Section 4.1.1).107  Screening/run -in activities include:
Obtain written informed consent  
Review inclusion and exclusion criteria and evaluate subject willingness for participation in the study
Collect demographic data:  gender, date of birth, race/ethnicit y
Measure bod y weight (kg or lb), height (cm or in), waist circumference (cm or in), hip 
circumference (cm or in), heart rate (bpm), ankle- brachial blood pressure index (mm 
Hg) 
Record concomitant medications
It is optional to administer all or some of the questionnaires (SAGE, DSS, MoCA, EQ-5D, Diet, and Phy sical Activity ) at Screening/Run- ininstead of at the Randomization 
Visit.  (I n patients randomized Day  4-[ADDRESS_1158483] CABG, the questionnaires should be 
performed at the 1 month visit).
108  
Conduct pregnancy  test (serum or urine) for premenopausal subjects
Record adverse events
Stop treatment with non- study  aspi[INVESTIGATOR_248]
                                                
106Text modified/added as per Amendment 6. (See Section 13.1.2 )
107Text deleted as per Amendment 6. (See Section 13.1.2 )
108Text modified/added as per Amendment 6. (See Section 13.1.2 )
[COMPANY_003]
Integrated Clinic al Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 56of 205
Obtain medication code for run- in study  treatment and dispense run- in study  
medications (not applicable for subjects who are randomized Day  4-7108after CABG 
surgery ) 
A subject can be re -screened/re -run-in, if not previously  randomized to study  treatment:108
Obtain written informed consent, if applicable108
Repeat/complete the rest of the screening/run-in activities, where applicable.108
[IP_ADDRESS] Randomization visit (Day 0 ± 5 days) -amended
The aim of the randomization visit is to assign blinded study  treatment.  Subjects may  be 
randomized if they  fulfill all study  inclusion and exclusion criteria, have the blood results of 
the serum creatinine and total cholesterol available within [ADDRESS_1158484] at 
least10880% adherence (except for extenuating circumstances)108to both run- in study  
treatments and remain committed to participate in the trial and randomization activities 
including: 
Perform run- in drug accountability ; assess adherence to run- in drug (not applicable for 
subjects who are randomized Day 4-7108after CABG surgery )
Record disease and surgical history
Record concomitant medications
Administer diet and activity  questionnaires (may  be administered at Screening/Run -in 
instead of Randomization)
Administer MoCA, DSS, and SAGE questionnaires (may  be administered at 
Screening -Run-in instead of Randomization). 
Administer EQ- 5D questionnaire (may  be administered at Screening/Run -in instead of 
Randomization). 
In patients randomized day 4-[ADDRESS_1158485] CABG perform questionnaires (SAGE, DSS, 
MoCA, EQ -5D, Diet, and Phy sical Activity )  at 1 month visit109  
Collect health care costs information
Assess driving status
Assess local laboratory  results of creatinine and total cholesterol109
Collect blood for local laboratory  assessment of creatinine in subjects being 
randomized post CABG 
Collect EuroSCORE for subjects being randomized post CABG surgery (if score is not 
available in medical chart, calculate EuroSCORE)
Collect blood (DNA) sample for storage and central evaluation in COMPASS MI ND 
substudy  subjects, if applicable109
                                                
109Text modified/added as per Amendment 6. (See Section 13.1.2 )
[COMPANY_003]
Integrated Clinic al Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 57of 205
MRI  of the brain will be performed onl y in COMPASS- MIND substud y subjects after 
randomization110
Record outcomes109
Record adverse events 
Randomize subject by  [CONTACT_834343] 
Dispense assigned stud y treatments.  Study treatments should be started on the day  of 
randomization or, if study  aspi[INVESTIGATOR_834186], study  treatment should be started the day  thereafter.  
[IP_ADDRESS] Follow-up visits
[IP_ADDRESS].1 Routine follow -up visits (Visits 3, 5, and 7-15+) -amended
Subjects will be seen in the clinic at Month 1 ( 7 day s), Month 6 (± 4 weeks), and thereafter 
at 6 month intervals (± 4 weeks) post- randomization until Visit 15. Thereafter, subjects will 
continue to be seen at the clinic every [ADDRESS_1158486] year, subjects will be phoned at Month 3 and 
Month 9 to assess and encourage adherence to study treatments, and a further phone call (End 
of Washout Telephone Visit) will be made 30 days after the Final Follow- up Visit to assess 
outcomes and adverse events.  Follow -up assessments include:
Record outcomes 
Record adverse events (if appropriate, complete the Hospi[INVESTIGATOR_834187] [MRU] data)
In patients randomized day 4-[ADDRESS_1158487] CABG perform questionnaires (SAGE, DSS, 
MoCA, EQ -5D, Diet, and Phy sical Activity ) (1 month).111  
Collect blood sample for storage and central evaluation in COMPASS MI ND substudy  
subjects at Visit 3 (1 month)
Dispense study  drug at Visits 5 and 7- 15 by  [CONTACT_834344] s ystem.
Assess adherence to study drug
Perform study  drug accountability  (pi[INVESTIGATOR_4382] c ount) at each in -clinic visit
Perform CT angiograph y only  at Visit 7 (1 y earor later if not performed at 1 y ear) in 
all subjects who are randomized during the first week after CABG to evaluate graft 
patency  (except in subjects with specific contraindications). In the event the subject 
undergoes an invasive coronary  angiography  at [ADDRESS_1158488] angiogram may  not be required.111
                                                
110“after randomization” was added as per Amendment 8.  (See Section 13.2.2 )
111Text added as per Amendments 6 and 8. (See Sections 13.1.2 and 13.2.2 )
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
Integrated Clinic al Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 58of 205
Additional assessments to be performed onl y at Visit 9 (2 y ears) include:
oPhysical measurements: body  weight (kg or lb), height (cm or in), waist 
circumference (cm or in), hip circumference (cm or in), heart rate (bpm), ankle -
brachial blood pressure index (mm Hg)
oRecord concomitant medications
oAdminister diet and activity  questionnaires at Visit [ADDRESS_1158489] the visit in person in whic h case the  
visit may  occur by  [CONTACT_834345].113
[IP_ADDRESS].2 Non-clinic assessments (Months 3 and 9 ± 4 weeks)
At Months [ADDRESS_1158490] the 
following data:
Record outcomes 
Record adverse events
Discuss study  drug adherence 
Additional interim phone calls or visits may  occur as required to appropriately  manage 
subjects during the stud y.  Further details are included in the Manual of Operations.
[IP_ADDRESS].3 Final Follow -up Visit (± 4 w eeks)
When the required number of primary  efficacy  outcomes ha vebeen collected, the study  
termination will be announced and subjects will return to the clinic for a Final Follow -up 
Visit.  Final follow- up assessments include:
Physical measurements:  body  weight (kg or lb), height (cm or in), waist 
circumference (cm or in), hip circumference (cm or in), heart rate (bpm), 
ankle -brachial blood pressure index (mm Hg)
Record concomitant medications
Administer MoCA, DSS, and SAGE questionnaires 
Administer EQ-5D questionnaire 
MRI  of the br ain will be performed onl y in COMPASS- MIND substud y subjects
Record outcomes 
                                                
112Text deleted as per Amendment 6. (See Section 13.1.2 )
113Sentence added as per Amendment 8. (Se e Section 13.2.2 )
[COMPANY_003]
Integrated Clinic al Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 59of 205
Record adverse events (if appropriate, complete the Hospi[INVESTIGATOR_834188])
Assess adherence to study drug
Perform study  drug accountability  (pi[INVESTIGATOR_692])
[IP_ADDRESS] End of w ashout telephone visit ([ADDRESS_1158491] Final Follow -up Visit ± 5 
days)
The washout visit will be conducted b y stud y staff via telephone interview.  Washout visit 
assessments include:
Record outcomes 
Record adverse events (if appropriate, comp lete the Hospi[INVESTIGATOR_834188])
Amended after early termination of rivaroxaban/aspi[INVESTIGATOR_834189]114
No washout will be scheduled for PPI  [CONTACT_6660].
[IP_ADDRESS] Long-Term Open -Label Extension −amended115
The LTOLE protocol amendment requir es clinic visits at initiation and every  6 months 
thereafter. For the COMPASS trial subjects continuing in the pantoprazole versus placebo 
randomization, L TOLE visits are recommended to coincide with the ongoing visits for 
pantoprazole comparison .If regulatory  and ethics approval is obtained shortly  after a 
pantoprazole versus placebo follow -up visit, an additional visit is recommended to evaluate 
eligibility and, if appropriate, initiation of L TOLE treatment .
[IP_ADDRESS].1 Initiation of Long -Term Open -Label Ex tension − amended116
The COMPASS trial subjects will be invited to participate in the LTOLE . Eligibility  for 
LTOLE is defined in Section5.1.3. 
The objective of the LTOLE initiation visit is to evaluate eligibility  of COMPASS trial 
subjects for LTOLE. Initiation activities include:
Obtain written informed consent 
Review inclusion and exclusion criteria 
Record concomitant medications
Conduct pregnanc y test (serum or urine) for premenopausal subjects
Obtain results of serum creatinine (if not available in within prior 1 y ear)
Dispense study  drug
                                                
114Text added as per Amendment 11. (See Section 13.3.1 )
115Text added as per Amendment 11. (See Section 13.3.1 )
116Text added as per Amendment 11. (See Section 13.3.1 )
[COMPANY_003]
Integrated Clinic al Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 60of 205
[IP_ADDRESS].2 Follow-up ofLong-Term Open -Label Extension − amended117
Subjects will be seen in the clinic every  6 months. Follow -up visit assessments include:
Record outcomes 
Record adverse events
Assess adherence to study drug
Perform study  drug accountability  (pi[INVESTIGATOR_692])
Dispense study  medication
[IP_ADDRESS].[ADDRESS_1158492] the final visit may  be conducted at the next scheduled 
visit. Thefinal visit assessments include:
Record outcomes
Record adverse events
Assess adherence to study drug
Perform study  drug accountability  (pi[INVESTIGATOR_692])
Record c oncomitant medication
Administer questionnaire s(MoCA, DSS, SAGE, EQ -5D)
In the case of permanent discontinuation of LTOLE treatment, the subject will be called in for 
a final visit.
7.2 Population characteristics
7.2.1 Demographics
Demographic data will be collected at the Screening Visit.  These data will include:
Gender
Date of birth
Race/ethnicit y
                                                
117Text added as per Amendment 11. (See Section 13.3.1 )
118Text added as per Amendment 11. (See Section 13.3.1 )
[COMPANY_003]
Integrated Clinic al Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 61of 205
7.2.2 Medical history
Medical history  (i.e. previous diagnoses, diseases or surgeries) meeting all criteria listed 
below will be collected:
Not pertaining to the study indication
Start before signing of the informed consent 
Considered relevant to the study .
Medical history  parameters to be collected at randomization w ill include , e.g. :
Disease history  associated with CAD or PAD (myocardial infarction, angina, 
intermittent claudication, diabetes, renal d ysfunction, heart failure, transient ischemic 
attack, stroke, liver disease, hypertension, cancer, bleeding requiring transfusion, 
tobacco use) or associated with gastrointestinal disease (bleeding, erosions, ulceration, 
obstruction, perforation) 
Surgical history  associated with CAD or PAD (coronary  percutaneous transluminal 
coronary  angioplasty , atherectom y, percutaneous coronary  intervention, coronary  
artery  by[CONTACT_9292], peripheral artery  by[CONTACT_4897] , peripheral percutaneous 
transluminal angioplast y, limb or foot amputation) or associated with gastrointestinal 
disease (bleeding, erosions, ulceration, obstruction, pe rforation)
7.2.3 Other baseline characteristics -amended
Validated health and quality  of life questionnaires (SAGE, MoCA, DSS, and EQ-5D) will be 
administered at screening/run- inorrandomization, or as soon as possible thereafter, at Month 
[ADDRESS_1158493] of randomized treatment on functional outcomes and quality  of life .  
Diet and activit y questionnaires will also be administered at screening/run -in or 
randomization, or as soon as possible thereafter, and at Month [ADDRESS_1158494] of an y other visit- related procedures.  119
7.3 Efficacy -amended
The primary  efficacy  outcome is a composite of my ocardial infarction, stroke, or 
cardiovascular death.
The seco ndary  efficacy  outcomes are : 120
a) A composite of coronary  heart disease death, my ocardial infarction, ischemic stroke or 
acute limb ischemia b) A composite of cardiovascular death, m yocardial infarction, ischemic stroke or acute limb 
ischemia
                                                
119Section was modified as per Amendments 6 and 8.  (See Sections 13.1.2 and 13.2.2 )
120Revised wi th Amendments 6 and 8.  (See Sections 13.1.2 and 13.2.2 )
[COMPANY_003]
Integrated Clinic al Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 62of 205
c) Mortality by [CONTACT_834346], MoCA, 
DSS, and EQ -5D inventories and the following:  individual components of the primary  and 
secondary  outcomes, hospi[INVESTIGATOR_059], revascularization, amputation, stent thrombosis, unstable 
angina, worsening angina, new angina, heart failure, resuscitated cardiac arrest, venous 
thromboembolism, new diagnosis of cancer, MRU, coronary  artery  by[CONTACT_541649].120
Hospi[INVESTIGATOR_834190]. These data 
will be anal yzed and reported to the sponsor separatel y and will include:
Total day s length of stay
Emergency  room visits
Intensive care unit /cardiac care unit day s 
Rehabilitation and skilled nursing facilities
Reason for medical resource use, i.e., major adverse cardiovascular event or bleeding
MRU data will be incorporated into economic modeling, which will be performed and reported separatel y from this study . 
The outcome for the pantoprazole randomization is a composite of overt bleeding of 
gastroduodenal origin confirmed b y endoscop y or radiograph y, overt upper gastrointestinal 
bleeding of unknown origin, bleeding of presumed occult gastrointestinal origin with documented decrease in Hb of 2 g/dL, symptomatic gastroduodenal ulcer, gastrointestinal 
pain with underlying multiple gastroduodenal e rosions, and gastrointestinal obstruction, or
perforation .
121
Long -Term Open -Label Extension − amended
The same primary , secondary and tertiary  efficacy outcomes collected during the COMPASS 
trialwill be collected during the LTOLE .122
7.4 Pharmacokinetics / pharmacodynamics
No measures of pharmacokinetics or pharmacod ynamics will be performed for this study .
7.5 Safety − amended
The primary  safet y outcome is Modified ISTH major bleeding, defined as:  i) fatal bleeding, 
and/or ii) sy mptomatic bleeding in a critic al area or organ, such as intracranial, intraspi[INVESTIGATOR_1304], 
intraocular, retroperitoneal, intraarticular or pericardial, or intramuscular with compartment 
syndrome, or bleeding into the surgical site requiring re -operation and/or iii) bleeding leading 
to hospi[INVESTIGATOR_11298].
                                                
121Text deleted as per Amendment 6. (See Sections 13.1.2 )
122Text added as per Amendment 11. (See Section 13.3.1 )
[COMPANY_003]
Integrated Clinic al Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 63of [ADDRESS_1158495] profile of rivaroxaban can be found in the Investigator Brochure (IB) ,
which is updated on a regular basis.  An y new, relevant information about side effects of 
rivaroxaban will be provided to the subject by  [CONTACT_680923].
Long -Term Open -Label Extension − amended
The safet y collection requirements for the COMPASS trialwill remain unchanged for the 
LTOLE.123
7.5.1 E6 Definition of (serious) adverse event -amended
An AE is any untoward medical occurrence including an exacerbation of a pre -existing 
condition or abnormal laboratory  finding in a clinical investigation subject administered a 
pharmaceutical product and which does not necessarily  have to have a causal relationship with 
this treatment. 
A serious adverse even t (SAE) is classified as an y untoward medical occurrence that, at an y 
dose, results in death, is life -threatening, requires inpatient hospi[INVESTIGATOR_4967], results in persistent or significant disability  / incapacity  is a 
congenital anomal y / birth defect and/or is another medically important serious event 
representing a significant hazard, which is comparable to the aforementioned criteria.124
Note:  If a subject is hospi[INVESTIGATOR_834191] a procedure that was planned or an ticipated prior to 
the subject signing the informed consent, the hospi[INVESTIGATOR_059]/procedure is considered part of 
medical  history  or a therapeutic intervention and is not the result of an (S)AE unless the 
severit y has worsened or changed unexpectedly. Addi tionally , a procedure is not an (S)AE, 
but the reason for the procedure may  be an (S)AE.125
7.5.2 Causal relationship - amended
The assessment of the causal relationship between an AE and the administration of study  drug 
is a clinical decision based on all available information at the time of the completion of the CRF. The causality  assessment should be done separatel y for each study treatment as detailed 
in the CRF. The assessment is based on the question whether there was a “reasonable causal relationship” to the study drug in question.
126
7.5.3 Protocol -specific adverse event definitions
[IP_ADDRESS] Protocol -specific exceptions to SAE reporting - amended
Rivaroxaban has been extensively studied in Phase [ADDRESS_1158496].
                                                
123Text added as per Amendment 11. (See Section 13.3.1 )
124Text modified as per Amendments 6 and 8. (See Sections 13.1.2 and 13.2.2 )
125Paragraph added w ith Amendment 8.  (See Section 13.2.2 )
126Section 7.5.2 and text within wa s added in Amendment 6.
[COMPANY_003]
Integrated Clinic al Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 64of 205
For the purposes of this trial, the following events will be captured on the CRF as study  
outcome events onl y and will be waived from unblinding and will be exempted from the 
expedited reporting but will be included in the final study  report. 
Primary  efficacy127outcomes:
oCardiovascular death
oMyocardial infarction
oStroke
Secondary  and tertiary  efficacy128outcomes
oCoronary  heart disease death
oIschemic stroke
oAcute limb ischemia
oCardiovascular hospi[INVESTIGATOR_834192]129
oAngina pectoris (unstable, worsening or new)[ADDRESS_1158497]
oNew diagnosis of cancer 
oCoronary  artery  by[CONTACT_541649]129
Primary  safet y outcomes:[ADDRESS_1158498] of 
rivaroxaban, bleeding events, including those resulting in hospi[INVESTIGATOR_059], will not be r eported 
as (S)AEs, but will be captured on the CRF only, and will be reported as outcomes.
Expected Events:129
In addition, events that are expected to occur with high frequency  in the population under 
study  and for which no safet y signal arose from more than 80,000129, 130patients alread y 
studied in clinical trials with rivaroxaban will be captured on the CRF only, will be waived from unblinding, and be will be exempted from expedited reporting.  These incl ude:
                                                
127Text modified/added as per Amendment 6.  (See Section 13.1.2 )
128Text revised as per Amendments 6 and 8. (See Sections 13.1.2 and 13.2.2)
129Text modified/added as per Amendment 6. Section [IP_ADDRESS] added. (See Section 13.1.2 )
130Number changed from 70,000 to 80,000 as per Amendment 8.
[COMPANY_003]
Integrated Clinic al Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 65of 205
Planned hospi[INVESTIGATOR_602] (e.g., for surgery , respi[INVESTIGATOR_4594]) 
Non-cardiovascular SAEs (including unplanned hospi[INVESTIGATOR_602]) that are expected to 
occur with high frequency in the population under study  (depression, pneumonia, 
trauma, chronic obstructive pulmonary  disease, diabetes mellitus)
[IP_ADDRESS] Reporting of (S)AEs - amended
The following events are to be reported to  on the SAE/ESI  CRF within 24 hours of the 
investigator becoming aware of the event/diagnosis.129Bayer HealthCare 
Pharmacovigilance129is responsible for reporting these even ts to the health authority :129
Any non-cardiovascular death of a subject occurring after signing informed consent or 
prior to the end of monitoring for adverse events. (note: fatal bleeding events are 
primary  safety  outco mes and are exempted)129
Any non- cardiovascular SAEs not listed in Section [IP_ADDRESS]
Any non- cardiovascular AE that recurs when the subject is restarted on study  drug 
(positive re -challenge).129
In addition, any  AEs of particular concern to the investigator may  be recorded on the CRF to 
bring them to the attention of the sponsor.
[IP_ADDRESS] Adverse events of special safety interest -amended
For ongoing pharmacovigilance, the large COMPASS trial is an opportunity to identify  rare 
events in the population that may  or may  not be drug -related.  The following events have, to 
date, not been observed with increased frequency with rivaroxaban, but ar e considered AEs of 
special safety  interest. These events must be reported to  independent of their 
seriousness, but within the same timelines as an SAE (within 24 hours) by  [CONTACT_834347]. Bayer HealthCare Pharmacovigilance may decide to upgrade the 
event based on the information received.
Pregnancy  outcome and any  congenital anomaly131
Events currently  under observation by  [CONTACT_834348].  The 
types of events that fall into this category  are listed in Table 7–4.
Events of special interest that are mild or moderate do not nee d to be reported in 
expedited fashion
                                                
131Text deleted as p er Amendment 6. (See Section 13.1.2 )
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
Integrated Clinic al Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 66of 205
Table 7–4.  Adverse events of special interest
System  Organ Class Example
Blood and lymphatic system Pancytopenia, aplastic anemia
Red cell aplasia
Agranulocytosis
Severe leukopeniaSevere neutropeniaSevere t hrom bocytopenia (< 50x 10
9/L)
Thrombotic thrombocytopenic purpura
Immune thrombocytopenic purpura
Heparin -induced thrombocytopenia
Hem olytic anemia
Severe m egaloblastic anemia
Disseminated intravascular coagulation
Skin and subcutaneous disorders Severe exfoliative dermatitis 
Severe b ullous skin reactions
Erythema multiformeStevens Johnson SyndromeToxic epi[INVESTIGATOR_834193] (not otherwise explained e.g. by [CONTACT_626353] -
inhibition)
Allergic vasculitis
Hepatobiliary disorders Hepatic failure (incl. fulminant hepatitis, hepatic necrosis) and associated disorders (like hepatorenal syndrome, encephalopathy)
Severe hepatocellular damage and hepatitis
Jaundice (if unrelated to gallstones)
Gastrointestinal disorders Pancreatitis
Retroperitoneal fibrosis
Pseudomembraneous colitis
Renal and urinary disorders Acute n ephritis (not caused by [CONTACT_80601])
Nephrotic syndrome
Acute renal failure (only if not related to cardiovascular event or 
bleeding)
Nervous system disorders Acute polyneuropathies 
Muscle disorders Rhabdomyolysis
Toxic myopathy
Respi[INVESTIGATOR_834194]’s disease
Eye and ear disorders Acute, sudden vision loss or acute reduced visual acuity (only if not 
related to stroke)Sudden hearing loss
Cardiac disorders Torsades de pointe
[COMPANY_003]
Integrated Clinic al Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 67of 205
[IP_ADDRESS] Non-serious adverse events
With the exception of the events of special interest defined in Section [IP_ADDRESS] , AEs which are 
not serious but which lead to permanent discontinuation of study  medication will be captured 
in the CRF but do not require expedited reporting.  
Non-serious AEs which do not lead to discontinuation of study  medication will not be 
collected.
[IP_ADDRESS] Pregnancies -amended
The investigator must report to the sponsor an y pregnancy occurring in a study  subject, or in 
the study  subject’s partner, during the subject’s participation in this study .  The report should 
be submitted within the same timelines as an SAE, although a pregnancy  per se is not 
considered an SAE.For a stud y subject, the outcome of the pregnancy should be followed up carefull y, and an y 
outcome of the mother or the child should be reported. Abnormal  pregnancy outcomes (eg, 
spontaneous abortion, stillbirth, and congenital anomaly ) are considered serious adverse 
events and must be reported using the Serious Adverse Event Form.
[ADDRESS_1158499]’s partner, all efforts should be made to obtain similar information on course and 
outcome, subject to the partner’s consent.
For all pregnancy  reports, the forms provided by   [CONTACT_834349].133
7.5.4 Reporting of events to Bayer by  [CONTACT_834350]’ reporting requirements -amended
Adverse events that require expedited reporting described in Sections [IP_ADDRESS], [IP_ADDRESS], and 
7.5.3.5132(protocol -specific adverse event reporting) are to be recorded on the appropria te 
SAE CRF page and are to be forwarded to  within [ADDRESS_1158500] y with regulatory authorities’ reporting requirements. 
7.6 Other procedures and variables
No other procedures will be conducted and no other variables will be explored in this trial.
                                                
132Text modified/added as per Amendment 6. (See Section 13.1.2 )
133Section ‘Data Safety Monitoring Board’ was deleted in Amendment 6. (See Section 13.1.2 )
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
Integrated Clinic al Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 68of 205
7.7 Appropriateness of procedures / measurements
With the exception of routine laboratory  assessments performed at screening, imaging studies 
performed in subjects randomized post CABG, and blood and imaging studies in those 
participating in the COMPASS MIND substudy , no invasive proce dures are planned for this 
study .  All study  visits will be used to collect safety  and outcome data, which are appropriate 
measures for this events -driven trial.  
8. Statistical methods and determination of sample size
8.1 General considerations
General description of the statistical methods is outlined below. A more detailed statistical analysis plan (SAP) will be provided in a separate document.
The core SAP document will provide a more technical and detailed elaboration of the principal features of the planned analyses, e.g. censoring schemes for time -to-event variables. 
The core SAP will be finalized ideally  prior to study  enrollment, at the latest before an y 
substantial information in the trial has accumulated.
Amendments and/or appendices to the core SAP wil l provide more details on the coding 
guidelines, data -handling, and output tables and figures. These SAP associated documents 
will be finalized ideally  [ADDRESS_1158501] of the trial that could influence study  
interpretation. All SAP associated documents will be finalized without knowledge of an y 
emerging results from the trial.Analy ses will be performed using SAS software (SAS I nstitute Inc, Cary , NC , [LOCATION_003]).
8.2 Analysis sets and data scopes
8.2.1 Analysis sets
Intention -to-treat analysis set
The intention- to-treat analy sis set, also termed full anal ysis set in the International Conference 
on Harmonization (ICH) E9 guideline, (31)will include all randomized subjects. 
Safety analysis set (for secondary safety analyses)
The safet y analysis set will include all randomized subjects who received at least one dose of 
study  medication. 
8.2.[ADDRESS_1158502].  For subjects who are unable to attend the Final 
Follow -up Visit within the acceptable closeout time -window (range of dates depending on 
date of announc ement of study  termination), a calendar date will be chosen after which events 
will not be counted for primary  anal ysis before unblinding.  Subjects will be kept in the study  
[COMPANY_003]
Integrated Clinic al Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 69of [ADDRESS_1158503] will be as 
long and complete as possible. 
Additional data scopes for secondary safety analyses
Additional analy ses of safety  outcomes will be based on the safety anal ysis set. Subjects will 
be kept in the study  group to which they  were randomized. The outcom e events will include:
All outcome events observed from randomization until the date of the Final Follow -up 
Visit or a chosen calendar date described above for each subject
All outcome events observed from randomization until 2 days following permanent 
discontinuation of the study  drug (“treatment emergent outcomes” analy sis)
All outcome events observed from randomization up to 30 day s following permanent 
discontinuation of the study  drug
All outcome events observed from randomization during the entire foll ow-up and 
wash -out periods
8.3 Variables –amended
Time (in day s) from randomization to the first occurrence of 
the primary , secondary , tertiary  efficacy  outcomes (except SAGE, MoCA, DSS, and 
EQ5D, and MRU) for the antithrombotic treatment randomization (Sect ions 8.3.1, 
8.3.2, 8.3.3),
the primary  safet y outcome for the antithrombotic treatment randomization 
(Section 8.3.4), and
the outcome for the pantoprazole randomization (Section 8.3.5) 
will be anal yzed as time -to-event variables. 
8.3.1 Primary efficacy outcome
The primary  efficacy  outcome is the composite of the following outcomes :
Myocardial infarction 
Stroke 
Cardiovascular death 
8.3.2 Secondary efficacy outcomes -amended
134The secondary  efficacy  outcomes are (in the following order):
The composite of outcomes ---coronary  heart disease death, my ocardial infarction, 
ischemic stroke, acute limb ischemia
The composite of outcomes ---cardiovascular death, my ocardial infarction, ischemic 
stroke, acute limb isc hemia
                                                
134Text m odified/added as per Amendments 6 and 8. (See Sections 13.1.2 and 13.2.2 )
[COMPANY_003]
Integrated Clinic al Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 70of 205
Mortality  (all-cause)
8.3.3 Tertiary and other efficacy outcomes -amended
The tertiary  efficacy  outcomes are:
Subject -reported SAGE, MoCA, DSS, and EQ -5D
Individual components of the primary  and secondary  outcomes
Hospi[INVESTIGATOR_834195]135
Hospi[INVESTIGATOR_059]
Revascularization135
Amputation136
Stent thrombosis134
Unstable angina 
Worsening angina 
New angina 
Heart failure 
Venous thromboembolism135
Resuscitated cardiac arrest
New diagnosis of cancer
MRU
Coronary  artery  by[CONTACT_541649]137
8.3.4 Primary safety outcome
The primary  safet y outcome is modified I STH major bleeding, defined as:
fatal bleeding, and/or 
symptomatic bleeding in a critical area or organ, such as intracranial, intraspi[INVESTIGATOR_1304], 
intraocular, retroperitoneal, intraarticular or pericardial, or intramuscular with 
compartment s yndrome, or bleeding into the surgical site requiring reoperation, and/or
bleeding leading to hospi[INVESTIGATOR_059]
8.3.5 Outcome for pantoprazole randomization - amended
The outcome for the pantoprazole randomization is the composite of the following outcomes: 
Overt bleeding of gastroduodenal origin confirmed by  [CONTACT_834351]  
Overt upper gastrointestinal bleeding of unknown origin 
                                                
135Added as per Amendment 8.  (See Section 13.2.2 )
136Text deleted as per Amendment 6. (See Section 13.1.2 )
137Text modified as per Amendment 6. (See Section 13.1.2 )
[COMPANY_003]
Integrated Clinic al Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 71of 205
Bleeding of presumed occult gastrointestinal origin with docu mented decrease in H b 
of 2g/dL138
Symptomatic gastroduodenal ulcer 
Gastrointestinal pain with underlying multiple gastroduodenal erosions, obstruction or 
perforation
8.3.[ADDRESS_1158504] will be examined for the following subgroup varia bles:
CAD137(yes, no)
PAD137(yes, no)
CAD and PAD (yes, no)
CAD only , PAD onl y, CAD and PAD 
CABG days 4-7 before randomization137(yes, no)
Any prior CABG (y es, no), further subdivided as CABG days 4-7 before 
randomization and other prior CABG139   
Region (North America, Western Europe, Eastern Europe, Asia Pacific and o ther, and 
South America)
History  of a prior heart failure (y es, no)
History  of non -lacunar ischemic stroke ≥1 months ago (y es, no)
Sex (male, female)
Age (<55, 55 -<65, 65 - 75, >75 y ears)
Race (White or Caucasian, Black or African American, Asian, other)
Baseline renal function (estimated glomerular filtration rate <60, ≥60mL/min)
Baseline diabetes (y es, no)
Smoking status at baseline (smoker, nonsmoker)
Baseline PPI [CONTACT_3225] (y es, no)
Additional subgroup variables, if identified, will be specified in the SAP prior to unblinding 
of the treatment assignment.
8.[ADDRESS_1158505] deviation, minimum, and maximum will be used to summarize continuous variables. 
Counts and percentages will be used to summarize categorical variables.
Testing strategy140
                                                
138Text deleted as per Amendment 6. (See Section 13.1.2 )
139Bullet was added as per Amendment 8.  (See Section 13.2.2 )
[COMPANY_003]
Integrated Clinic al Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 72of [ADDRESS_1158506] be compared to the common aspi[INVESTIGATOR_834196], followed by  [CONTACT_834352].  Figure 8–[ADDRESS_1158507] logical restrictions 
will be imposed, i.e., the null hypotheses will be split into two branches corresponding to the 
tests for rivaroxaban 2.5 mg plus aspi[INVESTIGATOR_248] (h ypotheses H 1A, H2A, H3A, H4A) and to the tests for 
rivaroxaban 5.0 mg (h ypotheses H 1B, H2B, H3B, H4B).  A null hy pothesis within each branch 
can be tested if and onl y if the immediately  preceding null hy pothesis is rejected, e.g., 
hypothesis H 2A, is “testable” if and onl y if h ypothesis H 1Ais rejected. In Figure 8–1, these 
logical restrictions are represented b y arrows.
Figure 8–1: Hypothesis testing problem
Multiple hy potheses testing will be performed according to a mixture gatekeepi[INVESTIGATOR_834197] a truncation fraction of γ= 0.9, which controls the 
family wise error rate at the pre -assigned level of significance α= 5% in the strong sense.  The 
Hochberg- based gatekeepi[INVESTIGATOR_834198] ( 33,34) was recentl y proposed in 
Brechenmacher et al . (32)  Details for the setting of this study  will be described in the SAP.  
8.4.1 Analysis of the primary efficacy outcome - amended
Analy sis of the primary  efficacy  outcome will be based on the intention -to-treat principle 
(Section 8.2).  Two comparisons will be performed to compare each of the rivaroxaban- based 
treatment groups to the common aspi[INVESTIGATOR_834199]:
Superiority  of rivaroxaban 2.5 mg bid + aspi[INVESTIGATOR_248] 100 mg od over 
rivaroxaban placebo + aspi[INVESTIGATOR_248] 100 mg od (control)
                                                                                                                                                        
140Testing strategy tex t added as per Amendment 8.  (See Section 13.2.2 )
[COMPANY_003]
Integrated Clinic al Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 73of 205
Superiority  of rivaroxaban 5 mg bid + asp irin placebo over 
rivaroxaban placebo + aspi[INVESTIGATOR_248] 100 mg od (control).
Each of the primary  null hy potheses H 0;riva2.5 and H 0;riva5 stating that “there is no difference 
between the considered rivaroxaban-based treatment group and the aspi[INVESTIGATOR_834200]” will be tested against the 
respective alternative h ypotheses H 1;riva2.5 and H 1;riva5 stating that “there is a difference 
between the two groups in the probability  of the primary  efficacy outcome for at least one 
time point”.
The [ADDRESS_1158508] with 
the pre -specified truncation parameter γ = 0.9 at =0.05 will be used. Further details will be 
described in the SAP.  P PI[CONTACT_3225] (3 strata levels: not randomized to a PPI ; pantoprazole 40 mg 
od; pantoprazole placebo) will be used as a stratification factor.  Study  center will not be used 
as a stratification factor.  There will be no formal comparison between the rivaroxaban 2.5 mg 
bid + aspi[INVESTIGATOR_248] 100 mg od and rivaro xaban 5 mg bid + aspi[INVESTIGATOR_834201].[ADDRESS_1158509] functions will be provided 
to evaluate the timing of event occurrence in the 3 antithrombotic study  groups and the 
consistency  of the respective treatment effects for all time points (the two survival curves in 
each comparison do not cross). Hazard ratio, relative risk reduction, and corresponding 2- sided 95% confidence intervals will 
be estimated based on [ADDRESS_1158510] ratio, (33)and by  [INVESTIGATOR_3086] a time -treatment interaction 
term in the Cox model (time log transformed).  The significance of the interaction will be 
tested at the 5% t ype I error level. If the interaction is significant and there is stron g evidence 
of non- proportionalit y from the plots, time -dependent hazard ratios will be estimated with the 
model that includes the interaction term.  Further details will be specified in SAP.
The trial success will be determined based on the totality  of evi dence for significance, 
magnitude, and direction of treatment effect from the anal ysis of primary  and secondary  
efficacy  outcomes. 
[ADDRESS_1158511] and/or interaction between rivaroxaban- based anti- thrombotic 
therap y and PPI[INVESTIGATOR_834202] 8.4.5.  Further details of this analy sis will be specified in SAP.
                                                
141Paragraph w as revised as per Amendment 8.  (See Section 13.2.2 )
142Text w as deleted from this paragraph as per Amendment 8.  (See Section 13.2.2 )
[COMPANY_003]
Integrated Clinic al Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 74of 205
8.4.2 Analysis of the secondary efficacy outcomes -amended
Analy sis of the secondary  efficacy  outcomes will be based on the intention -to-treat principle 
(Section 8.2) and will use a similar approach as described in Section 8.4.1. The famil y-wise 
error rate will be controlled using the truncated and/or regular Hochberg tests as described in 
Section 8.4and more detailed in the SAP.143
8.4.3 Analysis of the tertiary efficacy outcomes
Analy sis of the terti ary efficacy  outcomes will be based on the intention- to-treat principle 
(Section 8.2) and will use a similar approach as described in Section 8.4.1 (except for SAGE, 
MoCA, DSS, and EQ5D).  Analy sis of subject reported SAGE, MoCA, DSS, and EQ5D will 
be described in the SAP. Both comparison s of the rivaroxaban- based treatment groups to the 
common aspi[INVESTIGATOR_834203] 2- sided 5% t ype I error level.  
Additional exploratory  analy ses will be conducted, as described in the SAP.
The MRU data will be incorporated into econ omic modeling, which will be performed and 
reported separatel y from this study . 
8.4.4 Analysis of the primary safety outcome
The principal anal ysis of the primary  safet y outcome will be based on the intention -to-treat 
principle (Section 8.2). The anal ysis will follow similar methodology  as the anal ysis of the 
primary  efficacy  outcome described in Section 8.4.1.
In addition, the primary  safet y outcome will be analy zed based on the other data scopes 
defined in Section 8.2.2.  
8.4.5 Analysis of the outcome for pantoprazole randomization -amended
Analy sis of the outcome for pantoprazole randomization will be based on the intention -to-
treat principle (Section 8.2) and will include all subjects randomized to receive pantoprazole 
40mg od or pantoprazole placebo.
Pantoprazole 40 mg od treatment group and pantoprazole placebo control group will be 
compared. The null hy pothesis H 0;panto40 stating that “there is no difference between the 
pantoprazole treatment and control groups in the probability  of the outcome144for 
pantoprazole randomization for all time points” will be tested against the alternative hypothesis H
1;panto40 stating that “there is a difference between the two groups in the 
probability  of the outcome144for at least one time point”.
The comparison will be performed using a log- rank test stratified by  [CONTACT_834353] (3 strata levels: rivaroxaban 2.5 mg bid + aspi[INVESTIGATOR_248] 100 mgod; rivaroxaban 5 mg 
bid + aspi[INVESTIGATOR_397629] ; rivaroxaban placebo + aspi[INVESTIGATOR_248] 100 mg od), conducted at the 2 -sided 5% 
type I error level. There will be no interim analy ses for the pantoprazole randomization.
Kaplan -Meier estimates of cumulative risk and cumulative hazard functions will be provided 
to evaluate the timing of event occurrence in the [ADDRESS_1158512] for all time points (the 2 survival curves do not cross).
                                                
143Paragraph w as revised as per Amendment 8.  (See Section 13.2.2 )
144Text deleted as per Amendment 6. (See Section 13.1.2 )
[COMPANY_003]
Integrated Clinic al Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 75of [ADDRESS_1158513] ratio, relative risk reduction, and co rresponding 2- sided 95% confidence intervals will 
be estimated based on a Cox proportional hazards model stratified by  [CONTACT_834353].  Censoring will be assumed independent of the treatment group assignment. 
Similar strategies to those outlined in Section 8.4.[ADDRESS_1158514] and interac tion between the antithrombotic and pantoprazole study  
groups will be explored based on the intention- to-treat principle in subjects randomized to 
receive pantoprazole 40 mg od or pantoprazole placebo.  The anal ysis will use 2 separate Cox 
proportional haz ards models, one for the comparison of rivaroxaban 2.5 mg bid + aspi[INVESTIGATOR_248] 
100mg od vs. rivaroxaban placebo + aspi[INVESTIGATOR_248] 100 mg od, and one for the comparison of 
rivaroxaban 5 mg bid + aspi[INVESTIGATOR_834204]. rivaroxaban placebo + aspi[INVESTIGATOR_248] 100 mg od.  The 
models wil l include:
a covariate for the effect of the considered rivaroxaban -based treatment group vs. the 
aspi[INVESTIGATOR_834205],
a covariate for the effect of pantoprazole 40 mg od treatment group vs. pantoprazole 
placebo control group,
an interaction term of these 2 factors.
If the interaction term is significant at the 5% t ype I  error level, then the interaction ratio test
(36)will be performed to assess sy nergy  and sub -additivity  of the two treatment effects.  
Additional exploratory  analy ses, e.g. a comparison of subjects who used PPI [INVESTIGATOR_182914] (and 
therefore were not randomized to receive pantoprazole 40 mg od or pantoprazole placebo) 
with subjects randomized to pantoprazole placebo group, will be conducted as described in 
the SAP.
8.4.6 Subgroup analyses -amended
Subgroup anal yses for the primary  efficacy  and safety  outcomes, and the outcome145for 
pantoprazole randomization will be performed based on the same anal ysis sets and data 
scopes as in the main analy ses of the study  outcomes (Sections 8.4.1, 8.4.2, 8.4.3, 8.4.4, and 
8.4.5). Homogeneity  of treatment eff ect in subgroups, both in magnitude and direction, will be 
assessed b y adding a covariate for the subgroup variable (Section 8.3.6) and the correspo nding 
treatment -subgroup interaction to the respective stratified Cox proportional hazards model 
used in the main anal ysis.  Cox proportional hazards regression model (not stratified) will be 
used for baseline PPI[CONTACT_3225] (y es, no) variable.
As the number of s ubgroup anal yses may  be large, the probability  of observing at least one 
statistically  significant but spurious interaction is high despi[INVESTIGATOR_1851] a biological or 
pharmacological basis for expecting an interaction.  Thus any  significant interactions in the 
analysis of primary  outcomes will be interpreted as “flags” to prompt further investigation.
                                                
145Text deleted as per Amendment 6. (See Section 13.1.2 )
[COMPANY_003]
Integrated Clinic al Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 76of 205
No interactions with an y of the subgroup variables are expected.  If the interaction term is 
significant at the 5% t ype I  error level in the anal ysis of the primary  efficacy  outcome, 
secondary  and tertiary  efficacy  outcomes will be investigated to evaluate the plausibility  of 
such an effect.  Furthermore, in the anal ysis of all outcomes if the interaction term is 
significant at the 5% t ype I  error level the li kelihood ratio test proposed by  [CONTACT_834354] (37)will be performed to test the hy pothesis that there is no crossover or qualitative 
interaction at the 1% t ype I error level (H 0: The direction of treatment effect is the same for all 
levels of a subgroup variable vs. H 1:  The direction of treatment effect is different for at least 
one level of a subgroup variable).  As was shown by  [CONTACT_451401] (2007),( 38)the probability  of 
observing the treatment effect in the opposite direction to the true overall treatment effect for 
at least one subgroup level is not negligible. The contributing factors may  be small subgroup 
sizes, imbalance of randomized groups within the subgroups, and small true overall treatment effect.( 38)
Following the test of interaction, hazard ratio and relative risk red uction for the treatment 
effect will be estimated separately  within each level of a subgroup variable using the stratified 
Cox proportional hazards models that were used in the main anal yses of study  outcomes.
8.4.[ADDRESS_1158515] when information about the event was known.  This method for date estimation has been used in many  studies and is recommended b y Dubois and Hebert
(2001). (39)
8.4.8 Long-Term Open -Label Extension –amended146
All primary , secondary , tertiary  efficacy  outcomes and safet y outcomes will be summarized 
using frequency  table in a descriptive way . Further details will be included in a separate SAP .
The same subgroup variables as in the COMPASS trial will apply  to LTOLE.
                                                
146Text added as per Amendment 11. (See Section 13.3.1 )
[COMPANY_003]
Integrated Clinic al Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 77of [ADDRESS_1158516], will perform interim data analy ses 
to support the DSMB.
Two formal interim analys es are planned when 50% and 75% of the expected number of 
accumulated primary  efficacy  outcome events accrue. 
If the interim anal yses show clear and consistent benefit in both treatment arms, the DSMB 
may recommend earl y study  termination.  The Hay bittle -Peto rule will be used to guide the 
decision regarding early  stoppi[INVESTIGATOR_007]:  a reduction of [ADDRESS_1158517] is not temporary .
For a lack of efficacy , a futility  approac h will be utilized at the time of planned interim 
analysis. If the conditional probability of rejecting the null hy pothesis for either primary  
comparisons, given current trends, falls to an unacceptabl y low level (i.e. <5%), the DSMB 
may consider recommend ing earl y termination of the study.
Given these conservative monitoring boundaries and only  2 interim anal yses, the ty pe I error 
level adjustment for the final anal ysis will be negligible.  If the results are clear with one 
intervention, but not for the se cond intervention, the DSMB may decide to continue 
evaluation of both or one rivaroxaban treatment arms.  I f the study  is continued with both 
interventions, then the type I error levels specified in Section 8.4.1 will be used in the final 
analysis; if the decision is made to continue with only  one intervention, the final comparison 
will be made as follows: 147
If one intervention was stopped earl y for efficacy , the multiple testing procedure for 
the final anal ysis will be performed as described in Section 8.4with the assumption 
that the p -value fo r the primary  efficacy  outcome of the arm that was stopped earl y for 
overwhelming efficacy  is smaller than 0.025. For secondary  outcomes, the p -values 
will be obtained from log-rank tests based on all available data for the stopped arm 
(data from confirmat ion anal ysis 6 months after respective interim look) and the 
complete data from the comparator arm.
If one intervention was stopped earl y for futility , the final anal ysis will be performed 
when at least 1,513148subjects in the [ADDRESS_1158518] experie nced an event.
                                                
147The details in the bulleted paragraphs were added as per Amendment 8.  (See Section 13.2.2 )
148The whole study was planned to be stopped when at least 2,[ADDRESS_1158519] 826 + 687 = 1,[ADDRESS_1158520] experienced a primary event.
[COMPANY_003]
[COMPANY_003]
Integrated Clinic al Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 78of 205
The final analy sis will be performed according to the multiple testing strategy  as 
described in Section 8.4. P- values for the primar y and secondary  hypotheses for the 
intervention stopped early will be obtained from the log- rank tests based on all 
available data for the stopped arm and the complete data from the comparator arm. It 
can be assumed that for the stopped intervention the co rresponding p-value of the 
primary  efficacy  outcome will be greater than 0.05. Thus, for the intervention stopped 
early for futility  the primary  and none of the secondary  outcomes can achieve 
statistical significance at the overall t ype I error level of 5% .
The Steering C ommittee will review overall blinded event rates to ensure that they  meet 
protocol projections.  If overall event rates are lower than expected, consideration will be given to increasing the sample size or extending the study  duration without knowledge of any  
treatment effect.  The trial will aim to enroll about one -quarter
149subjects with PAD ; this will 
be monitored during the trial and steps may  be taken to adjust the proportion during the trial.
8.[ADDRESS_1158521] 90% power to detect a 20% relative risk red uction (RRR) for 
each of the 2 rivaroxaban -based treatment groups vs. the common aspi[INVESTIGATOR_834205].  The 
total number of events needed is shown in Table 8–1for different scenarios depending on the 
assumed annual incidence rate for the primary  outcome in the aspi[INVESTIGATOR_834206] 6 (integrated protocol Version 2.0), dated 03JUL 2014.  Due to the event- driven stud y design, the number of randomized subjects, 
length of enrollment and total study  duration may  vary .  If recruitment is going extremel y 
well, a larger number of subjects may  be recruited.  All numbers below refer to the minimum 
number of event s to be observed after successful completion of the run -in period.  For the 
total number of subjects to be enrolled in the run -in period, at least 10% must be added to the 
total number below.
Original a ssumptions for antithrombotic treatment randomization were:
3-arm stud y with 1:1:1 randomization
In total, a minimum of 21,400 subjects are randomized ( approximately  7,134 subjects 
per treatment group) according to a 1:2:3:4:4 pattern within 2.5 y ears
2-sided ty pe I error level of 2.7% for each of the two comparisons to control the 
overall ty pe I error level of 5%
Constant annual incidence rate in aspi[INVESTIGATOR_834207] 3.0% and 4.0%
Effect size: 20% relative risk reduction to be detected for each comparison
                                                
149Prior to Amendment 8, this was one -third subjects w ith PAD.
150This section was revised as per Amendments 6 and 8.  (See Sections 13.1.2 and 13.2.2 )
[COMPANY_003]
Integrated Clinic al Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 79of 205
Intention- to-treat anal ysis: all subjects randomized are included in the analysis as 
randomized and the follow -up period for each subject is as long as possible from 
randomization until the date of the Final Follow -up Visit for each subject
Length of recruitment period about 2.5 y ears 
Early disco ntinuation of study  drug: about 6% and 4% in the 1st and 2nd 6 -month 
periods, and 3% in the 6 -month periods thereafter
The expected total number of observed events and the estimated power for each of the two 
comparisons are display ed in Table 8–1. 
Table 8–1.  Events calculations
Assu med annual 
incidence rate in 
aspi[INVESTIGATOR_834208] (years)Estimated power for one 
comparisonExpected total number 
of events
3.0% 4.5 85.1% 1,642
5.0 89.2% 1,909
3.5% 4.5 90.2% 1,907
5.0 93.4% 2,215
4.0% 4.5 93.7% 2,171
5.0 96.0% 2,[ADDRESS_1158522] a true relative risk reduction of 20% in each of the rivaroxaban arms with at least 90% power, it was planned to randomize at least 21,[ADDRESS_1158523] 50 subjects.
The originally planned sample size of 21,400 and 5 y ear study  duration was based on an 
annual primary  incidence rate in the control group of 3.5% and 90% power to detect a relative 
risk reduction of 20% in each of the rivaroxaban arms. Based on an observed incidence rate of 
2.9% as of July 2015, it is now planned to randomize at least 27,400
151subjects. This new 
sample size will maintain current stud y timelines and 90% power to detect a 20% relative risk 
reduction in each of the rivaroxaban arms, based on the following revisions to the original assumptions:  
Overall length of recruitment period about 3 to 3.5 y ears and taking observed 
randomization times up to July  2015 into account
2-sided overall t ype I error level of 5% using a truncated Hochberg test (γ = 0.9) for 
the testing of the two primary  hypotheses
Constant overall incidence rate of about 2.9% per y ear, resulting in a constant 
incidence rate of about 3.3% per year for the aspi[INVESTIGATOR_834209] a 20% 
relative risk reduction for both hy potheses
Censoring due to non -CV death at an event rate of almost 1% per year
                                                
151Text modified as per Amendment 6. (See Section 13.1.2 )
[COMPANY_003]
Integrated Clinic al Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 80of 205
Assumptions for pantoprazole randomization are: 
Annual incidence rate for major upper gastrointestinal complications (overt or occult 
bleeding, s ymptomatic gastroduodenal ulcers or erosions, obstruction or perforation) 
in the range of 1.6% to 2.2%
At least 16,440 subjects included in the study  are not PPI[INVESTIGATOR_834210] 1:1 ratio
2-sided ty pe I error level of 5%
Effect size: 50% relative risk reduction to be detected
Intention- to-treat anal ysis: all su bjects randomized are included in the analysis as 
randomized and the follow -up period for each subject is as long as possible from 
randomization until the date of the Final Follow -up Visit for each subject
Under these assumptions, the expected total number of major upper gastrointestinal 
complications is between 570 and 780, depending on the observed event rates and the total 
study  duration. The estimated power for the detection of the true relative risk reduction of 
about 50% for major upper gastrointestin al complications for pantoprazole 40 mg od vs. 
pantoprazole placebo is close to 100% for all scenarios considered.
Sample size estimation was based on the method by [CONTACT_834355] (40)implemented in P ower 
Analy sis and Sample Size (PASS) software, version 11.0.7, and on a Statistical Anal ysis 
System (SAS)macro provided by  J. Shih (1995).( 41)  In addition, simulations were 
performed to confirm that the mixture gatekeepi[INVESTIGATOR_834211] 8.4for 
the anal ysis of the primary efficacy  outcome keeps the overall t ype I error level of 5%.  SAS 
calculations and simulations were performed using SAS software, version 9.2 (SAS I nstitute 
Inc, Cary , NC, [LOCATION_003]).
9. Data handling and quality assurance
9.[ADDRESS_1158524] the site prior to the start of the study  to 
review with the site staff the protocol, study  requirements, and their responsibilities to satisfy  
regulatory , ethical, and sponsor’s requirements.  When reviewing data collection procedures, 
the discussion will also include identification and documentation of source data items. 
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
Integrated Clinic al Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 81of [ADDRESS_1158525] been conducted as described in this protocol and to 
ensure the validity  of the study  results.  Study  monitors will follow the Site Management 
Coordination Plan to verify that: 
Data are authentic, accurate and complete 
Safety  and rights of subjects are being protected 
Study  is conducted in accordance with the currently  approved protocol (including 
study  treatment being used in accordance with the protocol)
Any other study  agreements, GCP, and all applicable regulatory  requireme nts are met 
Monitoring will encompass a variet y of methods at the central, national, and site levels; 
incorporate central data verification, national event verification, and local site monitoring; 
focus on key  aspects of the study ; and involve multiple levels of oversight to enable rapid and 
efficient identification and correction of issues that arise. Both the NL and  will perform 
central monitoring with close communication between  the NL, the Sponsor, and the sites. Additionally , the NL  will also oversee focused on- site monitoring visits to maintain the 
quality  and integrit y of the data. Signed informed consent will be verified to ensure that 
consent has been obtained and a sample of the cases will be reviewed to ensure that study  
procedures have been followed. 
The investigator and the head of the medical institution (where applicable) agrees to allow the monitor , auditors, and inspectors direct access to all relevant documents.
Long -Term Open -Label Extension –amended
The same details will apply  toLTOLE. An y specific considerations for LTOL E will be 
detailed in the Site Management Coordination Plan.
152
9.3 Data processing –amended
Data that may  be directl y recorded on the CRFs (ie., no prior written or electronic record of 
data) and can be considered to be source data are: 
Medical history  (excluding eligibility  criteria)
Adherence
Demographic data
Vital signs
Anthropometric measure ments
                                                
152Text added as per Amendment 11. (See Section 13.3.1 )
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
Integrated Clinic al Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 82of 205
Concomitant medications
Visit attendance153
Pi[INVESTIGATOR_10685]
Dietary  and exercise assessment
SAGE questionnaire responses
Adverse events
All other data entered into the CRFs (including all data associated with the primary  endpoints 
for the rivaroxaban and p antoprazole randomizations, as well as SAEs) must be supported by  
[CONTACT_834356], or at a later time following the visit.  
The CRFs and iDataFax software w ill be provided for each participating center along with the 
study  aids. Some sites will complete a paper CRF (instead of the electronic CRF) and submit 
the data to  by [CONTACT_834357].  At each subject visit, the investigator or research nurse 
will submit the data to  for data management.
Clinical data management will be performed in accordance with agreed standards and data 
cleaning procedures.  This is applicable for data recorded on CRF as well as for data from other sources (e.g., the  randomization and drug management s ystem, laboratory , events 
committees).
For data coding (e.g., AEs, medication), internationally  recognized and accepted dictionaries 
will be used.
9.4 Audit and inspection
To ensure compliance with GCP and regulatory  requiremen ts, a member of the sponsor’s QA
department may  arrange to conduct an audit to assess the performance of the study  at the 
study  site and of the study  documents originating there.  A representative from the  QA
department may  join the audit. The investi gator/institution will be informed of the audit 
outcome.  In addition to sponsor audits, with prior agreement from the sponsor,  may  
choose to also conduct audits and will coordinate with the sponsor to select appropriate sites 
for audit. 
In addition, inspections by  [CONTACT_834358] /institutional review boards (IECs/IRBs) are possible.  The investigator should 
notify   (or sponsor) immediately  of any  such inspection.  The Investigator/inst itution 
agrees to allow the auditor or inspector direct access to all relevant documents and allocate 
his/her time and the time of his/her staff to the auditor/inspector to discuss findings and an y 
issues.  Audits and inspections may  occur at any  time duri ng or after completion of the study .  
The investigator/institution will permit study -related monitoring, audits, I EC/IRB review, and 
regulatory  inspection, providing direct access to all related source data/documents.  Case 
report forms and all source docu ments, including informed consent forms and copi[INVESTIGATOR_1309] 
                                                
153Added w ith Amendment 8.  ( See Section 13.2.2 )
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
Integrated Clinic al Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 83of [ADDRESS_1158526] that ensures that they  
are readil y available upon authorities’ request.
The confidentialit y of all subjects will be protected at both the local centers and at  and 
Bayer.  Data at  will be kept secure during th e study , and for the time that is required by  
[CONTACT_834359] .  A duplicate cop y of the data will be stored 
securel y in a bank vault.  At the end of the stud y, a cop y of the data will be provided to the 
sponsor.
The investigator site file is not to be destroy ed without  and the sponsor’s approval.
The contract with the investigator/institution will contain all regulations relevant for the stud y 
center.
10. Premature termination of the study
The sponsor has the right to close this study  (or, if applicable, individual segments thereof 
[e.g. treatment arms; dose steps; centers]) at any  time for the following reasons: 
If risk- benefit ratio becomes unacceptable owing to, for example,
-Safety  findings from this study  (e.g. SAEs)
-Results of any  interim analy sis
-Results of parallel clinical studies
-Results of parallel animal studies 
(on e.g. toxicity , teratogenicity , carcinogenicity  or reproduction toxicity ).
If the study conduct (e.g. recruitment ra te; drop-out rate; data qualit y; protocol 
compliance) does not suggest a proper completion of the trial within a reasonable time frame as agreed upon b y the Steering Committee.
Long-Term Open -Label Extension –amended
The same premature termination reasons will apply  to LTOLE with the exception of the
interim analy sis.
[ADDRESS_1158527], evaluation, and documentation of this study , are designed to ensure that the sponsor and investigator abide by  
                                                
154Text added as per Amendment 11. (See Section 13.3.1 )
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
Integrated Clinic al Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 84of 205
GCP guidelines and under the guiding principles detailed in the Declaration of Helsinki.  The 
study  will also be carried out in keepi[INVESTIGATOR_39684](s) and regulation(s).
Documented approva l from appropriate IECs/IRBs will be obtained for all participating 
centers/countries before start of the study, according to GCP, local laws, regulations and organizations.  When necessary , an extension, amendment or renewal of the I EC/IRB 
approval must b e obtained and also forwarded to the Sponsor.  The responsible unit (e.g. 
IEC/IRB, head of the study center/medical institution) must supply to the Sponsor, upon request, a list of the IEC/IRB members involved in the vote and a statement to confirm that the IEC/I RB is organized and operates according to GCP and applicable laws and regulations.
Strict adherence to all specifications laid down in this protocol is required for all aspects of study  conduct; the investigator may  not modify  or alter the procedure s described in this 
protocol.  
Modifications to the study  protocol will not be implemented by  [CONTACT_834360] b y both parties.  However,  and the sponsor may  implement a 
deviation from, or a change of, the protocol to elim inate an immediate hazard(s) to the trial 
subjects without prior IEC/I RB/sponsor approval/favorable opi[INVESTIGATOR_1649].  As soon as possible, the 
implemented deviation or change, the reasons for it and if appropriate the proposed protocol 
amendment should be submitte d to the I EC/I RB/head of medical institution/sponsor.  Any  
deviations from the protocol must be explained and documented b y the investigator.
Details on discontinuation of the entire stud y or parts thereof can be found in Section 10.
11.[ADDRESS_1158528] / legal representative or proxy  consenter (if the subject is 
under legal protection), prior to his/her entry  into the study  (i.e. before an y examinations and 
procedures associated with the selection for the study  are performed or an y study-specific data 
are recorded on stud y-specific forms).
The investigator will also mention that written approval of the IEC/IRB has been obtained.
Each subject / legal representative or prox y consenter will have ample time and opportunity  to 
ask questions and will be informed about the right to withdraw from the study  at any  time 
without any  disadvantage and without having to provide reasons for this decision.
Only  if the subject / legal representative or proxy  consenter voluntaril y agrees to sign the 
informed consent form and has done so, may  he/she enter the stud y.  Additionally , the 
investigator and other information provider (if an y) will personally sign and date the form.  
The subject / legal representative or prox y consenter will receive a copy  of the signed and 
dated form.
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
Integrated Clinic al Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 85of [ADDRESS_1158529]’s note/file of the medical institution.   Any  other handling and storage 
of the signed informed consent statemen t will be detailed in the ICF.
The informed consent form and any other written information provided to subjects / legal 
representatives or prox y consenters will be revised whenever important new information 
becomes available that may  be relevant to the sub ject’s consent, or there is an amendment to 
the protocol that necessitates a change to the content of the subject information and / or the written informed consent form.  The investigator will inform the subject / legal representative or prox y consenter of changes in a timel y manner and will ask the subject to confirm his/her 
participation in the study  by [CONTACT_23667].  Any  revised written 
informed consent form and written information must receive the IEC/I RB`s approval / 
favora ble opi[INVESTIGATOR_19349].
Long -Term Open -Label Extension − amended
Documented i nformed consent will be required for the LTOLE.
[ADDRESS_1158530] made substantial and sustained contributions and will be on behalf of the whole study  group.
11.4 Compensation for health damage of subjects / insurance
The sponsor maintains clinical trial insurance coverage for this study  in accordance with the 
laws and regulations of the country  in which the study  is performed.
11.[ADDRESS_1158531] will be kept confidential and, t o the extent permitted by  [CONTACT_3999]/or regulations, will not be made publicly  available.
Only  the subject number and patient initials or ‘dummy ’ initials will be recorded in the CRF, 
and all efforts will be made to obliterate subject names th at appears on an y other document 
(e.g. pathologist report), before a cop y of the document is supplied to  or the sponsor.  
Study  findings stored on a computer will be stored in accordance with local data protection 
laws.  As part of the informed consen t process, the subjects will be informed in writing that 
 representatives of the sponsor, IEC/I RB, or regulatory  authorities may  inspect their 
medical records to verify the information collected, and that all personal information made 
                                                
155Text added as per Amendment 11. (See Section 13.3.1 )
156Text added as per Amendment 6. (See Section 13.1.2 )
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
Integrated Clinic al Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 86of [ADDRESS_1158532]’s identity  will remain confidential.
The investigator will maintain a list to enable subjects to be i dentified.
[COMPANY_003]
Integrated Clinic al Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 87of [ADDRESS_1158533] sheet: Cardiovascular diseases (CVDs): World Health Organization; 2013. 
Available from http://www.who.int/mediacentre/factsheets/fs317/en/157
2. WHO. The global burden of disease: 2004 update. Geneva: World Health 
Organi zation; 2008b.157
3. Hirsch AT, Criqui MH, Treat -Jacobson D, Regensteiner JG, Creager MA, Olin JW et 
al. Peripheral arterial disease detection, awaren ess, and treatment in primary  care. 
JAMA 2001 September 19;286(11):1317-24.
4. Hankey  GJ, Norman PE, Eikelboom JW. Medical treatment of peripheral arterial 
disease. JAMA 2006 February  1;295(5):547 -53.
5. Belch JJ, Topol EJ, Agnelli G, Bertrand M, Califf RM, Clement DL  et al. Critical 
issues in peripheral arterial disease detection and management: a call to action. Arch 
Intern Med 2003 April 28;163(8):884-92.
6. Turpie AG, Lassen MR, Eriksson BI, Gent M, Berkowitz SD, Misselwitz F et al. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplast y. Pooled analysis of four studies. Thromb Haemost 2011 
March;105(3):444 -53.
7. Buller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E et al. Oral rivaroxaban for the treatment of sy mptoma tic pulmonary  embolism. N Engl J Med 
2012 April 5;366(14):1287-97.
8. Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS et al. Oral rivaroxaban for s ymptomatic venous thromboembolism. N Engl J Med 2010 
December 23;363(26):2499-510.
9. Patel MR, Mahaffey  KW, Garg J, Pan G, Singer DE, Hacke W et al. Rivaroxaban 
versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011 September 8;365(10):883 -91.
10. Mega J L, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C et al. 
Rivaroxaban in pa tients with a recent acute coronary  syndrome. N Engl J Med 2012 
January  5;366(1):9 -19.
11. Collaborative meta -analysis of randomised trials of antiplatelet therap y for prevention 
of death, m yocardial infarction, and stroke in high risk patients. BMJ 2002 Janua ry 
12;324(7329):71-86.
12. Alexander JH, Hafley  G, Harrington RA, Peterson ED, Ferguson TB, Jr., Lorenz TJ 
et al. Efficacy  and safet y of edifoligide, an E2F transcription factor deco y, for 
prevention of vein graft failure following coronary artery  by[CONTACT_10956] : 
PREVENT IV: a randomized controlled trial. JAMA 2005 November 16;294(19):2446-54.
                                                
157Reference modified as per Amendment 6. (See Section 13.1.2 )
[COMPANY_003]
Integrated Clinic al Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 88of 205
13. A randomised, blinded, trial of clopi[INVESTIGATOR_834212] (CAPRIE). CAPRI E Steering Committee. L ancet 1996 November 
16;348( 9038):1329-39.
14. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of 
clopi[INVESTIGATOR_834213]-segment elevation. N Engl J Med [ADDRESS_1158534] 16;345(7):494-502.
15. Wallentin L , Beck er RC, Budaj A, Cannon CP, Emanuelsson H, Held C et al. 
Ticagrelor versus clopi[INVESTIGATOR_834214]. N Engl J 
Med 2009 September 10;361(11):1045-57.
16. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzy llo W, Gottlieb S et al.
Prasugrel versus clopi[INVESTIGATOR_834214]. N Engl J 
Med 2007 November 15;357(20):2001 -15.
17. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE et al. Clopi[INVESTIGATOR_834215]. N Engl 
J Med 2006 April 20;354(16):1706 -17.
18. Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalb y AJ, Fish MP et al. 
Vorapaxar in the secondary  prevention of atherothrombotic events. N Engl J Med 
2012 April 12;366(15):1404-13.
19. Anand SS, Yusuf S. Oral anticoagulants in patients with coronary  artery  disease. J 
Am Coll Cardiol 2003 February  19;41([ADDRESS_1158535] S):62S -9S.
20. Andreotti F, Testa L, Biondi -Zoccai GG, Crea F. Aspi[INVESTIGATOR_834216]: an updated and comprehensive meta -
analysis of 25,307 patients. Eur Heart J 2006 March;27(5):519-26.
21. Anand S, Yusuf S, Xie C, Pogue J, Eikelboom J, Budaj A et al. Oral anticoagulant 
and antiplatelet therap y and peripheral arterial disease. N Engl J Med 2007 July 
19;357(3):217 -27.
22. Connolly  SJ, Eikelboom J, Joy ner C, Diener HC, Hart R, Golitsy n S et al. Api[INVESTIGATOR_834217]. N Engl J Med 2011 March 3;364(9):806 -17.
23. Derry  S, Loke YK. Risk of gastrointestinal haemorrhage with long term u se of 
aspi[INVESTIGATOR_248]: meta -analysis. BMJ 2000 November 11;321(7270):1183 -7.
24. Lanas A, Wu P, Medin J, Mills EJ. L ow doses of acet ylsalicy lic acid increase risk of 
gastrointestinal bleeding in a meta -analy sis. Clin Gastroenterol Hepatol 2011 
September;9(9):[ADDRESS_1158536] 22;114(8):[ADDRESS_1158537]-segment elevation 
acute coronary  syndromes. Eur Heart J 2007 May ;28(10):1193-204.
[COMPANY_003]
Integrated Clinic al Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 89of 205
27. Bhatt DL, Cry er BL, Contant CF, Cohen M, Lanas A , Schnitzer TJ, et al ; COGENT 
Investigators. Clopi[INVESTIGATOR_834218].N 
Engl J Med. 2010 Nov 11;363(20):1909 -17
28. Lamy A, Devereaux PJ, Prabhakaran D, Taggart DP, Hu S, Paolasso E, et al.
CORONARY Investigators.  Off -pump or on -pump coronary -artery  by[CONTACT_834361] 30 day s. N Engl J Med 2012 Apr;19;366(16):[ADDRESS_1158538] 2012 April;10(4):521 -8.
30. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. 
Reversal of rivaroxaban and dabigatran b y prothrombin complex concentrate: a 
randomized, placebo -controlled, crossover stud y in healthy  subjects. Circulation 2011 
October 4;124(14):1573 -9.
31. ICH Harmonised Tripartite Guideline. Statistical principle s for clinical trials. 
International Conference on Harmonisation E9 Expert Working Group. Stat Med. 
1999;18(15):1905-42.
32. Brechenmacher, T, Xu, J, Dmitrienko, A, Tamhane, AC. A mixture gatekeepi[INVESTIGATOR_834219]. Journal of Biopharmaceutical Statistics, 2011; 21: 748 -767.
33. Dmitrienko, A, Tamhane, AC. Mixtures of multiple testing procedures for gatekeepi[INVESTIGATOR_834220]. Statistics in Medicine, 2011; 30: 1473 -
1488.
34. Dmitrienko, A, Tamha ne, AC. General theory  of mixture procedures for gatekeepi[INVESTIGATOR_007]. 
Biometrical Journal, 2013; 55: 402-419.
35. Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994, 81(3):515- 526.
36. McAlister FA, Straus SE, Sackett DL, Altman DG. Analy sis and reporting of 
factorial trials: a s ystematic review. JAMA 2003; 289(19):2545-53.
37. Gail M., Simon R. Testing for qualitative interactions between treatment effects and patient subsets. Biometrics 1985 41:[ADDRESS_1158539] is positive and homogeneous across all subgroups. Drug Information Journal 2007 41:47-56.
39. Dubois MF, Hébert R. Imputation of missing dates of death o r institutionalization for 
time-to-event anal yses in the Canadian Study  of Health and Aging. Int Psy chogeriatr. 
2001;13 Supp 1:91-7. 
40. Lakatos, Edward. Sample sizes based on the log -rank statistic in complex clinical 
trials. Biometrics 1988 44:229-241.
41. J. Shih. Sample size calculation for complex clinical trials with survival. Controlled 
Clinical Trials 1995 16:395-407
[COMPANY_003]
Integrated Clinic al Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 90of 205
42. Vermeer SE, Longstreth WT, Jr., Koudstaal PJ. Silent brain infarcts: a sy stematic 
review. Lancet Neurol 2007 July ;6(7):611-9.
43. Bonaca MP, Bhatt DL , Cohen M, Steg PG, Storey RF, Jensen EC, et al.  Long-term 
use of ticagrelor in patients with prior my ocardial infarction.  N Engl J Med 2015; 
372:1791-1800. 158
44. Mauri L , Kereiakes DJ, Yeh RW, Driscoll -Shempp P, Cutlio DE, Steg PG, et al.  
Twelve of 30 months of dual antiplatelet therapy  after drug- eluting stents.  N Engl J 
Med 2014; 371:2155-66. 158
45. Palmerini T, Benedetto U, Bacchi -Reggiani L, Della Riva D, Biondi- Zoccai G, Feres 
F, et al.  Mortalit y in patients treated with extended duration dual antiplatelet therap y 
after drug -eluting stent implantation: a pairwise and Bay esian network meta -analysis 
of randomised trial.  Lancet 2015;385;2371-82.158
46. Patel MR, Mahaffey  KW, Garg J, Pan G, Singer DE, Hacke W, et al.  Rivaroxaban 
versus warfarin in nonvalvular atrial fibrill ation.  N Engl J Med 2011;Sep 
8;365(10):883 -91.158
                                                
158Referenc es  added as per Amendment 8.
[COMPANY_003]
Integrated Clinic al Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 91of 205
13. Protocol amendments
Protocol version history
Original Protocol Version 1.0 – Approved [ADDRESS_1158540] 2012
Revised Protocol Version 1.1 – Approved [ADDRESS_1158541] “primary ” has been removed when linked to the outcome for the pantoprazole 
randomization, and similarly  a paragraph describing the “primary ” outcome for the 
pantoprazole randomization has been removed from the protocol sections where t hey are not 
applicable. Rationale and implications: Although the outcome of the composite of GI bleeding is the “primary ” objective of the pantoprazole randomization, it is not part of the primary  
objective of the trial and, thus, not a primary  variable of the trial. Therefore, the word 
“primary ” has been removed. The intent and the analy sis plan remains the same.
A consistent use of the terms “outcome” and “variable” has been ensured. While the term “outcome” is used to describe a clinical event to be observed in the trial, e.g. stroke, the term “variable” refers to the statistical variable to be analy zed, e.g. the time to the first occurrence 
of the outcome since randomization. The wording in section 4.[ADDRESS_1158542] been further clarified in respective protocol 
sections. Collection of two additional questionnaires (health care costs information and assessment of the driving status) and additional informat ion relative to the CABG surgery  for 
subjects randomized post CABG surgery  (EuroSCORE) have been added to the respective 
study  visit section.  Collection of two questionnaires (Diet and Activity ) has been removed 
from the Final Follow -up Visit. Collection of blood sampling relevant for COMPASS MIND 
study  has been included in the relevant study  visit section.
13.1 Amendment 6
The eligibility  criteria for study  population of subjects with coronary  artery  disease (CAD) 
and peripheral artery  disease (PAD) have been simplified and clarified.  Despi[INVESTIGATOR_834221], the target population remains largely unchanged. Additionally , there is an increase in the overall sample size of the study  by 1900, from 19,[ADDRESS_1158543] the overall study  
concept.
[COMPANY_003]
Integrated Clinic al Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 92of 205
Modification 1: Name [CONTACT_834398] n updated.
Rationale:  replaces  as the sponsor’s  
for the COMPASS study .
Sections affected:
Title page
Signature [CONTACT_8152]’s medically  responsible person
[INVESTIGATOR_267448] 2: Minor clarifications for the s econdary  and  tertiary  efficacy  outcomes
Rationale: The following sections now contain minor clarifications to address either the terms 
that were omitted  in the previous protocol or to reflect the changes in the associated sections of this protocol amendment. These clarifications are as follows:  1) addition of revascularization to the secondary  composite outcomes, and 2) addition of the stent 
thrombosis and coronary  artery  by[CONTACT_834362]. These additions 
do not affect the analysis of the corresponding statistical variables.
Sections affected:
Synopsis: Study  objectives
Section 2: Study  objectives
Section 7.3 Efficacy  
Section [IP_ADDRESS] Protocol-specific exceptions to SAE reporting (new section)
Section 8.3.2 Secondary  efficacy outcomes
Section 8.3.3 Tertiary  and other efficacy  outcomes
Modification 3: Clarifications in the main criteria for inclusion
Rationale: Originally , the protocol mandated that subjects with PAD under the age of [ADDRESS_1158544] a substantially  lower rate of 
cardiovascular death, myocardial infarction, or stroke than those over the age of 65.  
However, further scrutiny  of the recent data from the On-Target (1) and Transcend (2) trials 
demonstrated that event rates in subjects under the age of 65 with PAD are about 50% higher 
than those with CAD and are well over 4%. This observation prompted the removal of the requirement for two additional risk factors or disease in at least two vascular b eds for PAD 
subjects under the age of 65; such subjects are at high risk even without additional risk factors and will potentially  benefit from a more effective rivaroxaban- based treatment. 
Based on the questions received from the sites, it became evident that additional clarifications 
regarding definition of vascular beds were required. The definition is now specified in the protocol amendment.
References:
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
Integrated Clinic al Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 93of 205
1. The ONTARGET Investigators. Telmisartan, Ramipril, or Both in Patients at High Risk for 
Vascular Events. N Engl J Med 2008; 358:1547- 1559
2. The Telmisartan Randomised AssessmeNt Study  in ACE iNtolerant subjects with 
cardiovascular Disease (TRANSCEND) Investigators. Effects of the angiotensin- receptor 
blocker telmisartan on cardiovascular events in hi gh-risk patients intolerant to angiotensin-
converting enzy me inhibitors: a randomised controlled trial. L ancet. Published on -line [ADDRESS_1158545] 2008; 372(9644):1174-83.
Sections affected:
Synopsis: Diagnosis and Main Criteria for Inclusion
Section 5.1.1 I nclus ion criteria
Modification 4: Minor clarifications for consistency
Minor, consistency  and logistical clarifications were made throughout the document. These 
changes do not affect the overall study  concept.
Sections affected:
Synopsis: Methodology
List of abbreviations
Section 1.1 Background
Section 1.2.1 Rivaroxaban
Section 1.2.2 Aspi[INVESTIGATOR_834107]
Section 1.2.3 Proposed rivaroxaban evaluation
Section 4.1 Design overview
Section 4.1.1 Subjects randomized after CABG surgery
Section 4.3.1 Overall design rationale
Section 5 Study  population
Section 6.1 Treatments to be administered
Section 6.1.1 Run- in
Section 6.1.2 Randomization
Section 6.4.1 Dose modification
Section 6.4.2 Dose modification and treatment guidance
Section [IP_ADDRESS] Guidance for the treatment of subjects who require an invasive 
procedure
Section [IP_ADDRESS] Guidance for the treatment of subjects who require coronary artery 
by[CONTACT_834363] 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 94of 205
Section [IP_ADDRESS] Guidance for the treatment of subjects who develop an acute coronary  
syndrome and those who require percutaneous coronary  intervention with stenting
Section 6.6 Drug logistics and accountability
Section 6.9 Prior and concomitant therap y
Section 6.9.2 Clopi[INVESTIGATOR_7745] (or an y other non -study  antiplatelet treatment)
Section 6.9.4 Proton pump inhibitor treatment
Section 7.2.3 Other baseline characteristics
Section 7.3 Efficacy
Section 8.3.5 Outcome of pantoprazole randomization
Section 8.3.6 Subgroup variables
Section 8.4.5 Analy sis of the outcome for pantoprazole randomization
Section 8.4.6 Subgroup Analy sis
Section 14.1 COMPASS MI ND Substudy
Modification 5: Clarification about the subjects with the need for the proton pump inhibitor 
(PPI) treatment
Rationale: The initial protocol required that the subjects with a need for PPI[INVESTIGATOR_834222] . The clarification in this protocol amendment specifies that the need for 
the PPI  [INVESTIGATOR_834223] a continuous need for  treatment with the PPI .
Sections affected:
Synopsis: Methodology
Section 1.1 Background
Section 4.1 Design overview
Section 5.1.2 Exclusion criteria
Section 6.1.2 Randomization
Section 6.9.4 Proton pump inhibitor treatment
Modification 6: The number of subjects in the trial has been increased.
Rationale: The number of subjects in the trial has been incre ased to: ~23,500 enrolled and 
~21,400 randomized (10% non- compliance rate is anticipated the run -in period). The reason 
for increasing the number of subjects is based on emerging data from the ORI GIN trial (1) 
and the Vorapaxar secondary  prevention trial (2), a realistic event rate is 3.5- 4% rather than 4 -
4.5% which mandates an increase in numbers of subjects or duration of follow up to maintain 
study  power. 
References:
[COMPANY_003]
Integrated Clinic al Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 95of 205
1.The ORIGIN Trial Investigators. Basal Insulin and Cardiovascular and Other Outcomes in 
Dysglycemia. N Engl J Med 2012; 367:319-328
2. Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalb y AJ, Fish MP et al. Vorapaxar 
in the secondary  prevention of atherothrombotic events. N Engl J Med 2012 April 
12;366(15):1404-13.
Sections affected:
Synopsis: Number of subjects
Section 4.1 Study  design
Section 5 Study  population
Section 8.6 Determination of the sample size
Modification 7: Clarification on one of the referenced studies.
Rationale: Some additional clarification regarding the Voraxapar s tudy (TRA 2 P -TIMI 50) is 
now included.Sections affected:
Section 1.2.2 Aspi[INVESTIGATOR_834224] 8: Addition of CABG specific objectives
Rationale: I n the original protocol, the objectives for the CABG subjects and testing for graft 
patency were not formally  outlined.  The protocol amendment now includes these objectives. 
Sections affected:
Section 2 Study  Objectives
Modification 9: Clarification on the timing of the administration of the study  related 
questionnaires.Rationale: Considering the older subjects participating in the COMPASS study , it may  be 
difficult to have all of the study  related questionnaires administered at one visit. Therefore, the 
timing of the administration of the questionnaires now allows some flexibility  to when the se 
questionnaires should be completed.Sections affected:
Section 4.1 Design overview
Section 7.1.1 tabulated overview
Modification 10: Changes in the informed consent timing for CABG subjects, and 
requirement for the angiograph y at [ADDRESS_1158546] surgery  forCABG subjects
Rationale: CABG subjects can now sign consent for participation in the evaluation of graft 
patency  either before or after CABG surgery . Irrespective of the timing of consent, the 
decision to randomize is based on the information available to the investigator on Day  [ADDRESS_1158547]’s best interests. Moreover, in some centers, it is not 
[COMPANY_003]
Integrated Clinic al Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 96of [ADDRESS_1158548] angiography; thus, the protocol amendment now allows 
the  invasive angiography as an acceptable alternative to CT angiog raphy.
Sections affected:
Section 4.1.1 Subjects randomized after CABG surgery
Section 7.1.1 tabulated overview
Section [IP_ADDRESS].1 Routine follow -up visits (Visits 3, 5, and 7- 15+)
Modification 11: Clarification on the study population and the study investigators 
qualifications
Rationale: The  new paragraph in the protocol amendment summarizes that COMPASS study  
is enrolling subjects with the high risk of the incident cardiovascular disease. Additionally , 
based on the request from South American regul atory  authorit y, the investigator qualifications 
are now further clarified.Sections affected:
Section 5 Study  population
Modification 12: The section defining eligibility  criteria for subjects with coronary  artery  
disease has been modified Rationale: Fir st, only  subjects with a history  of previous my ocardial infarction (most recent 
epi[INVESTIGATOR_1865]) within the past [ADDRESS_1158549] four years prior to randomization (unless the patient 
had recurrent ischemic events in the first four years after surgery ). The recently  completed one 
year follow -up of the CORONARY trial (1) and the five y ear follow-up of the SYNTAX trial 
(2) have shown that event rate in subjects with prior CABG surgery  is in the order of 3.5- 4% 
per year, even during the first four years after s urgery .  Thus, these subjects need to be given 
the opportunity  to participate in COMPASS, as they  are at substantial risk and could benefit 
from a new treatment that is potentially  more effective than aspi[INVESTIGATOR_248].  
[COMPANY_003]
Integrated Clinic al Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 97of 205
References:
1. Andre Lam y et al. for CORONAR Y Investigators. Off-Pump or On- Pump Coronary -Artery  
By[CONTACT_834364] 30 Day s. N Engl J Med 2012; 366:1489-1497
2. Serru ys PW et al. for SYNTAX Investigators. Percutaneous Coronary  Intervention versus 
Coronary -Artery  By[CONTACT_834365]. N Engl J Med 2009; 
360:961-972Sections affected:
Section 5 Study  population
Modification 13: Section defining the eligibility  criteria for subjec ts with peripheral artery  
disease has been modified Rationale: Asy mptomatic carotid disease carries a higher risk of MI than stroke on average 
and carotid endarterectomy  (CEA), while reducing the risk of stroke (ARR 0.6% per year) 
does not alter the cardi ac risk. So a previous endarterectom y identifies an individual with an 
increased cardiac risk. The original observation was made b y John Norris (1). Incidentall y, the 
cardiac risk correlates with degree of stenosis and a cutoff of 50% ensures selection of high 
risk asy mptomatic disease. 
Inthe NASCET Trial of surgery  for sy mptomatic carotid stenosis, the rate of MI at 5 y ears 
was ~19% (2).References:1. Chambers BR, Norris JW. Outcome in patients with asy mptomatic neck bruits. N Engl J 
Med. [ADDRESS_1158550] 2;31 5(14):860-5.
2. Ferguson GG et al for The North American S ymptomatic Carotid Endarterectom y Trial 
(NASCET) investigators. The North American S ymptomatic Carotid Endarterectom y Trial. 
Stroke. 1999; 30: 1751-1758
Sections affected:
Section 5 Study  population
Modification 14: Clarifications in the Exclusion criteria
Rationale: I n the section on drug interactions, strong inducers of cy tochrome P450 3A4 are 
now excluded. These were not previously  listed in the protocol.  
Furthermore, there is an additional clarification on women who are pregnant, breastfeeding, or 
of childbearing potential.  
Participation of subjects who concomitantly  participate in another study  with an 
investigational drug, or have contraindication to a ny study  procedure is now excluded.
Additionally , it is now clarified that the subjects who a continuous need for treatment with 
PPI [INVESTIGATOR_834225].
Sections affected:
Section 5.1.2 Exclusion criteria
[COMPANY_003]
Integrated Clinic al Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 98of 205
Modification 15: Clarifications in the Discontinuations of subjects from study treatment
Rationale: The protocol now clarifies that even the subjects with study  outcomes need to be 
followed at regular stud y visits until the end of the study . Furthermore, besides collection of 
survival status information throughout the stud y, the outcome information is also required in 
subjects who prematurely  terminate the study /study  treatment.
Sections affected:
Section 5.2 Discontinuation of subjects from stud y treatment
Modification 16: Clarification about the aspi[INVESTIGATOR_834226]: The protocol amendment clarifies that the aspi[INVESTIGATOR_834227]. Furthermore, the clarification is now included that the terms “aspi[INVESTIGATOR_248]” and “acet yl 
salicy lic acid” are used interc hangeabl y. 
Sections affected:
Section 6.1 Treatments to be administered
Section 6.2 I dentity  of study  treatment
Modification 17:   Clarification on the treatment compliance during run -in 
Rationale: The intent of the run in is to optimize subject retention in the study . While the 80% 
drug adherence during run- in is still required in the protocol, it is recognized that they  may  be 
certain circumstances, e.g. outside of subject’s control, where the drug adherence may  be 
somewhat affected. Therefore, the targ et compliance during run -in was a mended to “at least 
80% except for extenuating circumstances”.
Sections affected:
Section 6.1.2 Randomization
Section [IP_ADDRESS] Randomization visit (Day  0 ± 5 day s)
Modification 18: Change in the section on treatment guidance with study  pantoprazole
Rationale: Compared to the initial protocol, the summary  of the treatment guidance with study  
pantoprazole is now found only  in one section. This was done to further simplify  the protocol. 
Sections affected:
Section 6.4.2 Dose modi fications and treatment guidance
Section [IP_ADDRESS] Guidance for the treatment of subjects who require an invasive 
procedure
Section [IP_ADDRESS] Guidance for the treatment of subjects who require coronary artery by[CONTACT_10956]
Section [IP_ADDRESS] Guidance for the treatment of subjects who develop an acute coronary  
syndrome and those who require percutaneous coronary  intervention with stenting
Section 6.9.1 Combined CYP 3A4 and p- glycoprotein inhibitors
Section 6.9.3 Anticoagulant treatment
[COMPANY_003]
Integrated Clinic al Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 99of 205
Section 6.9.4 Proton pump inhibitor treatment
Modification 19: Combined CYP 3A4 and p- Glycoprotein Inhibitors and systemic azole 
antimy cotics
Rationale: The title of the relevant protocol sections has been updated to include CYP 3A4 
inducers. Also, the concomitant use of stron g CYP 3A4 inducers has now been included in the 
protocol due to the potential for reduction in the rivaroxaban plasma concentrations if used 
concomitantly . Additionally , macrolide antibiotics are now removed: if used concomitantly  
with rivaroxaban, their e ffect on mean rivaroxaban AUC and Cmax is considered to be 
clinically  not relevant (see rivaroxaban IB and Company  Core Data sheet). Furthermore, the 
list of sy stemic antifungal drug provides some examples of the sy stemic antimy cotics that 
should not be ta ken concomitantly  with rivaroxaban.  
Sections affected:
Section 6.9.1 Combined CYP 3A4 and p- glycoprotein inhibitors
Modification 20: Revision of time windows and footnotes under section Tabulated overview
Rationale: Compared to previous protocol, the foo tnotes under section 7.1.[ADDRESS_1158551] week following CABG surgery  (4-7 day s), but randomization is allowed up to Day  [ADDRESS_1158552] -CABG for medical 
or logistical reasons.
Sections affected:
Section 7.1.1 Tabulated overview
Modification 21: Minor clarifications in timing of the visit assessments
Rationale: These protocol sections now contain minor editorial revisions/updates: A 
specification about the administration of the questionnaires for post -CABG subjects has now 
been included, as well as the allowance for the use of invasive or noninvasive coronary  
angiograph y for post -CABG s ubjects. Furthermore, these sections now include the 
specification on the timing of blood collection. Namely, at the start of the run-in period, blood 
samples (for creatinine and cholesterol) up to [ADDRESS_1158553]’s preli minary  eligibility . However, at randomization the blood samples should not be 
older than 3 months.
Sections affected:
Section [IP_ADDRESS] Screening and Run -in visit(s)
Section [IP_ADDRESS] Randomization visit (Day  0 ± 5 day s)
Section [IP_ADDRESS].1 Routine follow -up vis its (Visits 3, 5, and 7 -15+)
Modification 22: Changes in the efficacy section
[COMPANY_003]
Integrated Clinic al Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 100of 205
Rationale: The paragraph on hospi[INVESTIGATOR_834228] y section to 
efficacy  section. 
Sections affected:
Section 7.3 Efficacy
Section [IP_ADDRESS] Protocol- specific exceptions to SAE reporting
Modification 23: Changes in the safet y section 
Rationale: Due to errors in reporting of the study outcomes as e.g. SAEs, the whole safet y 
section has been revised to clarify  the requirements for the safet y reporting. Namel y, few new 
sections were included to specify  1) the categorization of the AEs, 2) to help with 
determination of the casual relationship between the study  drug and events, and 3) further 
outline which events are considered as outcomes and should be rep orted as such.  
Additionally , few sections have been placed in different order to help clarify  the AE reporting 
requirements. Data Safety Monitoring Board (DSMB) section is now removed, since the 
details on the DSMB procedures are specified in the respecti ve DSMB charter. Section on 
pregnancy  contains requirement(s) for the reporting of the abnormal pregnancies.
Sections affected:
Section 7.5.1 Definition of (Serious) Adverse Event
Section 7.5.2 Causal relationship
Section [IP_ADDRESS] Protocol Specific Exemptio ns to SAE Reporting
Section [IP_ADDRESS] Reporting of (S) AEs
Section [IP_ADDRESS] Adverse events of special safet y interest
Section [IP_ADDRESS] Pregnancies
Section 7.5.[ADDRESS_1158554]
Section 7.5.4 Reporting of events to Bay er by  [CONTACT_834366]’ reporting requirements
Modification 24: Changes in the determination of the sample size
Rationale: Modifications to the event rate assumptions have been inserted, reflecting the 
change in sample size. Sections affected:
Section 8.6 Determination of sample size
[COMPANY_003]
[COMPANY_003]
Integrated Clinic al Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 101of 205
Modification 25: Changes in the Publication policy
Rationale: The clarification that the Operations Committee also serves as Publication 
Committee is now included.
Sections affected:
Section 11.3 Publication policy
Modification 26:Reference update
Rationale: Two references have been updated: 1 and 2.
Sections affected:
Section 12 References
Modification 27: Changes in the MRI  sequence and DNA blood collection for the 
COMPASS MI ND
Rationale: This protocol section now clarifies the MRI  sequences and the timing of the 
DNA/blood collections.Sections affected:
Section 14.1 COMPASS MI ND Substudy
[COMPANY_003]
Integrated Clinic al Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 102of 205
13.1.2 Changes to protocol text
In this section, all affected protocol sections are detailed; the sequence of the sections follows 
the structure o f the original protocol. In the display  of modifications, the “old text” refers to 
the protocol version preceding this amendment. Deletions are crossed out in the “old text”. 
Additions are underlined in the “new text”. Corrections of ty pi[INVESTIGATOR_834229].
Title page
This section was chang ed as a result of Modification 1 . 
Old Text:Sponsor Clinical L eader:
Global Clinical Development 
Bayer Pharma AG
Aprather Weg 18a, Building 402
[ZIP_CODE] Wuppertal, [LOCATION_013]
Tel.:  
New Text:Sponsor Clinical L eader:
Global Clinical Development
[COMPANY_015], Inc.
[ADDRESS_1158555] , [PO_BOX]
Whippany , NJ  [ZIP_CODE]
[LOCATION_002]
Tel: 
Signature [CONTACT_8152]’s medically responsible person[INVESTIGATOR_834392] a result of Modification 1. 
Old Text:The signatory  agrees to the content of the final clinical st udy protocol as presented.
Name: [CONTACT_1221]:  
New Text:The signatory  agrees to the content of the final clinical study  protocol as presented.
Name: [CONTACT_1221]:  
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
Integrated Clinic al Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 103of 205
Synopsis
This section was changed as a result of Modification 2.
Old Text:
Study objective(s)Secondary objectives for rivaroxaban random ization
To determine whether each of rivaroxaban 2.5 mg bid + aspi[INVESTIGATOR_248] 
100mg od and rivaroxaban 5 mg bid alone reduces the risk of the 
composite of major thrombotic events (myocardial infarction, stroke, 
cardiovascular death, and venous thromboembolism) and cardiovascular hospi[INVESTIGATOR_834230] 100 mg od in 
subjects with CAD or PAD
New Text:
Study objective(s)Secon dary objectives for rivaroxaban random ization
To determine whether each of rivaroxaban 2.5 mg bid + aspi[INVESTIGATOR_248] 
100mg od and rivaroxaban 5 mg bid alone reduces the risk of the 
composite of major thrombotic events (myocardial infarction, stroke, cardiovascular death, revascularization ,and venous 
thromboembolism) and cardiovascular hospi[INVESTIGATOR_834230] 100 mg od in subjects with CAD or PAD
Synopsis
This section was changed as a result of Modifications 3.
Old Text:
Diagnosis and main criteria for 
inclusionPatients are eligible for inclusion if they have coronary artery disease or 
peripheral artery disease and meet at least one of the following criteria:
 Age 65 years
 Age [ADDRESS_1158556] iovascular risk factors 
Additional cardiovascular risk factors are:
Current smoker
Diabetes mellitus
Renal dysfunction with estimated glomerular filtration rate 
60ml/min 
Heart failure
Non-lacunar ischemic stroke 1 month ago
[COMPANY_003]
Integrated Clinic al Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 104of 205
New Text:
Diagnosis and main criteria for 
inclusionSubjects are eligible for  inclusion if they:
Meet criteria for CAD* and/or PAD
*Subjects w ith CAD must also meet at least one of the following criteria:
Age 65 years, or
Age [ADDRESS_1158557] 2 vascular beds§, or at least 2additional 
cardiovascular risk factors:
1)Current smoker (within 1 year of randomization )
2)Diabetes mellitus
3)Renal dysfunction with estimated glomerular filtration rate 
60ml/min
4)Heart failure
5)Non-lacunar ischemic stroke 1 month ago
§Because CAD involves disease in the coronary vasculature, only one 
additional vascular bed is required: e.g. the aorta and arterial supply to the 
brain, gastro -intestinal tract, low er limbs, upper limbs, o r kidneys .
Synopsis
This section was changed as a result of Modifications 4 and 5. 
Old Text:
MethodologyThe study will comprise 4 periods:  screening, run -in, follow -up, and washout. 
During the screening period, informed consent will be obtained and 
evaluations of subject eligibility will be performed.  The run -in period w ill 
occur during the 30days prior to initiation of study treatment, w ith the 
exception of subjects randomized afte r coronary artery by[CONTACT_834367] a run -in.  During run -in, subjects w ill discontinue any current 
anticoagulant therapy and will begin rivaroxaban placebo and 100 mg aspi[INVESTIGATOR_248].  Treatment of subjects who comply with the run -in treatment a nd who remain 
committed to the study, as well as those who are randomized after coronary 
artery by[CONTACT_834368] 0, which will also signal the 
initiation of the follow -up period.  
…*Subjects already taking a proton pump inhibitor at baseline will undergo only 
a single randomization (to rivaroxaban 2.5 mg bid + aspi[INVESTIGATOR_248] 100 mg od, 
rivaroxaban 5 mg bid + aspi[INVESTIGATOR_834231] + aspi[INVESTIGATOR_248] 
100mg od)
New Text:
MethodologyThe study will comprise 4 periods:  screening, run-in, follow -up, and washout.
During the screening period, informed consent will be obtained and evaluations of subject eligibility will be performed.  The run -in period w ill 
occur during the 28days prior to initiation of study treatment, w ith the 
[COMPANY_003]
Integrated Clinic al Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 105of [ADDRESS_1158558] s who comply with the run -in treatment and who 
remain committed to the study, as w ell as those who are randomized Day  4-7 
after coronary artery by[CONTACT_834368] 0, w hich will also 
signal the initiation of the follow -up period.  
…
*Subjects who have a continuous need for use of a proton pump inhibitor at 
baseline will undergo only a single randomization (to rivaroxaban 2.5 mg bid 
+ aspi[INVESTIGATOR_248] 100 mg od, rivaroxaban 5 mg bid + aspi[INVESTIGATOR_834232] + aspi[INVESTIGATOR_248] 100 mg od)
Synopsis
This section was chang ed as a result of Modification 6. 
Old Text:
Number of subjectsEnrolled = 21,500; randomized = [ZIP_CODE] in approximately 25 to 30 countries 
worldwide
Approximately 21,500 subjects will be enrolled; [ZIP_CODE] will be admitted to the
run-in period and 2000 subjects will undergo coronary artery by[CONTACT_834369] -in.  A non -compliance rate of 10% is anticipated for those subjects in 
the run -in period; thus, approximately 19,500 subjects w ill be randomized 
(approximately 17,500 subjects who completed run -in and 2000 who 
underwent coronary artery by[CONTACT_834370] -in) in approximately 25 to
30 countries w orldwide.
New Text:
Number of subjectsEnrolled = approximately 23, 500; randomized = 21,400 in approximately 30 
countries worldwide
Approximately 23,500 subjects will be enrolled; 21,500 will be admitted to the 
run-in period and 2000 subjects will undergo coronary artery by[CONTACT_834369] -in.  A non -compliance rate of 10% is anticipated fo r those subjects in 
the run -in period; thus, approximately  21,400 subjects w ill be randomized 
(approximately 19,400 subjects who completed run -in and 2000 who 
underwent coronary artery by[CONTACT_834370] -in) in approximately [ADDRESS_1158559] of abbreviations
This section was changed as a result of Modification 4. 
Old Text:
ECG Electrocardiogram
SAS Statistical Analy sis Software
New Text:
bpm Beats per minute
[COMPANY_003]
Integrated Clinic al Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 106of 205
CAD Coronary  artery  disease
cm Centimeter
CV Cardiovascular
GPV Global Pharmacovigilance
in Inch
IT Information technology
lb Pound
mmHg Millimeter of mercury
SAS Statistical Analy sis System
[LOCATION_003] [LOCATION_002] of America
Section 1.1 Background
This section was changed as a result of Modifications 4 and 5. 
Old Text:Aspi[INVESTIGATOR_248], statins and angiotensin converting enzyme (ACE) inhibitors are effective and widel y 
used for the prevention of cardiovascular events in patients with coronary and PAD but the 
risk of vascular events remains high despi[INVESTIGATOR_98356] …
…The evi dence of efficacy  of rivaroxaban for the prevention of atherothrombotic events on a 
background of dual antiplatelet therap y in patients with recent acute coronary s yndrome 
supports the hy pothesis that it may  also be effective for prevention of atherothromb otic events 
in patients with established coronary or PAD who are not treated with dual antiplatelet 
therap y.  
…
The trial described herein, Cardiovascular OutcoMes for People using Anticoagulation 
StrategieS (COMPASS), is a randomized double -blind trial u tilizing a 3 x 2 partial factorial 
design that will evaluate the efficacy  and safety  of rivaroxaban 2.5 mg twice daily  (bid) + 
aspi[INVESTIGATOR_248] 100 mg once daily  (od) versus aspi[INVESTIGATOR_248] [ADDRESS_1158560] prevention therapi[INVESTIGATOR_014] .  
In the (partial factorial) randomization, patients randomized to receive rivaroxaban in combination with aspi[INVESTIGATOR_248], rivaroxaban alone or aspi[INVESTIGATOR_834233] a 
PPI[INVESTIGATOR_834234] 40 mg od or placebo for the prevention of 
major upper gastrointestinal complications
New Text:
Aspi[INVESTIGATOR_248], statins and angiotensin con verting enzy me (ACE) inhibitors are effective and widel y 
used for the prevention of cardiovascular events in patients with CAD and PAD but the risk of 
vascular events remains high despi[INVESTIGATOR_98356].
…The evidence of efficacy  of rivaroxaban for the prevention of atherothrombotic events on a 
background of dual antiplatelet therap y in patients with recent acute coronary s yndrome 
supports the hy pothesis that it may  also be effective for prevention of atherothrombotic events 
in patients with established CAD or PAD, receiving usual care .  
[COMPANY_003]
Integrated Clinic al Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 107of 205
The trial described herein, Cardiovascular OutcoMes for People using Anticoagulation 
StrategieS (COMPASS), is a randomized double -blind trial utilizing a 3 x 2 partial factorial 
design that will evaluate the efficacy  and safety  of rivaroxaban 2.5 mg twice daily  (bid) + 
aspi[INVESTIGATOR_248] 100 mg once daily  (od) versus aspi[INVESTIGATOR_248] 100 mg od and rivaroxaban 5 mg bid versus 
aspi[INVESTIGATOR_248] 100 mg od for the prevention of myocardial infarction, stroke, and cardiovascular 
death in patients with estab lished CAD or PAD, who are receiving usual care .  In the (partial 
factorial) randomization, patients who do not have a continuous need for use of a PPI[INVESTIGATOR_834235] 40 mg od or placebo for the prevention of major upper 
gastrointestinal complications, and then randomized to receive rivaroxaban in combination 
with aspi[INVESTIGATOR_248], rivaroxaban alone or aspi[INVESTIGATOR_264086].
Section 1.2.1 Rivaroxaban
This section was changed as a result of Modification 4. 
Old Text:Rivaroxaban has been tested in randomized controlled trials involving more than 60,000
patients and has been used by  [CONTACT_834371].  
New Text:Rivaroxaban has bee n tested in randomized controlled trials involving more than 70,000
patients and has been used by  [CONTACT_834371].  
Section 1.2.2 Aspi[INVESTIGATOR_834236] a result of Modifications 4and 7.
Old Text:Other st udies have investigated the potential benefits of combined antiplatelet therap y for 
long-term prevention of cardiovascular disease. The TRA [ADDRESS_1158561], vorapaxar, and aspi[INVESTIGATOR_834237] 3 y earsreduced the risk of my ocardial 
infarction, stroke or cardiovascular death b y 13% in patients with a history of myocardial 
infarction, ischemic stroke or PAD but at the cost of an increase in ma jor and intracranial 
bleeding and with no reduction in cardiovascular mortality .
…
Preliminary evidence for the efficacy  and safety  of oral factor Xa inhibitors for the prevention 
of major cardiovascular events comes from the recently  completed AVERROES tr ial which 
demonstrated that the oral factor Xa inhibitor, api[INVESTIGATOR_3822], compared with aspi[INVESTIGATOR_834123].
New Text:
Other studies have investigated the potential benefits of combined antiplatelet therap y for 
long-term prevention of cardiovascular disease. The TRA [ADDRESS_1158562] therap y
[COMPANY_003]
Integrated Clinic al Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 108of [ADDRESS_1158563] therap yalone reduced the risk 
of my ocardial infarction, stroke, or cardiovascular death by  13% at [ADDRESS_1158564] of an increase in 
major and intracranial bleeding.
…Additional evidence for the efficacy  and safet y of oral factor Xa inhibitors for the prevention 
of major cardiovascular events comes from the recently completed AVERROES trial w hich 
demonstrated that the oral factor Xa inhibitor, api[INVESTIGATOR_3822], compared with aspi[INVESTIGATOR_834123]. 
Section 1.2.3 P roposed rivaroxaban evaluation
This section was changed as a result of Modification 4. 
Old Text:
…We hy pothesize that the combination of rivaroxaban and aspi[INVESTIGATOR_834238], strok e or cardiovascular 
death and that this benefit will readily  outweigh any  increase in bleeding.  
New Text:…We hy pothesize that the combination of rivaroxaban and aspi[INVESTIGATOR_834239], stroke, or cardiovascular 
death and that this benefit will readily  outweigh any  potential increase in bleeding.  
Section 2 Study objectivesThis section was changed as a result of Modification 8. 
Old Text:
Secondary objectives for rivaroxaban randomization
To determine whether each of rivaroxaban 2.5 mg bid + aspi[INVESTIGATOR_248] 100 mg od and 
rivaroxaban 5 mg bid alone reduces the risk of the composite of major thrombotic 
events (m yocardial infarction, stroke, cardiovascular death, and venous 
thromboemboli sm) and cardiovascular hospi[INVESTIGATOR_834230] 100 mg 
od in subjects with CAD or PAD
New Text:Secondary objectives for rivaroxaban randomization
To determine whether each of rivaroxaban 2.5 mg bid + aspi[INVESTIGATOR_248] 100 mg od and 
rivaroxaban 5 mg bid alone reduces the risk of the composite of major thrombotic 
events (m yocardial infarction, stroke, cardiovascular death, revascularization , and 
venous thromboembolism) and cardiovascular hospi[INVESTIGATOR_834230] 
100 mg od in subjects with CAD or PAD
…
[COMPANY_003]
Integrated Clinic al Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 109of [ADDRESS_1158565]-CABG randomization
To determine whether each of rivaroxaban 2.5 mg bid + aspi[INVESTIGATOR_248] 100 mg od and 
rivaroxaban 5 mg bid alone reduces the risk of by[CONTACT_834330][INVESTIGATOR_248] 100 mg od
To determine the association between post CABG graft failure and risk of a composite 
of my ocardial infarction, stroke, or cardiovascular death in subjects with CAD or PAD
Section 4.1 Design overview
This section was changed as a result of Modifications 4, 5, 6 and 9. 
Old Text:
This Phase 3, event- driven (at least 2,200 primary  efficacy  outcome events), randomized 
controlled trial will have a [ADDRESS_1158566] 19,500
subjects who will receive treatment for an expected average duration of 3 to 4 y ears.  The 
COMPASS trial will involve 4 periods:  screening, run -in, follow -up, and washout. 
Prescreening procedures may require informed consent in some countries.  In all other study  
sites, informed consent will be obtained prior to the ini tiation of any  screening procedures.  
Screening will be performed to determine subject eligibility  and will include the review of 
inclusion and exclusion criteria, the collection of medical history , phy sical measurements, and
laboratory  evaluations.  
The run -in period will occur during the 30 days prior to initiation of randomized study  
treatment, with the exception of subjects who are randomized after CABG surgery , who will 
not undergo a run -in phase (Section 4.1.1).  During run -in, subjects will disconti nue an y 
non-study  anticoagulant and non -study  aspi[INVESTIGATOR_834240] y aspi[INVESTIGATOR_248] 100 mg.  
Subjects who successfully  complete the run -in period and who remain committed to the study  
as well as those who are being randomized after CABG will be randomized and begin study  
treatments on Day  0, which will also signal the initiation of the follow -up period.  Subjects 
without an ongoing need for treatment with a PPI[INVESTIGATOR_834133] 1:1 to the pantoprazole 
or pantoprazole placebo and all subjects (including those subjects who entered the study  while 
alread y receiving a PPI) will then be randomized 1:1:1 to rivaroxaban alone, the combination 
of rivaroxaban and aspi[INVESTIGATOR_834134], and their matching placebos as shown in Table 4 -
1:
Table 4 -1.  Randomized study treatments* 
[COMPANY_003]
Integrated Clinic al Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 110of 205
Study Arm Treatm ent Assignments
ARivaroxaban 2.5 mg bid +
Aspi[INVESTIGATOR_248] 100 m g od +
Pantoprazole 40 mg odRivaroxaban 2.5 mg bid +Aspi[INVESTIGATOR_248] 100 mg od +Pantoprazole placebo od
BRivaroxaban 5 mg bid + 
Aspi[INVESTIGATOR_834135] + 
Pantoprazole 40 mg odRivaroxaban 5 mg bid + 
Aspi[INVESTIGATOR_834135] +
Pantoprazole placebo od
CRivaroxaban placebo + Aspi[INVESTIGATOR_248] 100 mg od +Pantoprazole 40 mg odRivaroxaban placebo + Aspi[INVESTIGATOR_248] 100 mg od + Pantoprazole placebo od
*Subjects already taking a proton pump inhibitor at baseline will undergo only a single randomization (to 
rivaroxaban 2.5 mg bid + aspi[INVESTIGATOR_248] 100 mg od, rivaroxaban 5 mg bid + aspi[INVESTIGATOR_834231] + 
aspi[INVESTIGATOR_248] 100 mg od)
Subjects will be seen in the clinic at [ADDRESS_1158567] information on treatment adherence, treatment 
interruption, outcomes, and adverse events (AEs).  Validated questionnaires will be administered at randomization and at Month [ADDRESS_1158568] health and quality  of 
life (Standard Assessment of Global- Activities in the Elderl y [SAGE], Montreal Cognitive 
Assessment [MoCA], DSS [Digital Sy mbol Substitution], European Quality  of Life -5 
Dimensions [EQ -5D], The I nterheart Diet Questionnaire, and The International Phy sical 
Activity  Questionnaire).  
New Text:
This Phase 3, event- driven (at least 2,200 primary  efficacy  outcome events), randomized 
controlled trial will have a [ADDRESS_1158569] 21,400
subjects who will receive treatment for an expected average duration of 3 to 4 y ears.  The 
COMPASS trial will involve 4 periods:  screening, run -in, follow -up, and washout. 
Prescreening procedures may  require informed consent in some countries.  In all other study  
sites, informed consent will be obtained prior to the initiation of any  screening procedures
(Section [IP_ADDRESS]) .  Screening will be performed to determine subject eligibility  and will 
include the review of inclusion and ex clusion criteria, physical measurements, laboratory  
evaluations, etc. (Section [IP_ADDRESS]) .  
The run -in period will occur during the 28 days prior to initiation of randomized study  
treatment, with the exception of subjects who are randomized after CABG surge ry, who will 
not undergo a run -in phase (Section 4.1.1).  During run -in, subjects will discontinue any  
antithrombotic therap y and will begin study rivaroxaban placebo and study aspi[INVESTIGATOR_248] 100 mg.  
Subjects who successfully  complete the run -in period and who remain committed to the study  
as well as those who are being randomized after CABG will be randomized and begin study  
treatments on Day  0, which will also signal the initiation of the follow -up period.  Subjects 
without a continuous need for treatment with a PPI[INVESTIGATOR_834133] 1:1 to the pantoprazole 
or pantoprazole placebo and all subjects (including those subjects who entered the study  while 
alread y receiving a PPI) will then be randomized 1:1:1 to rivaroxaban alone, the combination 
of rivaroxaban and aspi[INVESTIGATOR_834134], and their matching placebos as shown in Table 4 -
1:
[COMPANY_003]
Integrated Clinic al Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 111of 205
Table 4 -1.  Randomized study treatments* 
Study Arm Treatm ent Assignments
ARivaroxaban 2.5 mg bid +
Aspi[INVESTIGATOR_248] 100 mg od +
Pantoprazole 40 mg odRivaroxaban 2.5 mg bid +
Aspi[INVESTIGATOR_248] 100 m g od +
Pantoprazole placebo od
BRivaroxaban 5 mg bid + Aspi[INVESTIGATOR_834135] + Pantoprazole 40 mg odRivaroxaban 5 mg bid + Aspi[INVESTIGATOR_834135] +Pantoprazole placebo od
CRivaroxaban placebo + Aspi[INVESTIGATOR_248] 100 mg od +Pantoprazole 40 mg odRivaroxaban placebo + Aspi[INVESTIGATOR_248] 100 mg od + Pantoprazole placebo od
*Subjects who have a continuous need for use of a proton pump inhibitor at baseline will undergo only a single 
randomization (to rivaroxaban 2.5 mg bid + aspi[INVESTIGATOR_248] 100 mg od, rivaroxaban 5 mg bid + aspi[INVESTIGATOR_834105] + aspi[INVESTIGATOR_248] 100 mg od)
Subjects will be seen in the clinic at [ADDRESS_1158570] information on treatment adherence, treatment interruption, outcomes, and adverse events (AEs).  Validated questionnaires will be 
administered before or at the time of randomization , or as soon as possible thereafter, and at 
Month [ADDRESS_1158571] health and quality  of life (Standard Assess ment of Global-
Activities in the Elderly  [SAGE], Montreal Cognitive Assessment [MoCA], DSS [Digital 
Symbol Substitution], European Quality of Life -5 Dimensions [EQ -5D], The Interheart Diet 
Questionnaire, and The International Phy sical Activity  Questionnair e).  
Section 4.1.1 Subjects randomized after CABG surgery
This section was chang ed as a result of Modification 4 and 10. 
Old Text:Subjects randomized after CABG surgery  will undergo the same screening, follow -up and 
washout periods as other COMPASS trial subjects but will not undergo a run-in period.  The 
majority  of these subjects are expected to undergo screening during the 2- [ADDRESS_1158572] 
administration of any  anticoagulant (including DVT prophy laxis). 
Subjects randomiz ed after CABG surgery  will undergo computed tomography  (CT) 
angiograph y at [ADDRESS_1158573] angiograph y (e.g., contrast allergy , estimated glomerular filtration rate <30 ml/min). 
New Text:
Subjects randomized Day  4-[ADDRESS_1158574] administration of any anticoagulant (including DVT proph ylaxis) (Section 7.1.1 
Tabulated overview).
[COMPANY_003]
Integrated Clinic al Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 112of 205
Subjects randomized Day  4-7after C ABG surgery will undergo computed tomography  (CT)  
angiograph y at [ADDRESS_1158575] angiograph y (e.g., contrast allergy , estimated glomerular 
filtration rate <30 ml/min). In the event the subject undergoes an invasive coronary  
angiograph y at [ADDRESS_1158576] angiogram may not be required.
Section 4.3.1 Overall design rationale
This section was changed as a result of Modification 4. 
Old Text:The benefit of increasing the intensity  of antithrombotic therapy  for the prevention of 
recurrent thrombotic cardiovascular events by [CONTACT_1583] a second agent to aspi[INVESTIGATOR_834241] y after an acute coronary  syndrome when 
compared with aspi[INVESTIGATOR_264086].  
…To date, no trials have directl y compared a new anticoagulant with aspi[INVESTIGATOR_834144] -term 
secondary  prevention of cardiovascular disease.  Prior efforts to identify  more effective 
antithrombotic treatments than aspi [INVESTIGATOR_834145] (terutroban, 
a platelet thromboxane receptor antagonist; clopi[INVESTIGATOR_7745], prasugrel and ticagrelor, adenosine 
diphosphate (ADP) receptor antagonists; and vorapaxar, a PAR- [ADDRESS_1158577]) and 
warfarin.  
New Text:
The benefit of increased intensity  of antithrombotic therap y for the prevention of recurrent 
thrombotic cardiovascular events b y adding a second agent to aspi[INVESTIGATOR_834138] y after an acute coronary s yndrome when compared with 
aspi[INVESTIGATOR_264086].  
…
To date, no trials have directl y compared a new anticoagulant with aspi[INVESTIGATOR_834144] -term 
secondary  prevention of cardiovascular disease.  Prior efforts to identify  more effective 
antithrombotic treatments than as pi[INVESTIGATOR_834145] (terutroban, 
a platelet thromboxane receptor antagonist; clopi[INVESTIGATOR_7745], prasugrel and ticagrelor, P2Y12
antagonists; and vorapaxar, a PAR -[ADDRESS_1158578]) and warfarin.  
Section 5 Study population
This section was changed as a result of Modification s 4, 6, 11, 12 and 13. 
Old Text:Approximately  19,[ADDRESS_1158579] CABG and without run- in.  Approximately  10% of run -insubjects 
are expected to either be non- compliant with treatment or to decline further interest in 
participating; thus, the study  will randomize approximately  19,500 men and women with 
objectively  confirmed CAD or PAD from 25 to 30 countries worldwide.
Forthe purposes of this trial, the definition of CAD is:
[COMPANY_003]
Integrated Clinic al Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 113of 205
Previous myocardial infarction, or
Stable angina or unstable angina with documented multi -vessel CAD, > 50% stenosis 
in at least [ADDRESS_1158580] 
(electrocardiogram (ECG) or nuclear perfusion scintogram), or
Multi- vessel percutaneous coronary  intervention (PCI ), or
Multi- vessel CABG surgery  within [ADDRESS_1158581] 4 y ears ago or with recurrent 
angina or ischemia at an y time following surgery .1
1 Rationale:  The risk of thrombotic events and graft failure increases during the first year post CABG.12  Following 
a relatively stable period with low event rates between Year 1 and 4, the risk starts to rise again.28
For the purposes of this trial, th e definition of PAD is:
Previous aorto- femoral by [CONTACT_4897] , limb by [CONTACT_834372] y of the iliac or infrainguinal arteries, or
Previous limb or foot amputation for arterial vascular disease (i.e., excludes trauma), 
or
History  of intermittent claudication and either an ankle/arm blood pressure (BP) ratio 
≤0.90 or significant peripheral artery stenosis ( >50%) documented b y angiography  or 
non-invasive testing by [CONTACT_136665], or
Asymptomatic (i.e., no ipsilateral stroke or transient ischemic attack within 6 months) 
carotid artery  stenosis > 50% as diagnosed by  [CONTACT_834334] .
New Text:
Approximately  23,[ADDRESS_1158582] CABG and without run- in.  Approximately  10% of run -in subjects 
are expected to either be non- compliant with treatment or to decline further interest in 
participating; thus, the study  will randomize approximately  21,[ADDRESS_1158583] one or more of the following:
Myocardial infarction within the last 20 y ears, or
Multi- vessel coronary disease* with s ymptoms or history  of stable or unstable angina, 
or
Multi- vessel percutaneous coronary  intervention (PCI ), or
Multi- vessel CABG surgery  
[COMPANY_003]
Integrated Clinic al Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 114of 205
*Refers to stenos is of greater than or equal to 50% in two or more coronary  arteries, 
confirmed b y invasive coronary  angiography , or non-invasive imaging or stress studies 
(e.g. exercise or pharmacologic) s uggestive of significant ischemia in 2 or more coronary  
territories; or in [ADDRESS_1158584] o ne or more of the following:
Previous aorto- femoral by [CONTACT_4897] , limb by [CONTACT_4897] , or percutaneous 
transluminal angioplast y revascularization of the iliac, or infrainguinal arteries, or
Previous limb or foot amputation for arterial vascular disease (i.e., excludes trauma), 
or
History  of intermittent claudication and one or more of the following: 1) an ankle/arm 
blood pressure (BP) ratio < 0.90, or 2) significant peripheral artery  stenosis ( ≥50%) 
documented b y angiography , or b y duplex ultrasound, or
Previous carotid revascularization (e.g., endarterectomy, stenting) or asymptomatic 
(i.e., no ipsilateral stroke or transient ischemic attack within 6 months) carotid artery  
stenosis ≥ 50% as diagnosed by [CONTACT_834373] y.
Section 5.1.1 Incl usion criteria
This section was changed as a result of Modification 3. 
Old Text:
CAD or PAD plus at least one of the following:
oAge ≥65
oAge <[ADDRESS_1158585] two
additional risk factors
Additional risk fa ctors are: 
Current smoker
Diabetes mellitus
Renal dy sfunction with estimated glomerular filtration rate <60 ml/min 
Heart failure
Non-lacunar ischemic stroke ≥1 month ago
New Text:
Meet criteria for CAD * and/ or PAD
*Subjects with CAD must also meet at least one of the following criteria:
Age ≥65, or
Age <[ADDRESS_1158586] 2
vascular beds§, or at least 2 additional risk factors:
[COMPANY_003]
Integrated Clinic al Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 115of 205
1) Current smoker (within 1 year of randomization)
2) Diabetes mellitus
3) Renal dy sfunction with estimated glomerular filtration rate 
<60ml/min 
4) Heart failure 
5) Non-lacunar ischemic stroke ≥1 month ago
§Because CAD involves disease in the coronary  vasculature, onl y one additional vascular bed 
is required: e.g. the aorta and arterial supply  to the brain, gastro -intestinal tract, lower limbs, 
upper limbs, or kidney s.
Section 5.1.2 Exclusion criteria
This section was changed as a result of Modification 5 and 14. 
Old Text:
History  of hypersensitivity  or known contraindication for rivaroxaban, aspi[INVESTIGATOR_248], or
pantoprazole
Systemic treatment with strong CYP 3A4 and p -glycoprotein (P -gp) inhibitors (e.g., 
systemic azole antim ycotics, such as ketoconazole, and human immunodeficiency  
virus [HI V]-protease inhibitors, such as ritonavir) 
Any known hepatic disease associated with coagulopathy
Female subjects, premenopausal who are not surgically  sterile , or, ifsexually  active 
not practicing an effective method of birth control (e.g., prescription oral 
contraceptives, contraceptive injection s, intrauterine device, double -barrier method, 
contraceptive patch, male partner sterilization) before entry  and throughout the study ; 
and, for those of childbearing potential, who have a positive pregnancy  test at 
screening
Previous assignment to treatmen t during this study
An additional exclusion for the pantoprazole randomization is:
Need for treatment with a PPI
[INVESTIGATOR_834242]:
History  of hypersensitivity  or known contraindication for rivaroxaban, aspi[INVESTIGATOR_248], 
pantoprazole, or excipi[INVESTIGATOR_840], if applicable .
Systemic treatment with strong inhibitors of both CYP 3A4 and p- glycoprotein (P -gp) 
(e.g., s ystemic azole antimy cotics, such as ketoconazole, and human 
immunodeficiency  virus [HI V]-protease inhibitors, such as ritonavir), or strong 
inducers of CYP 3A4, i.e. rifampi[INVESTIGATOR_2513], rifabutin, phenobarbital, pheny toin, and 
carbamazepi[INVESTIGATOR_050]
Any known hepatic disease associated with coagulopathy
Subjects who are pregnant, breastfeeding or are of childbearing potential, and sexually  
active and not practicing an effective me thod of birth control (e.g. surgically sterile, 
[COMPANY_003]
Integrated Clinic al Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 116of 205
prescription oral contraceptives, contraceptive injections, intrauterine device, double -
barrier method, contraceptive patch, male partner sterilization) 
Previous assignment to treatment during this study
Concomitant participation in another study  with investigational drug
Known contraindication to any  study  related procedures
An additional exclusion for the pantoprazole randomization is:
Need for continuous treatment with a PPI
[CONTACT_8985] 5.2 Discontinuation of subjects from study treatment
This section was changed as a result of Modification 15. 
Old Text:
…In all cases, every effort must be made to continue to follow the subject andsurvival 
status information must be determined for all subjects at the end of the study .
New Text:…In all cases, including the subjects with the study outcome , every effort must be made 
to continue to follow the subject at regular study visits. Additionally, survival status and 
outcome information must be determined for all subjects. 
Section 6.1 Treatments to be administeredThis section was changed as a result of Modifications 4 and 16. 
Old Text:The study  drugs to be administered in this trial include the antithrombotic drugs, rivar oxaban 
and aspi[INVESTIGATOR_248]; the PPI[INVESTIGATOR_834149]; and their matching placebos.  
New Text:The study  drugs to be administered in this trial include the antithrombotic drugs, rivaroxaban 
and enteric -coated aspi[INVESTIGATOR_248]; the PPI[INVESTIGATOR_834149]; and their matching placebos.   
Section 6.1.1 Run- in
This section was changed as a result of Modification 4. 
Old Text:During the run- in period, Day  -30to Day  -1 (± 5 day s),eligible subjects (excluding those who 
are randomized during the first week after CABG surgery ) who have signed informed consent 
and stopped non -study  anticoagulants and aspi[INVESTIGATOR_834243] 100 mg od.  
New Text:During the run- in period, Day  -28to Day  -1, eligible subjects (excluding those w ho are 
randomized Day 4-7after CABG surgery ) who have signed informed consent and stopped 
non-study  anticoagulants and aspi[INVESTIGATOR_834150] 100 mg 
[COMPANY_003]
Integrated Clinic al Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 117of 205
od.  
Section 6.1.2 Randomization
This section was chan ged as a result o f Modifications 4, 5and 17. 
Old Text:Subjects who have completed the run -in period with at least 80% adherence to treatment with 
rivaroxaban placebo bid and aspi[INVESTIGATOR_248] [ADDRESS_1158587] a need to take a PPI, will initially  be randomized 1:1 to receive pantoprazole 40 mg od or 
matching placebo od, stratified by  [CONTACT_384].  
New Text:Subjects who have completed the run -in period with adherence to treatment with rivaroxaban 
placebo bid and aspi[INVESTIGATOR_248] [ADDRESS_1158588] 80% except forextenuating circumstances , and
who wish to continue in the study  will be randomized.  Subjects being randomized after run -in 
and those who are being rand omized  Day 4-7after CABG surgery (Section 7.1.1 Tabulated 
overview) and who do not have a continuous need to take a PPI, will initially  be randomized 
1:1 to receive pantoprazole 40 mg od or matching placebo od, stratified b y center.  
Section 6.2 Identi ty of study treatment
This section was changed as a result of Modification 16. 
Old Text:…Label text will be approved according to the sponsor’s agreed procedures, and a copy  of the 
labels will be made available to the study site upon request.
New Text:
…Label text will be approved according to the sponsor’s agreed procedures, and a copy  of the 
labels will be made available to the study site upon request. For the purpose of this study , the 
term “aspi[INVESTIGATOR_248]” is used interchangeabl y with the term “acet yl salicy lic acid”.
Section 6.4.1 Dose modificationsThis section was changed as a result of Modification 4. 
Old Text:Permanent study  drug interruption should be recorded on the corresponding follow- up case 
report form, giving the date and primary  reason for stoppi[INVESTIGATOR_49080].  If one of the 
study  treatments needs to be interrupted, other study  treatments must be continued.  
[COMPANY_003]
Integrated Clinic al Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 118of 205
New Text:
Permanent st udy drug interruption should be recorded on the corresponding follow -up case 
report form, giving the date and primary  reason for stoppi[INVESTIGATOR_49080].  If one of the 
study  treatments needs to be discontinued , other study  treatments must be continued. 
Section 6.4.2 Dose modifications and treatment guidanceThis section was changed as a result of Modification s 4and 18. 
Old Text:This section provides a general guide for investigators on the management of subjects who 
develop intercurrent illnesses or bl eeding during the course of the COMPASS trial.  The 
guidance provided in this section does not replace clinical judgment in determining the appropriate management strategy  for individual subjects. 
New Text:
This section provides a general guide for investig ators on the management of subjects who 
develop intercurrent illnesses or bleeding during the course of the COMPASS trial.  The 
guidance provided in this section does not replace clinical judgment nor usual care in 
determining the appropriate management strategy  for individual subjects. For specific 
treatment guidance with study  pantoprazole/pantoprazole placebo see Section 6.9.4   
Section [IP_ADDRESS] Guidance for the treatment of subjects who require an invasive procedure
This section was chang ed as a result of Modification s 4and 18. 
Old Text:…If study aspi[INVESTIGATOR_248]/aspi[INVESTIGATOR_834156], non -study  aspi[INVESTIGATOR_834244].  Study  
pantoprazole/pantoprazole placebo should not be interrupted unless subjects develop a need 
for treatment with a PPI .  
New Text:
…If study aspi[INVESTIGATOR_248]/aspi[INVESTIGATOR_834156], non -study  aspi[INVESTIGATOR_834244].  
Section [IP_ADDRESS] Guidance for the treatment of subjects who require coronary artery 
by[CONTACT_834374] a result of Modification s 4 and 18. 
Old Text:
Subjects who are scheduled to be randomized during the first week after CABG surgery  will 
not participate in the run -in phase but will sign informed consent and undergo screening 
before the surgery (Section 4.1.1).  The timing of randomization should be no earlier than [ADDRESS_1158589] tubes are removed and 
hemostasis is secure.   
…
[COMPANY_003]
Integrated Clinic al Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 119of 205
In all cases, the goal should be to resume study  antithrombotic drugs within 7days and prior 
to being discharged from hospi[INVESTIGATOR_307].  
Study  pantoprazole/pantoprazole placebo should not be interrupted unless subjects develop a 
need for treatment with a PPI.  
New Text:
Subjects who are scheduled to b e randomized Day 4 -7after CABG surge ry will not 
participate in the run -in phase (Section 4.1.1).  Randomization should only be performed
between Day  4-7post-CABG and at least [ADDRESS_1158590] administration of any  anticoagulant ( including DVT proph ylaxis).
In all cases, the goal should be to resume study  antithrombotic drugs within 14days and prior 
to being discharged from hospi[INVESTIGATOR_307].  
Section [IP_ADDRESS] Guidance for the treatment of subjects who develop an acute coronary 
syndrome and those who require percutaneous coronary intervention with stenting
This section was chang ed as a result of Modifications 4and18. 
Old Text:
…Standard anticoagulant therap y can be used without regard to the timing of the most recent 
dose of study  rivaroxaban/rivaroxaban placebo because the doses of rivaroxaban being tested 
in the COMPASS trial are lower than the 20 mg dose given for stroke prevention in atrial 
fibrillation and the half -life is short, 5 -13 hours.  
Study  pantoprazole/pantoprazole placebo should not be interrupted unless subjects have 
developed a need for treatment with a PPI .  
New Text:…Standard anticoagulant therap y can be used without regard to the timing of the most recent 
dose of study  rivaroxaban/rivaroxaban placebo because the do ses of rivaroxaban being tested 
in the COMPASS trial are lower than the 15 or 20mg dose given for stroke prevention in 
atrial fibrillation and the half-life is short, 5- 13 hours.  
Section 6.6 Drug logistics and accountabilityThis section was changed as a result of Modification 4. 
Old Text:…  The responsible site personnel will confirm the date and time of receipt of study  drug and 
will use the study  drug only  within the framework of this clinical study  and in accordance 
with this protocol.  .
New Text:
…The responsible site personnel will confirm the date of receipt of stud y drug and will use 
the study  drug onl y within the framework of this clinical study  and in accordance with this 
protocol.  
[COMPANY_003]
Integrated Clinic al Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 120of 205
Section 6.9 Prior concomitant therapy
This section was chan ged as a result of Modification 4. 
Old Text:As described in Section 5.1.2, Exclusion Criteria, the use of the following agents is not 
permitted at study  entry :  systemic treatment with strong CYP 3A4 and P -gp inhibitors(e.g., 
systemic azole antim ycotics,such as ketoconazole, and HIV -protease inhibitors, such as 
ritonavir).  Additionally, subjects with a need for dual antiplatelet therapy  or oral 
anticoagulant therap y are not eligible for inclusion in COMPASS.
New Text:As described in Section 5.1.2, Excl usion Criteria, the use of the following agents is not 
permitted at study  entry :  systemic treatment with strong inducers of CYP 3A4 (e.g. 
rifampi[INVESTIGATOR_2513]) and inhibitors of both CYP 3A4 and P -gp (e.g., s ystemic azole antimy cotics, such 
as ketoconazole, and HIV -protease inhibitors, such as ritonavir).  Additionally , subjects with a 
need for dual antiplatelet therap y or oral anticoagulant therap y are not eligible for inclusion in 
COMPASS.
Section 6.9.1 Combined CYP 3A4 and p -glycoprotein inhibitors
This section w as changed as a result of Modifications 18 and 19. 
Old Text:
6.9.1 Combined CYP 3A4 and p -glycoprotein inhibitors
Strong inhibitors of both CYP 3A4 and p- glycoprotein increase plasma concentrations of 
rivaroxaban and are contraindicated in subjects taking rivaroxaban.  These include systemic 
azole antifungal drugs (ketoconazole), macrolide antibiotics (ery thromy cin, a zithromy cin, 
clarithrom ycin) and HIV protease inhibitors.  If any  of these treatments are needed, 
randomized study  rivaroxaban/rivaroxaban placebo and aspi[INVESTIGATOR_248]/aspi[INVESTIGATOR_834245] -label aspi[INVESTIGATOR_834246].  Study  
pantoprazole/pantoprazole placebo should not be interrupted unless subjects develop a need 
for treatment with a PPI .  
New Text:
6.9.1 Combined CYP 3A4 and p -glycoprotein inhibitors and CYP 3A4 inducers
Strong inhibitors of both CYP 3A4 and p- glycoprotein i ncrease plasma concentrations of 
rivaroxaban and are contraindicated in subjects taking rivaroxaban. These include systemic 
azole antifungal drugs ( e.g. ketoconazole, itraconazole, posaconazole , etc.), and HIV protease 
inhibitors.  Additionally , strong inducers of CYP 3A4 such as, i.e. rifampi[INVESTIGATOR_2513], rifabutin, 
phenobarbital, phen ytoin, and carbamazepi[INVESTIGATOR_834173]. If any of these treatments are needed, randomized study rivaroxaban/rivaroxaban 
placebo and aspi[INVESTIGATOR_248]/aspi[INVESTIGATOR_834247] y discontinued and open -label aspi[INVESTIGATOR_834174]. 
[COMPANY_003]
Integrated Clinic al Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 121of 205
Section 6.9.2 Clopi[INVESTIGATOR_7745] (or any other non- study antiplatelet treatment)
This section was changed as a result of Modification 4. 
Old Text:
Subjects who develop a need for treatment with non- study  antiplatelet therapy , such as aspi[INVESTIGATOR_834248] (e.g., subjects who experience an acute coronary  syndrome, those who 
undergo percutaneous coronary  intervention with stent insertion) must discontinue study  
rivaroxaban/rivaroxaban placebo.  Study rivaroxaban/rivaroxaban placebo must be restarted 
once dual antiplatelet therap y is stopped (i.e., after completion of an adequate duration of dual 
antiplatelet treatment).  Additional guidance is provid ed in Section [IP_ADDRESS].  
New Text:
Subjects who develop a need for treatment with non- study  dual antiplatelet therap y, such as 
aspi[INVESTIGATOR_259941] (e.g., subjects who experience an acute coronary  syndrome, those 
who undergo percutaneous coronary  inter vention with stent insertion) must interrupt study  
treatment of rivaroxaban/rivaroxaban placebo.  Study  rivaroxaban/rivaroxaban placebo must 
be restarted once dual antiplatelet therap y is stopped (i.e., after completion of an adequate 
duration of dual antiplatelet treatment).  Additional guidance is provided in Section [IP_ADDRESS].  
Section 6.9.3 Anticoagulant treatment
This section was changed as a result of Modification 18. 
Old Text:
…In subjects who develop a need for anticoagulant therapy , study  aspi[INVESTIGATOR_248]/a spi[INVESTIGATOR_834249], at the discretion of the investigator.  Study  pantoprazole/pantoprazole 
placebo should not be interrupted unless subjects have a need for treatment with a PPI.  
New Text:…In subjects who develop a need for anticoag ulant therapy , study  aspi[INVESTIGATOR_248]/aspi[INVESTIGATOR_834249], at the discretion of the investigator.  
Section 6.9.4 Proton pump inhibitor treatment
This section was changed as a result of Modifications 4and 18. 
Old Text:Subjects who develop a need for treatment with a PPI(e.g., gastroduodenal ulcer) should 
discontinue study  pantoprazole/pantoprazole placebo while receiving non- study  PPI 
[CONTACT_3148].  Study  pantoprazole/pantoprazole placebo must be restarted in all subjects who no 
longer have a need for PPI[CONTACT_48831] . 
New Text:Subjects who develop a continuous need for treatment with a PPI [CONTACT_61641] (e.g., 
gastroduodenal ulcer) should discontinue study  pantoprazole/pantoprazole placebo while 
receiving non- study  PPI [CONTACT_3148].  Study  pantoprazole/pantoprazole placebo should be 
restarted in all subjects who no longer have a continuous need for PPI[CONTACT_48831] . 
[COMPANY_003]
Integrated Clinic al Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 122of 205
Section 7.1.1 Tabulated overview
This section was chang ed as a re sult of Modification 20 . 
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 123of 205
Old Text:
Table 7 -1.  Schedule of evaluations
Pre-Screeninga
Screening/Run-in
RandomizationFollow -up
Washout
Visit [ADDRESS_1158591] 
Finalm
Windows ± 5d ± 7d ± 2w ± 4w ± 4w ± 4w ± 4w ± 4w ± 4w ± 4w ± 4w ± 4w ± 4w ± 4w ± 4w ± 5d
Informed consent (if required for 
pre-screening)X
Informed consent X
Inclusion/exclusion criteria X X
Demographics X
Medical histor y X
Physical measurementsbX X X
Concomitant medications X X X X
Pregnancy test if pre -
menopausalX
Laboratory testscXdXe
Blood/DNA collection and storageX
fXf
Diet and activity questionnaires XoXoX
MoCA, DSS, and SAGE XoXoX X
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 124of 205
Pre-Screeninga
Screening/Run-in
RandomizationFollow -up
Washout
Visit [ADDRESS_1158592] 
Finalm
Windows ± 5d ± 7d ± 2w ± 4w ± 4w ± 4w ± 4w ± 4w ± 4w ± 4w ± 4w ± 4w ± 4w ± 4w ± 4w ± 5d
EQ-5DgXoXoX X
Health Care Costs X
Driving Status X
EuroSCORE for subjects 
randomized post CABG surgeryX
CT coronary angiographyhXh
MRI brainiX X
Outcomes X X X X X X X X X X X X X X X
Adverse eventsjX X X X X X X X X X X X X X X X X X
Study drug dispensed XkXlX X X X X X X X X X
Study drug adherence X X X X X X X X X X X X X X X
Study drug accountability X X X X X X X X X X X X X
Abbreviations:  w = week; m = month; y = year; d = day; DNA = deox yribonucleic acid; MoCA =Montreal Cognitive Assessment; DSS = 
Digit Sy mbol Substitution test; SAGE = Standard Assessment of Global -Activities in the Elderly; EQ -5D = European Quality of Life- 5 
Dimensions questionnaire; CT = computed tomography; MRI = magnetic resonance imaging; CABG = coronary artery by[CONTACT_9292]
a.Pre-screening visit is not mandatory and will be c onducted only in some centers and for some subjects. Subjects who will be 
randomized during the first week after CABG surger y do not require pre -screening.
b.Weight, height, waist and hip circumference, heart rate, ankle -brachial blood pressure index
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 125of [ADDRESS_1158593] CABG surgery
f.Blood & DNA collection at randomization and blood collection at [ADDRESS_1158594] week after CABG (except in 
subjects those with specific contraindications)
i.MRI of the brain will be performed only in COMPASS -MIND substudy subjects, at the time of randomization (or soon thereafter) 
and at the end of the follow- up
j.Adverse events will be assessed from time of consent to [ADDRESS_1158595] week after CABG surgery and will not be 
dispensed run -in study drug; however, the Screening/Run- In Visit CRFs are still required to be completed for these subjects.  
l.Stop run -in medication and begin randomized treatment assignment
m.Telephone visits
n.Visits wil l continue every 6 months until the required number of primary  efficacy outcomes has been collected
o.It is optional to administer all or some of the questionnaires (SAGE, DSS, MoCA, EQ -5D, Diet, and Physical Activity) at 
Screening/Run -in instead of at the R andomization Visit 
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 126of 205
New Text:
Pre-Screeninga
Screening/Run -
in
Randomizations
Follow -up
Washout
Visit [ADDRESS_1158596] 
Finalm
Windowsq± 5d ± 7d± 2w ± 4w ± 4w ± 4w ± 4w ± 4w ± 4w ± 4w ± 4w ± 4w ± 4w ± 4w ± 4w ± 5d
Informed consent (if required for 
pre-screening)X
Informed consent Xr
Inclusion/exclusion criteria X X X
Demographics X
Medical histor y X
Physical measurementsbX X X
Concomitant medications X X X X
Pregnancy test if pre -
menopausalX
Laboratory testscXdXe
Blood/DNA collection andstorageX
fXf
Diet and activity questionnaires XoXoXpX
MoCA, DSS, and SAGE XoXoXpX X
EQ-5DgXoXoXpX X
Health Care Costs X
Driving Status X
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 127of 205
Pre-Screeninga
Screening/Run -
in
Randomizations
Follow -up
Washout
Visit [ADDRESS_1158597] 
Finalm
Windowsq± 5d ± 7d± 2w ± 4w ± 4w ± 4w ± 4w ± 4w ± 4w ± 4w ± 4w ± 4w ± 4w ± 4w ± 4w ± 5d
EuroSCORE for subjects 
randomized post CABG surgeryX
CT coronary angiographyhXh
MRI brainiX X
Outcomes X X X X X X X X X X X X X X X X
Adverse eventsjX X X X X X X X X X X X X X X X X X
Study drug dispensed XkXlX X X X X X X X X X
Study drug adherence X X X X X X X X X X X X X X X
Study drug accountability X X X X X X X X X X X X X
Abbreviations:  w = week; m = month; y = year; d = day; DNA = deox yribonucleic acid; MoCA =Montreal Cognitive Assessment; DSS = 
Digit Sy mbol Substitution test; SAGE = Standard Assessment of Global -Activities in the Elderly; EQ -5D = European Quality of Life- 5 
Dimensions questionnaire; CT = computed tomography; MRI = magnetic resonance imaging; CABG = cor onary artery by[CONTACT_9292]
a.Pre-screening visit is not mandatory and will be conducted only in some centers and for some subjects. Subjects who will be rando mized  
Day [ADDRESS_1158598] CABG surger y For other, non -CABG subjects, the blood results o f 
creatinine and total cholesterol  should be available within 3 months of this visit.
f.Collection of blood & DNA samples for central evaluation in subjects participating in the COMPASS -MIND substudy is optional.  If 
collected, obtain samples at randomizat ion, before starting study drug, and at 1 month , or as close to one month after randomization as 
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 128of [ADDRESS_1158599] angiography will be performed at 1 year in all subjects who are randomized Day 4 -7 after CABG to evaluate graft patency (except in 
subjects those with specific contraindications ).In the event the subject undergoes an invasive coronary angiography at [ADDRESS_1158600] angiogram may  not be required.
i.MRI of the brain will be performed only in COMPASS -MIND substudy subjects, at the time of randomization (or soon thereafter , within 3 
months) and near the end of the follow -up
j.Adverse events will be assessed from time of consent to [ADDRESS_1158601] dose of study treatment
k.Stop treatment with non -study  aspi[INVESTIGATOR_248]. Dispense run -in medications. CABG surgery patients will be randomized Day 4-7after CABG 
surgery and will not be dispensed run- in study drug; however, the Screening/Run- In Visit CRFs are still required to be completed for 
these subjects.  
l.Stop run -in medication and begin randomized tr eatment assignment
m.Telephone visits
n.Visits will continue every 6 months until the required number of primary  efficacy outcomes has been collected
o.It is optional to administer all or some of the questionnaires (SAGE, DSS, MoCA, EQ -5D, Diet, and Physical Activit y) at Screening/Run -in 
instead of at the Randomization Visit , or as soon as possible thereafter (with the exception of patients randomized Day [ADDRESS_1158602] CABG; 
see “p”).   
p.For patients randomized Day [ADDRESS_1158603] CABG, questionnaires (SAGE, DSS, MoCA, EQ -5D, Diet, and Physical Activity) should be 
performed at the [ADDRESS_1158604] to return within the visit "window," especially due to unforeseen circumstance beyond the control of the subject or 
the study center, then the visit should be scheduled as close to the interval as is convenient for the subject and study cent er.
r.CABG subjects can sign the informed consent before or after surgery.
s.CABG subjects should be randomized between Day [ADDRESS_1158605] -CABG.
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 129of 205
Section [IP_ADDRESS] Screening and Run -in visit(s)
This section was changed as a result of Modification 21. 
Old Text:
The aim of the screening visit is to confirm eligibility  and perform baseline laboratory  
assessments and in most subjects will be performed on the day  of the run -in visit as long as 
laboratory  tests have been performed within [ADDRESS_1158606] week
after CABG surgery  the screening visit will be performed prior to surgery  (Section 4.1.1).  
The Screening/Run -in Visit will occur 4 weeks prior to randomization; however, screening 
may be earlier if performed on a separate day .  Screening/run- in activities include:
…
It is optional to administer all or some of the questio nnaires (SAGE, DSS, MoCA, EQ -
5D, Diet, and Phy sical Activity ) at Screening/Run- in instead of at the Randomization 
Visit
Collect blood for local laboratory  assessment of creatinine and total cholesterol (if not 
performed at pre -screening/screening/run- in, or previous laboratory  assessments were 
conducted > 3 months prior)
Collect blood for local laboratory  assessment of creatinine and total cholesterol ( 
previous laboratory  assessments were conducted > 3 months prior)
…
Obtain medication code for run- in stud y treatment and dispense run -in study  
medications (not applicable for subjects who are randomized during the first week
after CABG surgery )
New Text:The aim of the screening visit is to confirm eligibility . Laboratory  results of creatinine and 
total cholesterol performed within a y ear of this visit can be used to assess eligibility . 
Otherwise, obtain relevant laboratory  tests.  For subjects who are randomized D ay 4-7after 
CABG surgery , the screening visit may be performed prior to or after surgery  (Section 4.1.1).  
Screening/run- in activities include:
…
It is optional to administer all or some of the questionnaires (SAGE, DSS, MoCA, EQ-
5D, Diet, and Phy sical Activity ) at Screening/Run- in instead of at the Randomization 
Visit. (In patients randomized D ay 4-[ADDRESS_1158607] CABG, the questionnaires should be 
performed at the 1 month visit).  
…
Obtain medication code for run- in study  treatment and dispense run- in study  
medications (not applicable for subjects who are randomized Day 4-7 after CABG 
surgery ) 
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 130of [ADDRESS_1158608] can be re -screened/re -run-in, if not previously  randomized to study  treatment:
Obtain written informed consent, if applicable 
Repeat/c omplete the rest of the screening/run -inactivities, where applicable.
Section [IP_ADDRESS] Randomization visit (Day 0 ± 5 days)
This section was changed as a result of Modification 21. 
Old Text:
The aim of the randomization visit is to assign blinded study  treatment.  Subjects may  be 
randomized if they  fulfill all study  inclusion and exclusion criteria, have at least 80% 
adherence to both run -in study  treatments, and remain committed to participate in the trial.  
Randomization activities include : 
Perform run- in drug accountability ; assess adherence to run- in drug (not applicable for 
subjects who are randomized during the first week after CABG surgery )
Collect blood (DNA) sample for storage and cen tral evaluation in COMPASS MI ND 
substudy  subjects
New Text:The aim of the randomization visit is to assign blinded study  treatment.  Subjects may  be 
randomized if they  fulfill all study  inclusion and exclusion criteria, have the blood results of 
the serum creatinine and total cholesterol available within [ADDRESS_1158609]
80% adherence (except for extenuating circumstances) to both run- in study  treatments and 
remain committed to participate in the trial andrandomization activities including : 
Perform run- in drug accountability ; assess adherence to run- in drug (not applicable for 
subjects who are randomized Day 4-7after CABG surgery )
In patients randomized day 4-[ADDRESS_1158610] CABG perform questionnaires (SAGE, DSS, 
MoCA, EQ -5D, Diet, and Phy sical Activity ) at 1 month visit  
Assess local laboratory  results of creatinine and total cholesterol
Collect blood (DNA) sample for storage and central evaluation in COMPASS MI ND 
substudy  subjects, if applicable
Record outcomes
Section [IP_ADDRESS].1 Routine follow -up visits (Visits 3, 5, and 7-15+)
This section was changed as a result of Modification 21. 
Old Text:
Perform CT angiograph y only  at Visit 7 (1 y ear) in all subjects who are randomized 
during the first week after CABG (except in subjects those with specific 
contraindications)
o Administer diet and activity  questionnaires at Visit 9 (2 y ears)
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 131of 205
New Text:
In patients randomized Day 4-[ADDRESS_1158611] CABG perform questionnaires (SAGE, DSS, 
MoCA, EQ -5D, Diet, and Phy sical Activity ) (1 month).  
…
Perform CT  angiography onl y at Visit 7 (1 year) in all subjects who are randomized 
during the first week after CABG to evaluate graft patency (except in subjects with 
specific contraindications). In the event the subject undergoes an invasive coronary  
angiography  at [ADDRESS_1158612] angiogram may not be required.
o Administer diet and activity  questionnaires at Visit 9 
Section 7.2.3 Other baseline characteristics
This section was changed as a result of Modification 4. 
Old Text:
Validat ed health and quality  of life questionnaires, SAGE, MoCA, DSS, EQ -5D will be 
administered at randomization, as well as Month 24, and the Final Follow -up Visit to measure 
the effect of randomized treatment on functional outcomes and quality  of life, and die t and 
activity  questionnaires will also be administered in order to explore the determinants and 
consequences of cognitive decline in patients with CAD and PAD.
New T ext:  
Validated health and quality  of life questionnaires, SAGE, MoCA, DSS, EQ- 5D will be
administered at screening/run- in or randomization, as well as Month 24, and the Final Follow-
up Visit to measure the effect of randomized treatment on functional outcomes and quality  of 
life, and diet and activity  questionnaires will also be administered in order to explore the 
determinants and consequences of cognitive decline in patients with CAD and PAD.Section 7.3 Efficacy
This section was changed as a result of Modifications 2, 4 and 22. 
Old Text:
The secondary  efficacy  outcome is a composite of my ocardial infarction, stroke, 
cardiovascular death, venous thromboembolism, and cardiovascular hospi[INVESTIGATOR_059].  Mortality  
by [CONTACT_834375] a secondary  efficacy  outcome.
Tertiary  efficacy  outcomes include the evaluation of responses recorded for the SAGE, 
MoCA, DSS, and EQ- 5D inventories and the following:  individual components of the 
primary  and secondary  outcomes, hospi[INVESTIGATOR_059], revascularization, amputation, unstable 
angina, worsening angina, new angina, heart failure, resuscitated cardiac arrest , new diagnosis 
of cancer.
MRU data will be incorporated into economic modeling, which will be performed and 
reported separatel y from this study . 
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 132of 205
The primary outcome for the pantoprazole randomization is a composite of overt bleeding of 
gastroduodenal ori gin confirmed b y endoscop y or radiograph y, overt upper gastrointestinal 
bleeding of unknown origin, bleeding of presumed occult gastrointestinal origin with documented decrease in Hb of 2 g/dL from baseline , symptomatic gastroduodenal ulcer, 
gastrointestin al pain with underly ing multiple gastroduodenal erosions, and gastrointestinal 
obstruction or perforation.
A detailed description of outcomes to be anal yzed for this study  will be provided in the 
separate statistical anal ysis plan.
New Text:
The secondary  efficacy  outcome is a composite of my ocardial infarction, stroke, 
cardiovascular death, revascularization , venous thromboembolism, and cardiovascular 
hospi[INVESTIGATOR_059].  Mortality  by [CONTACT_834375] a secondary  efficacy  outcome.
Tertiary  efficacy  outcomes include the evaluation of responses recorded for the SAGE, 
MoCA, DSS, and EQ- 5D inventories and the following:  individual components of the 
primary  and secondary  outcomes, hospi[INVESTIGATOR_059], amputation, stent thrombosis , unstable 
angina, worsening angina, n ew angina, heart failure, resuscitated cardiac arrest, new diagnosis 
of cancer, MRU, coronary  artery  by[CONTACT_541649].
Hospi[INVESTIGATOR_834190]. These data 
will be anal yzed and reported to the spon sor separatel y and will include:
Total day s length of stay
Emergency  room visits
Intensive care unit /cardiac care unit day s 
Rehabilitation and skilled nursing facilities
Reason for medical resource use, i.e., major adverse cardiovascular event or bleeding
MRU data will be incorporated into economic modeling, which will be performed and 
reported separatel y from this study . 
The outcome for the pantoprazole randomization is a composite of overt bleeding of gastroduodenal origin confirmed b y endoscop yor radiography , overt upper gastrointestinal 
bleeding of unknown origin, bleeding of presumed occult gastrointestinal origin with documented decrease in Hb of 2 g/dL, symptomatic gastroduodenal ulcer, gastrointestinal 
pain with underly ing multiple gastroduodenal erosions, and gastrointestinal obstruction, or 
perforation.
A detailed description of outcomes to be anal yzed for this study  will be provided in the 
separate statistical anal ysis plan.
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 133of 205
Section 7.5.1 Definition of (serious) adverse event
This sectio n was changed as a result of Modification 23. 
Old Text:
7.5.1 International Conference of Harmonisation E6 Definition of (serious) adverse 
event
A serious adverse event (SAE) is classified as an y untoward medical occurrence that, at an y 
dose, results in death, is life -threatening, requires inpatient hospi[INVESTIGATOR_4967], results in persistent or significant disability  / incapacity  is a 
congenital anomal y / birth defect and/or is another medically important serious eve nt 
representing a significant hazard, which is comparable to the aforementioned criteria. 
New Text:
7.5.1 Definition of (serious) adverse event
A serious adverse event (SAE) is classified as an y untoward medical occurrence that, at an y 
dose, results in de ath, is life -threatening, requires inpatient hospi[INVESTIGATOR_4967], results in persistent or significant disability  / incapacity  is a 
congenital anomal y / birth defect and/or is another medically important serious even t 
representing a significant hazard, which is comparable to the aforementioned criteria. A 
surgical procedure or hospi[INVESTIGATOR_834250] . However, the condition 
for which the surgery  or hospi[INVESTIGATOR_834251].
Section 7.5.2 Casual relationship (new section)
This section was changed as a result of Modification 23. 
New Text:
7.5.2 Causal relationship 
The assessment of the causal relationship between an AE and the administration of study  drug 
is a clinical decision based on all available information at the time of the completion of the 
CRF. The causality  assessment should be done separatel y for each stud y treatment as detai led 
in the CRF. The assessment is based on the question whether there was a “reasonable causal 
relationship” to the study drug in question.
Section 7.5.3 Protocol- specific adverse event defin itions
This section was changed as a result of Modifications 2, 22 and 23. 
Old Text:
Rivaroxaban has been extensively  studied in Phase [ADDRESS_1158613].
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 134of 205
For the purposes of this trial, the following events will be captured on the CRF as study  
outcome events onl y and will be waived from unblinding and will be exempted from the 
expedited reporting but will be included in the final study  report. 
Primary  Outcomes:
oCardiovascular death
oMyocardial infarction
oStroke
Secondary  and tertiary  outcomes
oCardiovascular hospi[INVESTIGATOR_834252], events that are expected to occur with high frequency  in the populati on under 
study  and for which no safet y signal arose from the >60,000 patients already  studied in 
clinical trials with rivaroxaban will be captured on the CRF only , will be waived from 
unblinding, and be will be exempted from expedited reporting.  These inc lude:
Planned hospi[INVESTIGATOR_602] (e.g., for surgery , respi[INVESTIGATOR_4594]) 
Non-cardiovascular SAEs (including unplanned hospi[INVESTIGATOR_602]) that are expected to 
occur with high frequency in the population under study  (depression, pneumonia, 
trauma, chronic obstructive pulmonary  disease, diabetes mellitus)
As bleeding, including fatal bleeding, from all tissues and organs is a known side effect of rivaroxaban, bleeding events, including those resulting in hospi[INVESTIGATOR_059], will not be reported as (S)AEs, but w ill be captured on the CRF onl y, and will be reported as outcomes.
Any other non -cardiovascular SAEs must be reported by [CONTACT_834376] 24 
hours and will be transmitted to the sponsor via expedited SAE reporting. The sponsor is 
responsible for reporting these events to the health authority . 
In addition, any  AEs of particular concern to the investigator may  be recorded on the CRF to 
bring them to the attention of the sponsor.
Hospi[INVESTIGATOR_834253] a nalysis of MRU.  These data 
will be anal yzed and reported to the sponsor separatel y and will include:
Total day s length of stay
[COMPANY_003]
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 135of 205
Emergency  room visits
Intensive care unit /cardiac care unit day s 
Rehabilitation and skilled nursing facilities
Reason for medical resource use, i.e., major adverse cardiovascular event or bleeding
[IP_ADDRESS] Adverse events of special safety interest
For ongoing pharmacovigilance, the large COMPASS trial is an opportunity to identify  rare 
events in the population that may  or may  not be drug -related.  The following events have, to 
date, not been observed with increased frequency with rivaroxaban, but are considered AEs of 
special safety  interest. These events must be reported to  independent of their 
seriousness, but within the sa me timelines as an SAE (within 24 hours) by  [CONTACT_834347]. Bayer HealthCare Global Pharmacovigilance may decide to 
upgrade the event based on the information received.
A non- cardiovascular AE that recurs when the participant is restarted on study  drug 
New Text:
[IP_ADDRESS] Protocol -specific exceptions to SAE reporting 
Rivaroxaban has been extensively  studied in Phase [ADDRESS_1158614].
For the purposes of this trial, the following events will be captured on the CRF as study  
outcome events onl y and will be waived from unblinding and will be exempted from the 
expedited reporting but will be included in the final study report. 
Primary  efficacy outcomes:
oCardiovascular death
oMyocardial infarction
oStroke
Secondary  and tertiary  efficacy outcomes
oCardiovascular hospi[INVESTIGATOR_834254] (unstable, worsening or new)
oHeart failure
[COMPANY_003]
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 136of [ADDRESS_1158615]
oNew diagnosis of cancer 
Coronary  artery  by[CONTACT_541649]
o Primary  safet y outcomes:
As bleeding, including fatal bleeding, from all tissues and organs is a known side effect of 
rivaroxaban, bleeding events, including those resulting in hospi[INVESTIGATOR_059], will not be reported as (S)AEs, but will be captured on the CRF only, and will be reported as outcomes.
Expected Events:
In addition, events that are expected to occur w ith high frequency  in the population under 
study  and for which no safet y signal arose from the more than 70,000 patients alread y studied 
in clinical trials with rivaroxaban will be captured on the CRF only , will be waived from 
unblinding, and be will be ex empted from expedited reporting.  These include:
Planned hospi[INVESTIGATOR_602] (e.g., for surgery , respi[INVESTIGATOR_4594]) 
Non-cardiovascular SAEs (including unplanned hospi[INVESTIGATOR_602]) that are expected to 
occur with high frequency in the population under study  (depres sion, pneumonia, 
trauma, chronic obstructive pulmonary  disease, diabetes mellitus)
Section [IP_ADDRESS] Reporting of (S)AEs 
The following events are tobe reported to  on the SAE/ESI  CRF within 24 hours of the
investigator becoming aware of the event/diagn osis Bayer HealthCare Global 
Pharmacovigilance is responsible for reporting these events to the health authority :
Any non- cardiovascular death of a subject occurring after signing informed consent or 
prior to the end of monitoring for adverse events. (note: fatal bleeding events are 
primary  safety  outcomes and are exempted)
Any non-cardiovascular SAEs not listed in Section [IP_ADDRESS]
Any non- cardiovascular AE that recurs when the subject is restarted on study  drug 
(positive re -challenge).
In addition, any AEs of particular concern to the investigator may  be recorded on the CRF to 
bring them to the attention of the sponsor.
[IP_ADDRESS] Adverse events of special safety interest
For ongoing pharmacovigilance, the large COMPASS trial is an opportunity to identify  rare 
events in the population that may  or may  not be drug -related.  The following events have, to 
date, not been observed with increased frequency with rivaroxaban, but are considered AEs of 
special safety  interest. These events must be reported to  independent of their 
seriousness, but within the same timelines as an SAE (within 24 hours) by  [CONTACT_834347]. Bayer HealthCare Global Pharmacovigilance may decide to 
upgrade the event based on the information received.
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 137of 205
Section 7. 5.3.5 Pregnancies
This section was changed as a result of Modification 23. 
Old Text:
For a stud y subject, the outcome of the pregnancy should be followed up carefull y, and an y 
abnormal outcome of the mother or the child should be reported.
For the pregnan cy of a study  subject’s partner, all efforts should be made to obtain similar 
information on course and outcome, subject to the partner’s consent.
New Text:
For a stud y subject, the outcome of the pregnancy should be followed up carefull y, and an y 
outcome of the mother or the child should be reported. Abnormal  pregnancy  outcomes (eg, 
spontaneous abortion, stillbirth, and congenital anomaly ) are considered serious adverse 
events and must be reported using the Serious Adverse Event Form.   For the pregnancy  of a 
study  subject’s partner, all efforts should be made to obtain similar information on course and 
outcome, subject to the partner’s consent.
Section 7.5.[ADDRESS_1158616] (section deleted):
This section was changed as a result of Modification 23. 
Old text:
7.5.[ADDRESS_1158617]
A DSMB will monitor the safet y data in the study on an ongoing basis.  Serious AEs that are 
outcome events (e.g., stroke, my ocardial infarctions), or expected AEs associated with 
anticoagulation therap y (e.g. bleeding), or common events that are part of the natural history  
of the disease (as defined in Section 7.5.2) will be collected on the CRFs and evaluated b y the 
DSMB.  These events will not be collected on the SAE page in the CRF for expedited review 
or reporting.  The details of this review will be defined in the DSMB -charter.
Section 7.5.4 Reporting of events to Bayer by  [CONTACT_834350]’ reporting requirements
This section was changed as a result of Modification 23. 
Old Text:
SAEs that require expedited reporting described in Section 7.5.2 (protocol -specific adverse 
event reporting) are to recorded on the appropriate SAE CRF page and are to be forwarded to 
 within 24 hours of the investigator having been made aware of the event.  Upon receipt 
of this form it will be reported to Bay er Global Pharmacovigilance by   [INVESTIGATOR_874] 24 hours, 
or 3 calendar day s for weekends or public holidays, or next working day  whichever is earlier. 
New Text:Adverse events that require expedited reporting described in Section 7.5.3. 2, [IP_ADDRESS] and 
[IP_ADDRESS] (protocol -specific adverse event reporting) are to be recorded on the appropriate SAE 
CRF page and are to be forwarded to  within 24 hours of the investigator having been 
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 138of 205
made aware of t he event. Inthis trial, exempted outcomes are to be recorded on the 
appropriate outcome CRF page, not the SAE CRF page.   Upon receipt of an SAE CRF page
this form will be reported to Bay er Global Pharmacovigilance b y  within 24 hours, or 3 
calendar da ys for weekends or public holiday s, or next working day  whichever is earlier. 
Section 8.3.2 Secondary efficacy outcomes
This section was changed as a result of Modification 2. 
Old Text:
The composite of outcomes ---myocardial infarction, stroke, cardio vascular death, 
venous thromboembolism, and cardiovascular hospi[INVESTIGATOR_834255]:
The composite of outcomes ---myocardial infarction, stroke, cardiovascular death, 
revascularization, venous thromboembolism, and cardiovascular hospi[INVESTIGATOR_834256] 8.3.3 Tertiary and other efficacy outcomesThis section was changed as a result of Modification 2. 
Old Text:
Section 8.3.3 Tertiary efficacy outcomes
The tertiary  efficacy  outcomes are:
…

Revascularization
Amputation 
…
MRU 
New Text:
Section 8.3.3 Tertiary and other efficacy outcomes
The tertiary  efficacy  outcomes are:
…
Amputation
Stent thrombosis
…
MRU 
Coronary  artery  by[CONTACT_834377] 8.3.5 Outcome for pantoprazole randomization
This section was changed as a result of Mo dification 4. 
[COMPANY_003]
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 139of 205
Old Text:
Bleeding of presumed occult gastrointestinal origin with documented decrease in Hb 
of 2g/dL from baseline
New Text:
Bleeding of presumed occult gastrointestinal origin with documented decrease in Hb of 2g/dL 
Section 8.3.6 Subgroup variables
This section was changed as a result of Modification 4. 
Old Text:
Homogeneity  of treatment effect will be examined for the following subgroup variables:
Coronary  artery  disease (yes, no)
Peripheral artery  disease (yes, no)
CAD and PAD ( yes, no)
CAD only , PAD onl y, CAD and PAD 
CABG at Baseline (yes, no)
New Text:Homogeneity  of treatment effect will be examined for the following subgroup variables:
CAD (yes, no)
PAD (yes, no)
CAD and PAD (y es, no)
CAD only , PAD onl y, CAD and PAD 
CABG days 4-7before randomization (yes, no)
Section 8.4.5 Analysis of the outcome for pantoprazole randomization
This section was changed as a result of Modification 4. 
Old Text:Pantoprazole 40 mg od treatment group and pantoprazole placebo control group will be 
compared. The null hy pothesis H
0;panto40 stating that “there is no difference between the 
pantoprazole treatment and control groups in the probability  of the primary outcome for 
pantoprazole randomization for all time points” will be tested against the alternative 
hypothesis H 1;panto40 stating that “there is a difference between the two groups in the 
probability  of the primary outcome for at least one time point”.
New Text:Pantoprazole 40 mg od treatment group and pantoprazole placebo control group will be 
compared. The null hy pothesis H
0;panto40 stating that “there is no difference between the 
pantoprazole treatment and control groups in the probability of the outcome for pantoprazole 
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 140of 205
randomization for all time points” will be tested against the alterna tive hy pothesis H 1;panto40
stating that “there is a difference between the two groups in the probability  of the outcome for 
at least one time point”.
Section 8.4.6 Subgroup Analyses
This section was changed as a result of Modification 4. 
Old Text:Subgrou p anal yses for the primary  efficacy  and safety  outcomes, and the primary outcome for 
pantoprazole randomization will be performed based on the same anal ysis sets and data 
scopes as in the main analy ses of the study  outcomes (Sections 8.4.1, 8.4.2, 8.4.3, 8 .4.4 and 
8.4.5). 
New text:
Subgroup anal yses for the primary  efficacy  and safety  outcomes, and the outcome for 
pantoprazole randomization will be performed based on the same anal ysis sets and data 
scopes as in the main analy ses of the study  outcomes (Sect ions 8.4.1, 8.4.2, 8.4.3, 8.4.4 and 
8.4.5).
Section 8.6 Determination of sample size
This section was changed as a result of Modification 24. 
Old Text:In this trial, it is planned to randomize at least 19,500 subjects and to continue the study  until 
a minimum of 2,200 subjects experience an event for the primary efficacy outcome.
…
Assumptions for antithrombotic treatment randomization were:
3-arm stud y with 1:1:1 randomization
In total, a minimum of 19,500 subjects are randomized ( at least 6,500 subjects per 
treatment group)
2-sided ty pe I error level of 2.7% for each of the two comparisons to control the 
overall ty pe I error level of 5%
Constant annual event rate in aspi[INVESTIGATOR_834207] 4.0% and 4.5%
…The expected total number of observed events and the estimated power for each of the two 
comparisons are display ed in Table 8 -1. 
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 141of 205
Table 8 -1.  Events calculations
Assu med annual event 
rate in aspi[INVESTIGATOR_834257] (years)Estimated power for one 
comparisonExpected total number 
of events
4.0% 4.5 90.6% 1,923
5.0 93.6% 2,227
4.5% 4.5 93.6% 2,150
5.0 95.9% 2,[ADDRESS_1158618] a true relative risk reduction of 20% in each of the rivaroxaban arms with at least 90% power, it is planned to randomize at least 19,[ADDRESS_1158619] 50 subjects.
Assumptions for pantoprazole randomization are: 
Annual event rate for major upper gastrointestinal complications (overt or occult 
bleeding, s ymptomatic gastroduodenal ulcers or erosions, obstruction or perforation) 
in the range of 1.6% to 2.2%
At least 14,000 subjects included in the study  are not proton pump inhibitor users and 
they are randomized to pantoprazole trea tment and control groups in 1:1 ratio
…
Under these assumptions, the expected total number of major upper gastrointestinal complications is between 300 and 580, depending on the observed event rates and the 
total study  duration. The estimated power for the detection of the true relative risk 
reduction of about 50% for major upper gastrointestinal complications for 
pantoprazole 40 mg od vs. pantoprazole placebo is close to 100% for all scenarios 
considered.
Sample size estimation was based on the method by [CONTACT_834378] (PASS) software, version 11.0.7, and on a Statistical Analy sis Software
(SAS) macro provided by J. Shih (1995).  In addition, simulations were performed to confirm 
that the Dunnett step -up testing procedure as described in Section 8.4.1 for the anal ysis of the 
primary  efficacy  outcome keeps the overall t ype I error level of 5%.  SAS calculations and 
simulations were performed using SAS software, version 9 .2 (SAS I nstitute Inc, Cary , NC, 
[LOCATION_003]).
New Text:
In this trial, it is planned to randomize at least 21,400 subjects and to continue the study  until 
a minimum of 2,200 subjects experience an event for the primary efficacy outcome.
…Assumptions for antithrombotic treatment randomization were:
3-arm stud y with 1:1:1 randomization
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 142of 205
In total, a minimum of 21,400 subjects are randomized ( approximately  7,134 subjects 
per treatment group)
2-sided ty pe I error level of 2.7% for each of the two comparisons to control the 
overall ty pe I error level of 5%
Constant annual event rate in aspi[INVESTIGATOR_834207] 3.0% and 4.0%
…
The expected total number of observed events and the estimated power for each of the two 
comparisons are display ed in Table 8 -1. 
Table 8-1.  Events calculations
Assu med annual event 
rate in aspi[INVESTIGATOR_834257] (years)Estimated power for one 
comparisonExpected total number 
of events
3.0% 4.5
5.085.1%
89.2%1,642
1,909
3.5% 4.5 90.2% 1,907
5.0 93.4% 2,215
4.0% 4.5 93.7% 2,171
5.0 96.0% 2,[ADDRESS_1158620] a true relative risk reduction of 20% in each of 
the rivaroxaban arms with at least 90% power, it is planned to randomize at least 21,[ADDRESS_1158621] 50 subjects.
Assumptions for pantoprazole randomization a re: 
Annual event rate for major upper gastrointestinal complications (overt or occult 
bleeding, s ymptomatic gastroduodenal ulcers or erosions, obstruction or perforation) 
in the range of 1.6% to 2.2%
At least 12,840 subjects included in the study  are not proton pump inhibitor users and 
they are randomized to pantoprazole treatment and control groups in 1:1 ratio
…
Under these assumptions, the expected total number of major upper gastrointestinal 
complications is between 450 and 730, depending on the observed event rates and the total 
study  duration. The estimated power for the detection of the true relative risk reduction of 
about 50% for major upper gastrointestinal complications for pantoprazole 40 mg od vs. 
pantoprazole placebo is close to 100% for all scenarios considered.
Sample size estimation was based on the method by [CONTACT_834378] (PASS) software, version 11.0.7, and on a Statistical Analy sis System (SAS) 
macro provided b y J. Shih (1995).  In addition, simulations were performed to confirm that 
the Dunnett step -up testing procedure as described in Section 8.4.1 for the anal ysis of the 
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 143of 205
primary  efficacy  outcome keeps the overall t ype I error level of 5%.  SAS calculations and 
simulations were performed using SAS software, version 9.2 (SAS I nstitute Inc, Cary , NC, 
[LOCATION_003]).
Section 11.3 Publication policy
This section was changed as a result of Modification 25. 
Old Text:The key  design elements of this protocol will be posted in a publicly  accessible database such 
as clinicaltrials.gov. The study  results will be reported irrespective of the outcome of the 
study .  The Operations Committee will decide on the authorship of al l papers.  The main study  
results will be written by a writing group lead by [CONTACT_834379], and 
may include additional individuals who have made substantial and sustained contributions and 
will be on behalf of the whole study  group.
New Text:The key  design elements of this protocol will be posted in a publicly  accessible database such 
as clinicaltrials.gov. The study  results will be reported irrespective of the outcome of the 
study .  The Operations Committee which will also serve as a Publication Committee, will 
decide on the authorship of all papers.  The main study  results will be written by  a writing 
group ledby [CONTACT_834379], and may  include additional individuals 
who have made substantial and sustained contr ibutions and will be on behalf of the whole 
study  group.
Section 12 ReferencesThis section was changed as a result of Modification 26. 
Old Text:
1.
Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, de SG et al. Executive 
summary : heart disease and stro ke statistics--2010 update: a report from the American 
Heart Association. Circulation 2010 February  23;121(7):948-54.
2.Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N et al. Heart disease and 
stroke statistics --2008 update: a report from the American Heart Association Statistics 
Committee and Stroke Statistics Subcommittee. Circulation 2008 January  29;117(4):e25-
146.
New Text:1. Fact sheet: Cardiovascular diseases (CVDs): World Health Organization; 2013. Available 
from http://www.who.int/mediacentre/ factsheets/fs317/en/
2.WHO. The global burden of disease: 2004 update. Geneva: World Health Organization; 
2008b.
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 144of 205
Section 14.1 COMPASS MIND Substudy
This section was changed as a result of Modifications 4 and 27. 
Old Text:Design: A phase II trial seeking evidence of efficacy  in which a convenience sample of 1500 
COMPASS participants over age 65 undergo will be invited to participate –500 assigned to 
each treatment arm, but balanced for age, prior stroke, and h ypertension.  Partic ipants will 
undergo limited brain MRI sequences (Fluid Attenuated Inversion Recovery  [FLAIR]), T-1 
and T- 2 sequences at entry  and near end -study  coupled with assessment of function (SAGE), 
and cognition (MoCA, digit sy mbol substitution).  Recruitment will occur at COMPASS sites 
with access to high -quality  (>1.5Tesla) reasonably -priced MR imaging.  Images will be 
transmitted to the central MR imaging center via discs.  Two-stage central interpretation 
blinded to treatment will be carried -out, with all incid ent covert infarcts confirmed by  a 
second independent interpreter.  The  has experience with collection and anal ysis of 
brain MRI s performed in substudies of several randomized trials:  AVERROES, PURE, 
APOLLO, and (planned) TI PS [ADDRESS_1158622] a plausible association with cardiovasc ular outcomes.  Detailed 
information concerning blood collection, processing, storage, and shippi[INVESTIGATOR_834258].
Implications:   The COMPASS MRI  substudy  would be the first randomized trial of an 
anticoagulant to prevent covert b rain infarcts in patients with atherosclerotic vascular disease. 
Evidence that rivaroxaban reduces covert stroke better than or in addition to aspi[INVESTIGATOR_834259].  Within COMPASS trial, the MRI  substudy  
offers an opportunity  to develop evidence of rivaroxaban efficacy  for a separate clinical 
indication applicable to a burgeoning population.
New Text:
Design: A phase II trial seeking evidence of efficacy  in which a convenience sample of 1500 
COMPASS participants over age 65 undergo will be invited to participate –500 assigned to 
each treatment arm, but balanced for age, prior stroke, and h ypertension.  Participants will 
undergo limited brain MRI sequences (Fluid Attenuated Inversion Recovery  [FLAIR]), T-1, 
T-2, and T-2* GRE sequences at entry  and near end -study  coupled with assessment of 
function (SAGE), and cognition (MoCA, digit s ymbol substitution).  Recruitment will occur 
at COMPASS sites with access to high -quality  (>1.0 Tesla) reasonabl y-priced MR imaging.  
Images will be transmitted to the central MR imaging center via discs.  Two -stage central 
interpretation blinded to treatment will be carried -out, with all incident covert infarcts 
confirmed b y a second independent interpreter.  The  has experience with collection and 
analysis of brain MRIs performed in substudies of several randomized trials:  AVERROES, 
PURE, APOLLO, and (planned) TIPS 3 MIND.
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 145of [ADDRESS_1158623] DNA collected at baseline and blood collected at baseline and at the 1 month visit. DNA and blood collections are optional (Section 7.1.1, [IP_ADDRESS] and [IP_ADDRESS].1) .
The samples will be processed, and aliquots will be shipped for long -term storage in liquid 
nitrogen at the coordinating center in  Canada.  Blood samples will be 
processed and stored in such a way  to allow future anal ysis of these aliquots for selected 
biomarkers, some of which have been observed in other studies to be predictors of stroke, and others which have a plausible association with cardiovascular outcomes.  De tailed information 
concerning blood collection, processing, storage, and ship
pi[INVESTIGATOR_834258].Implications:   The COMPASS MRI  substudy  isthe first randomized trial of an anticoagulant 
to prevent covert brain infarcts in patien ts with atherosclerotic vascular disease. Evidence that 
rivaroxaban reduces covert stroke better than or in addition to aspi[INVESTIGATOR_834260].  Within COMPASS trial, the MRI  substudy  offers an 
opportunity  to develop e vidence of rivaroxaban efficacy  for a separate clinical indication 
applicable to a burgeoning population.
13.[ADDRESS_1158624] the 
overall study  concept.  These changes are not described in this section. 
The following changes are introduced in Protocol Version 3.0.
Modification 1: Secondary  and tertiary  efficacy  outcomes were revised.  
Rationale:  The secondary  outcomes have been modified to include [ADDRESS_1158625] sensitive to the experimental antithrombotic treatment under investigation.
Sections affected:
Synopsis: St udy objectives
Section 2  Study  objectives
Section 7.3 Efficacy
Section [IP_ADDRESS] Protocol-specific exceptions to SAE reporting
Section 8.3.2 Secondary  efficacy  outcomes
Section 8.3.3 Tertiary  and other efficacy  outcomes
Modification 2: The multiple testing strategy  was revised to ensure the control of the 
family wise t ype I error for both testing of primary  and secondary  efficacy  variables.   
Rationale:  Originally  it had been planned to use the step- up Dunnett procedure for the testing 
of the 2 primary  outc omes to control the overall t ype I error level of 5% and to test secondary 
[COMPANY_003]
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 146of 205
outcomes at the 5% level without any  adjustment for multiplicity .  Triggered by  [CONTACT_834380] 2014,  this decision was revised to make use of the opportunityof a potential label claim for secondary  outcomes if convincing results will be obtained.  Since 
the Dunnett step -up test is not separable, the former testing strategy  was replaced b y a mixture 
gatekeepi[INVESTIGATOR_834261] a trunc ation fraction of γ = 0.9, which 
controls the familywise error rate at the pre -assigned level of significance α = 5% in the strong 
sense.
Sections affected:
Section 8.4 Statistical and anal ytical plans
Section 8.4.1 Analy sis of the primary  efficacy  outcome
Section 8.4.2 Analy sis of the secondary  efficacy  outcomes
Modification 3: I nterim anal ysisrevised.   
Rationale:  The statistical anal ysis plan for the interim analy sis was corrected according to the 
advice received b y the FDA in the letter received in A UG 2014. The description for the 
analysis in the case where only  1 of the 2 interventional arms is continued after an interim 
analysis was updated. 
Section affected:
8.5 Planned interim analy ses
Modification 4: The number of subjects in the trial has been increased.
Rationale:   During the first [ADDRESS_1158626], the observed 
cumulated overall annual incidence was at the lower end of the projected range of 3.0% to 
4.0%. This led to the decision to continue enrollment and to thereb y roughly maintain the 
study  duration in the originally  planned range of 4.5 to 5 y ears.
Sections affected:
Synopsis: Number of subjects
Section 4.1 Design overview
Section 5 Study  population
Section 8.6 Determination of sample size
Modification 5:  Emphasis was made that all subjects, including those who experience a 
primary  study  outcome, need to be followed to the scheduled end of the study .
Rationale:  Some investigators are under the impression that subjects who experience MI or 
stroke no longer need to be followed up because they  have already  contributed to the study  
outcomes. This is not the case; all outcomes need to be collected until the end of the study . 
Section affected: 
Section 5.2  Discontinuation of subjects from study treatment
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 147of 205
Modification 6: Clarification was added regarding the start of interim study 
rivaroxaban/rivaroxaban placebo and the continued use of study  aspi[INVESTIGATOR_248]/placebo.
Rationale:  The protocol appeared to mandate the use of interim study  rivaroxaban/
rivaroxaban placebo in subjects who were treated with long -term dual antiplatelet therap y.  
This was never the intent; it is optional for investigators to commence subjects on interim study  rivaroxaban/rivaroxaban placebo. This change to the protocol clarifies that it is optional.  
Elsewhere in the protocol it is clearly  indicated that study  aspi[INVESTIGATOR_248]/placebo can be continued in 
subjects who are treated with dual antiplatelet therap y. This clarification has now also been 
included in this section.   
Section affected:
Section [IP_ADDRESS]  Guidance for the treatment of subjects who develop an acute coronary  
syndrome and those who require percutaneous coronary  intervention with stenting
Modification 7: Minor clarifications were made.
Rationale:  Minor clarifications were made that do not affect the overall study  concept.
Sections affected:
Section 3.1 Study  committees
Section 4.3.1  Overall design rationale
Section 6.3  Treatment assignment
Modification 8: The reference to a lack of an antidote for rivaroxaban was removed.
Rationale:  A provision has been made for the future availabilit y of a specific reversal agent 
for rivaroxaban.Sections affected:
Section [IP_ADDRESS] Guidance for the treatment of subjects who overdose on study 
rivaroxaban/rivaroxaban placebo
Section [IP_ADDRESS] Guidance for the treatment of subjects who experience a major bleed
Modification 9: Text regarding post -study  therapy was revised.
Rationale:  At the beginning of the stud y, subjects are transitioned from non -study  aspi[INVESTIGATOR_834262]. At the end of the study  they  should be transitioned back to non-
study  aspi[INVESTIGATOR_248].  Other antithrombotic therapi[INVESTIGATOR_834263] y is therefore being deleted.
Section affected:
Section 6.[ADDRESS_1158627] -study  therapy
Modification 10:  Text regarding the concomitant use of aspi[INVESTIGATOR_248]/aspi[INVESTIGATOR_834264].
Rationale:  The use of study  aspi[INVESTIGATOR_248]/aspi[INVESTIGATOR_834265]- study  
aspi[INVESTIGATOR_834170] y is optional. As written in the previous version of the 
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 148of 205
protocol, the implication was that this was mandatory  but it has been clarified that it is 
optional. Also, study  aspi[INVESTIGATOR_248]/aspi[INVESTIGATOR_834266]; co ntrary  to what was written in Section 6.9.1, aspi[INVESTIGATOR_248]/aspi[INVESTIGATOR_834267].  
Section saffected:
Section 6.9  Prior and concomitant therap y
Section 6.9.1  Combined CYP 3A4 and p- glycoprotein inhibitors and CYP 3A4 
inducers   
Modi fication 11: Clarification was added regarding the reasons for planned 
hospi[INVESTIGATOR_602]/procedures and when they  should be considered (S)AEs
Rationale:   This revision reminds investigators that hospi[INVESTIGATOR_834268] a SAE.  This is not a change to the protocol; 
previously  planned hospi[INVESTIGATOR_834269].
Section affected:
Section 7.5.1  E6 Definition of (serious) adverse event
Modification 12:  Text was updated with re vised data/results from newl y published studies.
Rationale:  To provide the most recent data.Sections affected:
Section 1.2.1 Rivaroxaban
Section 1.2.2  Aspi[INVESTIGATOR_834107]
Section 1.3  Benefit- risk assessment
Section 4.3.1 Overall design rationale
Section [IP_ADDRESS]  Protocol- specific exceptions to SAE reporting 
Section [ADDRESS_1158628]
Modification 13:  Clarification was made when the questionnaires should be completed.
Rationale:   The questionnaires are being used to measure the impact of study  treatments on 
function and quality  of life. This revision is aimed at ensuring that the questionnaires are also 
completed following major outcomes.  This was inadvertentl y omitted from prev ious versions 
of the protocol.Section saffected:
Section 4.1  Design overview
Section 7.1.1  Tab ulated overview
Section 7.2.3  Other baseline characteristics
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 149of 205
Modification 14:  For subjects who are randomized after CABG surgery, clarification was made as t o when the first dose of study  drug will be administered.
Rationale:   The goal is to avoid use of stud y antithrombotic therapi[INVESTIGATOR_6523] [ADDRESS_1158629] 
administration of any  anticoagulant.
Sections affected:
Section 4.1.1  Subjects randomized after CABG surgery
Section 6.4  Dosage and administration
Section [IP_ADDRESS] Guidance for the treatment of subjects who require coronary artery 
by[CONTACT_834381] 15:  Guidance for the management of subjects who develop stroke and who are 
being considered for reperfusion therapy was added.
Rationale:  Investigators have asked for guidance about the management of subjects who 
develop an ischemic stroke a nd who are being considered for reperfusion therapy .  In response 
to these requests, a section was added to the protocol as the topic was not addressed in the 
previous version.
New section:
Section [IP_ADDRESS]  Guidance for the treatment of subjects who develo p a stroke and who 
are being considered for reperfusion therap y 
Modification 16:  An additional subgroup was added to those that will be examined :  “Any 
prior CABG, further subdivided as CABG day s 4-7 before randomization and other prior 
CABG”Rationale: Approximately one -quarter of all subjects enrolled in COMPASS have had a prior 
CABG.  We wish to separatel y examine outcomes in subjects with prior CABG and those 
who have not had prior CABG, to explore whether the effect of treatment is consistent in 
these subgroups. Similarly, within the CABG population we propose to explore the 
consistency  of the treatment effect in those who were randomized earl y post -CABG and those 
who were randomized later post- CABG.  
Section affected:
Section  8.3.6  Subgroup varia bles
Modification 17:   Revisions to the description and procedures of the COMPASS -MIND 
substudy  were made.  
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 150of 205
Rationale:
a) It had been stated that the substudy would examine the effect of therapi[INVESTIGATOR_834270]. The reference to “asy mptomatic” cerebral ischemia is 
inaccurate. The se epi[INVESTIGATOR_834271]; rather, the sy mptoms 
are not attributed to the cerebral ischemia because the event is not recognized. These epi[INVESTIGATOR_834272] “covert.”  
b) The substudy  does not examine the effect of antithrombotic therapi[INVESTIGATOR_834273] , just microbleeds .  To avoid confusion the reference to bleeding assessment has been 
omitted.
c) As originall y designed , the COMPASS MIND substudy  was restricted to subjects over the 
age of [ADDRESS_1158630] covert cerebral ischemia than 
those who are younger. The age cut off is, however, purel y arbitrary. In order to simplify  
recruitm ent and increase generalizability  of the results the age restriction has been removed.
d) The original timeframe for obtaining an MRI scan was within [ADDRESS_1158631] recruitment and this gain will outweigh any  possible loss of statistical 
power resulting from a shorter time between the initial and the final scan. The revised 
protocol now ind icates that MRI  scan should be performed within 3 months or as soon as 
possible thereafter and at the end of the stud y.  
Section saffected:
Section 2  Study  objectives
Section [IP_ADDRESS]  Randomization visit (Day  0 ± 5 day s)
Section 14.1  COMPASS MI ND substu dy
Modification 18:  Text regarding the timing of CT angiograms for COMPASS CABG 
subjects has been added.  Also, in the event that subjects are unable to attend a study  visit in 
person, follow -up by  [CONTACT_72031].
Rationale:   To provide some flex ibility .
Section saffected:
Section 4.1.1 Subjects randomized after CABG surgery
Section 7.1.1 Tabulated overview
Section [IP_ADDRESS].1  Routine follow -up visits (Visits 3, 5, and 7- 15+)
Section 9.3  Data processing
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 151of 205
Modification 19 :  Text was revised to allow greater flexibility  in the event a reduction of dose 
of study  treatment is necessary .
Rationale:  To provide more flexibility .
Section affected:
Section 6.4.1  Dose modifications
13.2.2 Changes to protocol text
In this section, all affected protocol sections are detailed; the sequence of the sections follows 
the structure of the original protocol. In the display of modifications, the “old text” refers to the protocol version preceding this amendment and “new text” display s the updated text.
Deletions are crossed outand a dditions are underlined. Corrections of t ypi[INVESTIGATOR_834274].
Synopsis –Study objectives
This section was changed as a result of Modification 1.
Old Text:
Study objective(s)Secondary objectives for rivaroxaban random ization
To determine whether each of rivaroxaban 2.5 mg bid + aspi[INVESTIGATOR_248] 100 
mg od and rivaroxaban 5 mg bid alone reduces the risk of the 
composite of major thrombotic events (myocardial infarction, stroke, 
cardiovascular death, revascu larization, and venous 
thromboembolism) and cardiovascular hospi[INVESTIGATOR_834275] 100 mg od in subjects with CAD or PAD
New Text:
Study objectivesSecondary objectives for rivaroxaban random ization
To determine whether each of rivaroxaban 2.5 mg bid + aspi[INVESTIGATOR_248] 
100mg od and rivaroxaban 5 mg bid alone reduces the risk of the 
composite of major thrombotic events :  (1) coronary heart disease 
death, myocardial infarction, ischemic stroke, acute limb ischemia; 
(2) cardiovascular death , myocardial infarction, ischemic stroke, 
acute limb ischemia compared w ith aspi[INVESTIGATOR_248] 100 mg od in subjects 
with CAD or PAD
Synopsis – Number of subjects
This section was changed as a result of Modification 4.
Old Text:
Number of subjectsEnrolled = approximately 23,500 ; randomized = 21,400 in approximately 30
countries worldwide
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 152of 205
Approximately 23,500 subjects will be enrolled; 21,500 will be admitted to the 
run-in period and 2000 subjects will undergo coronary artery by[CONTACT_834369] -in.  A non -compliance rate of 10% is anticipated for those subjects in 
the run -in period; thus, approximately  21,400 subjects w ill be randomized 
(approximately 19,400 subjects who completed run -in and 2000 who 
underwent coronary artery by[CONTACT_834382] -in) in approximately 30 
countries worldwide.
New Text:
Number of subjectsEnrolled = approximately 29,940 ; randomized = approximately 27,400 in 
approximately 33countries worldwide
Approximately 29,940 subjects will be enrolled; approximately 28,300 will be 
admitted to the run -in period and 2000 subjects w ill undergo coronary artery 
by[CONTACT_834324] -in.  A non -compliance rate of 10% is anticipated for 
those subjects in the run -in period; thus, approximately  27,400 subjects will 
be rando mized ( of which approximately 2000 subjects who underwent 
coronary artery by[CONTACT_834383] -in) in 
approximately 33countries worldwide.
Section 1.2.1 Rivaroxaban
This section was changed as a result of Modification 12. 
Old Text:
Rivaroxaban has been tested in randomized controlled trials involving more than 70,000
patients and has been used by  [CONTACT_834371].  
New Text:Rivaroxaban has been tested in randomized controlled trials involving more than 80,000
patients and has been used by  [CONTACT_834371].  
Section 1.2.2  Aspi[INVESTIGATOR_834276] a result of Modification 12.
Added Text to end of 5
thparagraph:
The PEGASUS trial demonstrated that 33 months of treatme nt with ticagrelor (90 mg twice -
daily  or 60 mg twice -daily ) compared with placebo reduced the risk of cardiovascular death, 
myocardial infarction or stroke by  15-16% (ticagrelor 90 mg: 7.85%, ticagrelor 60 mg: 7.77%, 
placebo 9.04%; p=0.008 and p=0.004, res pectively ) in patients with a history  of my ocardial 
infarction [ADDRESS_1158632] of a 2 -3 fold increase in major bleeding 
(ticagrelor 90 mg: 2.60%, ticagrelor 60 mg: 2.30%, placebo 1.06%; p<0.01 for each dose vs. 
placebo), and the re was no reduction in total mortality  (ticagrelor 90 mg: 5.15%, ticagrelor 60 
mg: 4.69%, placebo 5.16%; p=0.99 and p=0.14, respectively ).
The DAPT trial randomized 9,961 patients with a history  of coronary  stenting with a drug 
eluting stent who had comple ted 12 months of dual antiplatelet therap y with a thienopy ridine 
and aspi[INVESTIGATOR_834119] 75 mg once dail y or prasugrel 10 mg once dail y 
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 153of 205
or placebo for another 18 months. All patients continued receiving aspi[INVESTIGATOR_248]. Continuing 
treatment w ith a thienopy ridine as compared with placebo reduced the rates of stent 
thrombosis by  71% (0.4% vs. 1.4%, p<0.001) and the composite, death, MI  or stroke by  29% 
(4.3% vs. 5.9%, p<0.001) but at the cost of excess moderate or severe bleeding (2.5% vs. 
1.6%, p=0.001) and a borderline significant 36% increase in all- cause death from an y cause 
(2.0% vs. 1.5%, p=0.05).
Excess mortality  seen with extended dual antiplatelet therapy  in the DAPT trial was 
confirmed in a subsequent meta -analysis of 10 randomized tria ls including 31,666 patients 
who had undergone coronary  artery  stenting comparing different durations of dual antiplatelet 
therap y. Shorter duration dual antiplatelet therap y was associated with an 18% reduction in 
all-cause mortality  (HR 0.82, 95% CI  0.69- 0.98; p=0.02), predominantl y due lower non-
cardiac mortality  (HR 0.67, 0.51 -0.89; p=0.006), with similar cardiac mortality  (HR 0.93, 
0.73-1.17; p=0.52). Shorter duration dual antiplatelet therap y was also associated with a lower 
risk of major bleeding (HR 0.58, 0.47- 0.72; p<0.001), but a higher risk of my ocardial 
infarction (HR 1.51, 1.28 -1.77; p<0.001) and stent thrombosis (HR 2.04, 1.48- 2.80; p<0.001).
Section 1.3  Benefit -risk assessment
This section was changed as a result of Modification 12.
Old Text:
In the ROCKET -AF trial, the 20 mg od dose was associated with an annualized rate of 
International Societ y on Thrombosis and Haemostasis (I STH) major and non -major 
gastrointestinal (GI) combined bleeding rate of 2.23/100 patient y ears. (Sponsor data on file)
New Text:
In the ROCKET -AF trial, the 20 mg od dose was associated with an annualized rate of 
International Societ y on Thrombosis and Haemostasis (I STH) major and non -major 
gastrointestinal (GI) combined bleeding rate of 3.2/100 patient y ears.
Section 2  Study objectives
This section was changed as a result of Modifications 1and 17. 
Old Text (first secondary objective) :
To determine whether each of rivaroxaban 2.5 mg bid + aspi[INVESTIGATOR_248] 100 mg od and 
rivaroxaban 5 mg bid alone reduces the risk of the composite of major thrombotic 
events ( myocardial infarction, stroke, cardiovascular death, revascularization, and 
venous thromboembolism) and cardiovascular hospi[INVESTIGATOR_834230] 
100 mg od in subjects with CAD or PAD
Old Text (Substudy obje ctives):
The COMPASS -MIND substudy will examine the effect of the antithrombotic therapi[INVESTIGATOR_834277] , thereby  [CONTACT_834384].  
New Text:
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 154of 205
To determine whether each of rivaroxaban 2.5 mg bid + aspi[INVESTIGATOR_248] 100 mg od and 
rivaroxaban 5 mg bid alone reduces the risk of the composite of major thrombotic 
events ( coronary  heart disease death, my ocardial infarction, ischemic stroke, acute 
limb ischemia; cardiovascular death, my ocardial infarction, ischemic stroke, acute 
limb ischemia ) compared with aspi[INVESTIGATOR_248] [ADDRESS_1158633] of the antithrombotic therapi[INVESTIGATOR_834278], thereb y providing additional information 
about mechanisms of disease and treatment benefits.  
Section 3.1  Study committees
This section was changed as a result of Modification 17.
Old Text:An Operations Committee will be responsible for ensuring that study  execution and 
management of the stud y are of the highest quality.  This committee will determine its own 
guidelines and approve the criteria and guidelines of the other committees.   The operations 
committee will convene regularl y to discuss and report on the ongoing supervision of the 
study .  The committee will consist of the study  chair and principal investigators, project 
leader, senior study  coordinator, 2 -3 sponsor representatives, and 3- 4 National Leaders (NL). 
A Steering Committee comprising members of the Operations Committee, university -based 
and sponsor -based scientists with clinical and methodological expertise, and national leaders 
from each country , will be responsible for producing and conducting a scientific ally sound 
study  design and ensuring accurate reporting of the study .  The steering committee will meet 
periodicall y to address and resolve scientific and practical issues encountered during the 
study . 
An Events Committee consisting of members with clinical and methodological expertise will 
oversee the process of event verification . The process of event verification is detailed in the 
Manual of Operations . 
New Text:
An Operations Committee will be responsible for ensuring that study  execution and 
manageme nt of the study are of the highest quality.  This committee is a subcommittee of the 
Steering Committee and will convene regularly to discuss and report on the ongoing 
supervision of the study .  The committee will consist of the study  chair and principal 
investigators, project leader, senior stud y coordinator, 2- 3 sponsor representatives, and 3 -4 
National Leaders (NL). 
A Steering Committee comprising members of the Operations Committee, university -based 
and sponsor -based scientists with clinical and methodological expertise, and national leaders 
from each country , has overall responsibility  for the study . The Steering Committee will be 
responsible for producing and conducting a scientifically  sound study  design and ensuring 
accurate reporting of the study . The steering committee will meet periodically  to address and 
resolve scientific and practical issues encountered during the stud y. 
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 155of 205
An Events Committee consisting of members with clinical and methodological expertise will oversee the process of event adjudication. The process of event adjudication is detailed in the 
Event Adjudication Plan.  
Section 4.1  Design overview
This section was changed as a result of Modifications 4 and 13.
Old Text:This Phase 3, event- driven (at least 2,200 primary  efficacy  outcome events), randomized 
controlled trial will have a [ADDRESS_1158634] 21,400
subjects who will receive treatment for an expected average duration of 3 to 4 y ears.
….
Subjects will be seen in the clinic at [ADDRESS_1158635] information on treatment adherence, treatment interruption, outcomes, and adverse events (AEs).  Vali dated questionnaires will be 
administered before or at the time of randomization, or as soon as possible thereafter, and at 
Month [ADDRESS_1158636] health and quality  of life (Standard Assessment of Global -
Activities in the Elderly  [SAGE], Mont real Cognitive Assessment [MoCA], DSS [Digital 
Symbol Substitution], European Quality of Life -5 Dimensions [EQ -5D], The Interheart Diet 
Questionnaire, and The International Phy sical Activity  Questionnaire).  All subjects will be 
followed for the duration of the study , irrespective of whether they  are receiving study  
treatments or whether an event has occurred. Additional follow -up visits will be conducted b y 
telephone at Months 3 and 9.  The Final Follow- up Visit will occur as soon as possible after 
the required pre -specified number of subjects experience a primary  efficacy  outcome event for 
the antithrombotic randomization (close out is expected to occur over a period of about 2
months).  A final washout period visit (End of Washout Telephone Visit) will be conducted 
by [CONTACT_756] (performed 30 day s after the Final Follow -up Visit) to collect information on 
outcomes and protocol specific adverse events.  Adverse events will continue to be collected up to [ADDRESS_1158637] study  drug treatment.  Bay er Global Pharma covigilance will continue to 
follow the reported AEs until stabilized or resolved.
New Text:
This Phase 3, event- driven (at least 2,200 primary  efficacy  outcome events), randomized 
controlled trial will have a [ADDRESS_1158638] 27,400
subjects who will receive treatment for an expected average duration of 3 to 4 y ears.
….
Subjects will be seen in the clinic at [ADDRESS_1158639] informat ion on treatment adherence, treatment 
interruption, outcomes, and adverse events (AEs).  Validated questionnaires (Standard 
Assessment of Global -Activities in the Elderly  [SAGE], Montreal Cognitive Assessment 
[MoCA], Digital Sy mbol Substitution [DSS], European Qualit y of Life -5 Dimensions [EQ -
5D]) will be administered at screening/run -in or randomization, or as soon as possible 
thereafter, as well as at Month [ADDRESS_1158640] 
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 156of 205
health and qualit y of life.  The SAG E, MoCA, DSS, and EQ -5D will also be administered at 
the next study  clinic visit after each outcome event.  The Interheart Diet Questionnaire and the 
International Ph ysical Activity  Questionnaire will be administered at screening/run- in or 
randomization, or as soon as possible thereafter, and at Month 24.  All subjects will be 
followed for the duration of the study , irrespective of whether they  are receiving study  
treatments or whether an event has occurred. Additional follow -up visits will be conducted b y 
telephone at Months 3 and 9.  The Final Follow- up Visit will occur as soon as possible after 
the required pre -specified number of subjects experience a primary  efficacy  outcome event for 
the antithrombotic randomization (close out is expected to occur over a period of about 3
months).  A final washout period visit (End of Washout Telephone Visit) will be conducted 
by [CONTACT_756] (performed 30 day s after the Final Follow -up Visit) to collect information on 
outcomes and protocol specific adverse events.  Advers e events will continue to be collected 
up to [ADDRESS_1158641] study  drug treatment.  Bay er Global Pharmacovigilance will continue to 
follow the reported AEs until stabilized or resolved.
Section 4.1.1  Subjects randomized after CABG surgery
This section was changed as a result of Modification s 14 and 18.
Old Text:Subjects randomized Day  4-[ADDRESS_1158642] administration of an y anticoagulant (including DVT proph ylaxis) (Section 7.1.1 
Tabulated overview).
Subjects randomized Day  4-7 after CABG surgery  will undergo computed tomography  (CT)  
angiograph y at [ADDRESS_1158643] angiograph y (e.g., contrast allergy , estimated glomerular 
filtration rate <30 ml/min). In the event the subject undergoes an invasive coronary  
angiograph y at [ADDRESS_1158644] angiogram may not be required.
New Text:
Subjects randomized Day  4-[ADDRESS_1158645] administration of any  
anticoagulant (including DVT proph ylaxis) (Section 7.1.1 Tabulated overview).
Subjects randomized Day  4-7 after CABG surgery  will undergo computed tomography  (CT)  
angiograph y at [ADDRESS_1158646] angiography  (e.g., contrast allergy , estimated 
glomerular filtr ation rate <30 ml/min). In the event the subject undergoes an invasive 
coronary  angiography  at approximately [ADDRESS_1158647] 
angiogram may  not be required.
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 157of 205
Section 4.3.1 Overall design rationale
This section was changed as a result of Modification s 7and 12.
Added Text (5thparagraph) :
…In most cases, the benefit of the experimental treatment has either been of insufficient 
magnitude to warrant a switch in treatment (e.g., clopi[INVESTIGATOR_7745], prasugrel) or has been 
accompanied b y a substantial excess of bleeding (e.g., vorapaxar, ticagrelor, warfarin).
Old Text (6thparagraph):
The use of aspi[INVESTIGATOR_248] -alone antiplatelet therap y (as provided as a comparator treatment in Arm C)
for atherosclerotic CAD and PAD is well established . As such, most patients will be 
candidates for aspi[INVESTIGATOR_690230] y.  This is in line with current practice guidelines and the 
current prescribing information for secondary  prevention.   The dose of aspi[INVESTIGATOR_834279] 100 mg/d.  
New Text ( 6th paragraph):
The use of aspi[INVESTIGATOR_248] -alone antiplatelet therap y for atherosclerotic CAD and PAD is widely  
accepted . As such, most patients will be candidates for aspi[INVESTIGATOR_512998] .  This is in line 
with current practice guidelines and the current prescribing information for secondary prevention.   The dose of aspi[INVESTIGATOR_834147] 100 mg/d.  
Section 5 Study population
This section was changed as a result of Modification 4.
Old Text: 
Approximately  23,[ADDRESS_1158648] CABG and without run- in.  Approximately  10% of run -in subjects 
are expected to either be non- compliant with treatment or to decline further interest in 
participating; thus, the study  will randomize approximately  21,400 men and women with 
objectively confirmed CAD or PAD from approximately  30countries wor ldwide.
New Text: Approximately  28,[ADDRESS_1158649] CABG and without run- in.  Approximately  10% of run -in subjects 
are expected to either be non- compliant with treatme nt or to decline further interest in 
participating; thus, the study  will randomize approximately  27,400 men and women with 
objectively confirmed CAD or PAD from approximately  33countries worldwide.
Section 5.2 Discontinuation of subjects from study treatm ent
This section was changed as a result of Modification 5.
Old Text: 
In all cases, including the subjects with the study outcome, every effort must be made to 
continue to follow the subject at regular study visits.
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 158of 205
New Text: 
In all cases, including the subjects who have had any of the primary study outcome 
events , every effort must be made to continue to follow the subject at regular study 
visits.Section 6.3  Treatment assignment
This section was changed as a result of Modification 7.
Old Text:For subjects who successfully  complete the run- in period, the investigator or delegate will 
access the  randomization and drug management sy stem to confirm eligibility  and that 
run-in rivaroxaban placebo bid and aspi[INVESTIGATOR_834280]. 
New Text:
For subjects who successfully  complete the run- in period, the investigator or delegate will 
access the  randomization and drug management sy stem to confirm eligibility and 
complianc e to run- in rivaroxaban placebo bid and aspi[INVESTIGATOR_834281]. 
Section 6.4  Dosage and administration
This section was changed as a result of Modification 14.
Added Text :
….The first doses of study  drug should be adm inistered on the day  of randomization, or at 
least [ADDRESS_1158650] -
CABG.   
Section 6.4.1  Dose modificationsThis section was changed as a result of Modification 19.
Old Text:
If there is concern that the subject may  be intolerant of study  treatments or if the subject is 
reluctant to take the full dose of study  treatments, a possible approach to restarting study  
medications is to reduce the frequency  of dosing to once -daily or a lternate -daily .
New Text:If there is concern that the subject may  be intolerant of study  treatments or if the subject is 
reluctant to take the full dose of study  treatments, a possible approach to restarting study  
medications is to reduce the frequency  ofdosing (eg, to once -daily or alternate -daily).
Section [IP_ADDRESS]  Guidance for the treatment of subjects who require coronary artery 
by[CONTACT_834374] a result of Modification 14.
Old Text:
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 159of 205
…Randomization should only  be performed between Day  4-[ADDRESS_1158651] administration of 
any anticoagulant (including DVT prophy laxis).
New Text:
…Randomization should only be performed between Day  4-[ADDRESS_1158652] administration of any  anticoagulant (including DVT prophy laxis).
Section [IP_ADDRESS] Guidance for the treatment of subje cts who develop an acute coronary 
syndrome and those who require percutaneous coronary intervention with stentingThis section was changed as a result of Modification 6.
Old Text:Subjects who remain on long term dual antiplatelet therapy  should commence “ interim study  
rivaroxaban/rivaroxaban placebo” once an y non -study  anticoagulant therapy  is stopped.  
New Text:Subjects who remain on long term dual antiplatelet therapy  may commence “interim study  
rivaroxaban/rivaroxaban placebo” once an y non -study  antic oagulant therapy  is stopped.  
Study  aspi[INVESTIGATOR_248]/placebo may  be continued.
Section [IP_ADDRESS] Guidance for the treatment of subjects who overdose on study 
rivaroxaban/rivaroxaban placebo
This section was changed as a result of Modification 8.
OldText :
A specific antidote for rivaroxaban is not available.   If rivaroxaban overdose is suspected, the 
use of activated charcoal up to [ADDRESS_1158653] of an 
overdose of rivaroxaban is expected to be limited. 
New Text:
If rivaroxaban overdose is suspected, the use of activated charcoal up to [ADDRESS_1158654] of an overdose of rivaroxaban is expected to be limited.  If available, consideration may be given t o the use of a specific reversal agent.
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 160of 205
Section [IP_ADDRESS] Guidance for the treatment of subjects who experience a major bleed
This section was changed as a result of Modification 8.
OldText :
The management of bleeding in subjects receiving stud y rivaroxaban /rivaroxaban placebo is 
supportive, as rivaroxaban does not have a specific antidote.  Temporary  discontinuation of 
rivaroxaban is expected to be sufficient to control bleeding in most cases because the drug 
half-life is onl y 5-13 hours.  L ocal measures should be applied if needed to control bleeding 
(e.g., local pressure, endoscopy  and injection of a bleeding vessel, embolization) and 
intravenous fluids and blood transfusion support should be provided as indicated.  In the rare case of life -threatening ble eding, the investigator may  consider obtaining advice from a 
hematologist.  Animal studies suggest that both prothrombin complex concentrates and recombinant factor VIIa partially  restore hemostasis following treatment with factor Xa 
inhibitors such as riv aroxaban and a randomized trial involving healthy  subjects treated with 
rivaroxaban has demonstrated that prothrombin concentrates reverse prolongation of the prothrombin time.(30)  Rivaroxaban cannot be dialy zed as it is highl y protein bound.  
New Text:
Temporary  discontinuation of rivaroxaban is expected to be sufficient to control bleeding in 
most cases because the drug half -life is onl y 5-13 hours.  L ocal measures should be applied if 
needed to control bleeding (e.g., local pressure, endoscopy  and inje ction of a bleeding vessel, 
embolization) and intravenous fluids and blood transfusion support should be provided as 
indicated.  In the rare case of life -threatening bleeding, the investigator may  consider 
obtaining advice from a hematologist.  Animal studies suggest that both prothrombin complex concentrates and recombinant factor VIIa partiall y restore hemostasis following treatment 
with factor Xa inhibitors such as rivaroxaban and a randomized trial involving healthy  
subjects treated with rivaroxaban has demonstrated that prothrombin concentrates reverse 
prolongation of the prothrombin time.(30)  Rivaroxaban cannot be dial yzed as it is highly  
protein bound.  If available, consideration may be given to the use of a specific reversal agent.
Section [IP_ADDRESS] Guidance for the treatment of subjects who develop a stroke and who are 
being considered for reperfusion therapy (Section added)
This section was added as a result of Modification 15.
Added Text:
The decision to use reperfusion therapi[INVESTIGATOR_014] (including intravenous, intra -arterial thromboly sis,
or mechanical endovascular approaches) in acute ischemic stroke should follow local practice, 
experience, and guidelines. At present there are limited data to guide treatment in this setting 
in subjects taking riva roxaban. The following guidance is intended to aid clinical decision 
making in this setting. 
At or around the time of the peak drug levels (we suggest in the first 6 hours after a dose), 
clinicians may  choose to unblind and to avoid thromboly sis if the subject is taking 
rivaroxaban. Alternatively, if it is possible to obtain a rivaroxaban anti -Xa level in this time 
period, clinicians may  use this information to decide on the appropriateness of starting 
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 161of [ADDRESS_1158655] -study therapy
This section was changed as a result of Modification 9.
Old Text:
At the conclusion of treatment with study  medication, the study staff should encourage the 
subject to begin treatment with open -label aspi[INVESTIGATOR_834282] y, as 
indicated.
New Text:
At the conclusion of treatment with study  medication, the study  staff should encourage the 
subject to resume treatment w ith open- label aspi[INVESTIGATOR_834168].
Section 6.9  Prior and concomitant therapyThis section was changed as a result of Modification 10.
OldText:
As described in Section 5.1.2, Exclusion Criteria, the use of the following agents is not 
permitted at study  entry :  systemic treatment with strong inducers of CYP 3A4 (e.g. 
rifampi[INVESTIGATOR_2513]) and inhibitors of both CYP 3A4 and P- gp (e.g., s ystemic azole antimy cotics, such 
as ketoconazole, and HIV -protease inhibitors, such as ritonavir) .  
…
Study  aspi[INVESTIGATOR_248]/aspi[INVESTIGATOR_834283] o should be continued irrespective of the need for aspi[INVESTIGATOR_834284] y.  
New Text:
As described in Section 5.1.2, Exclusion criteria, the use of the following agents is not 
permitted at study  entry :  systemic treatment with strong inducers of CYP 3A4 (e.g. 
rifampi[INVESTIGATOR_2513]) and inhibitors of both CYP 3A4 and P- gp (e.g., s ystemic azole antimy cotics, such 
as ketoconazole, and HIV -protease inhibitors, such as ritonavir) (see Section 6.9.1).  
…
Study  aspi[INVESTIGATOR_248]/aspi[INVESTIGATOR_834285] y.  
Section 6.9.1  Combined CYP 3A4 and p -glycoprotein inhibitors and CYP 3A4 inducers
This section was changed as a result of Modification 10.
OldText:
Strong inhibitors of both CYP 3A4 and p- glycoprotein increase plasma concentrations of 
rivaroxaban and are contraindicated in subjects taking rivaroxaban. These include systemic 
azole antifungal drugs (e.g. ketoconazole, itraconazole, posaconazole, etc. ), and HIV protease 
inhibitors.  Additionally ,  strong inducers of CYP 3A4 such as i.e.rifampi[INVESTIGATOR_2513], rifabutin, 
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 162of 205
phenobarbital, phen ytoin, and carbamazepi[INVESTIGATOR_834173]. If an y of these treatments are needed, randomized study rivaroxaban/rivaroxaban 
placebo and aspi[INVESTIGATOR_248]/aspi[INVESTIGATOR_834247] y discontinued and open -label aspi[INVESTIGATOR_834174].
New Text:
Strong inhibitors of both CYP 3A4 and p- glycoprotein increase plasma concentrations of 
rivaroxaban and are contraindicated in subjects taking riv aroxaban. These include sy stemic 
azole antifungal drugs (e.g. ketoconazole, itraconazole, posaconazole, etc. ), and HIV protease 
inhibitors.  Additionally ,  strong inducers of CYP 3A4 such as rifampi[INVESTIGATOR_2513], rifabutin, 
phenobarbital, phen ytoin, and carbamazepin e can reduce the plasma concentrations of 
rivaroxaban. If an y of these treatments are needed, randomized study rivaroxaban/rivaroxaban 
placebo must be temporarily  discontinued and open- label aspi[INVESTIGATOR_834246].
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 163of 205
Section 7.1.1 Tabulated overview, Table 7−1
This section was changed as a result of Modifications 13 and 18.
Old Text:
Pre-Screeninga
Screening/
Run-in
Randomizations
Follow -up
Washout
Visit [ADDRESS_1158656] 
Finalm
Windows ± 5d ± 7d ± 2w ± 4w ± 4w ± 4w ± 4w ± 4w ± 4w ± 4w ± 4w ± 4w ± 4w ± 4w ± 4w ± 5d
…..
MoCA, DSS, and SAGE XoXoXpX X
……
h CT angiography will be performed at 1 year in all subjects who are randomized Day 4 -7after CABG to evaluate graft patency  (except in subjects those with 
specific contraindications). In the event the subject undergoes an invasive coronary angiography at [ADDRESS_1158657] angiogram may 
not be required.
i MRI of the brain will be performed only in COMPASS- MIND substudy subjects, at the time of randomization (or soon thereafter, within 3 months) and near the 
end of the follow -up
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 164of 205
New Text:
Pre-Screeninga
Screening/
Run-in
Randomizations
Follow -up
Washout
Visit [ADDRESS_1158658] 
Finalm
Windows ± 5d ± 7d ± 2w ± 4w ± 4w ± 4w ± 4w ± 4w ± 4w ± 4w ± 4w ± 4w ± 4w ± 4w ± 4w ± 5d
…..
MoCA, DSS, and SAGE t XoXoXpX X
……
h.  CT angiography will be performed at 1 year or later in all subjects who are randomized Day 4 -7 after CABG to evaluate graft patency  (except in subjects 
those with specific contraindications). In the event the subject undergoes an invasive coronary ang iography at [ADDRESS_1158659] angiogram may not be required. 
i.   MRI of the brain will be performed only in COMPASS -MIND substudy subjects after randomization and near the end of the follow-up
…
t.  Also to be administered atthe next study clinic visit after each outcome event
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 165of 205
Section [IP_ADDRESS]  Randomization visit (Day 0 ± 5 days)
This section was changed as a result of Modification 17.
Added Text:
MRI  of the brain will be performed onl y in COMPASS- MIND substud y subjects after 
randomization
Section [IP_ADDRESS].1  Routine follow- up visits (V isits 3, 5, and 7-15+)
This section was changed as a result of Modification 18.
Added Text:
Perform CT  angiography onl y at Visit 7 (1 year or later if not performed at 1 y ear) in 
all subjects who are randomized during the first week after CABG to evaluate graft 
patency  (except in subjects with specific contraindications). In the event the subject 
undergoes an invasive coronary  angiography  at [ADDRESS_1158660] angiogram may  not be required.
…
While every  effort should be made for the subject to attend those visits that are meant to be in 
person, infrequently  it may  not be possible to conduct the visit in person in which case the  
visit may  occur by  [CONTACT_834345]. 
Section 7.2.3 Other baseline characteristics
This section was changed as a result of Modification 13.
Old Text:Validated health and quality  of life questionnaires, SAGE, MoCA, DSS, EQ- 5D will be 
administered at screening/run- in or randomization, as well as Month 24, and the Final Follow -
up Visit to measure the effect of randomized treatment on functional outcomes a nd quality  of 
life, anddiet and activity  questionnaires will also be administered in order to explore the 
determinants and consequences of cognitive decline in patients with CAD and PAD.  
New Text:
Validated health and quality of life questionnaires ( SAG E, MoCA, DSS, andEQ-5D) will be 
administered at screening/run- in or randomization, or as soon as possible thereafter, atMonth 
[ADDRESS_1158661] of randomized treatment on functional outcomes and quality  of life.  
Diet and activit y questionnaires will also be administered at screening/run -in or 
randomization, or as soon as possible thereafter, and at Month 24 in order to explore the 
determinants and consequ ences of cognitive decline in patients with CAD and PAD.  
Section 7.3 Efficacy
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 166of 205
This section was changed as a result of Modification 1.
Old Text:
The secondary  efficacy  outcome isa composite of my ocardial infarction, stroke, 
cardiovascular death, revascularization, venous thromboembolism, and cardiovascular 
hospi[INVESTIGATOR_059].   Mortality b y any cause is also a secondary  efficacy  outcome .
Tertiary efficacy  outcomes include the evaluation of responses recorded for the SAGE, 
MoCA, DSS, and EQ- 5D inventor ies and the following:  individual components of the 
primary  and secondary  outcomes, hospi[INVESTIGATOR_059], amputation, stent thrombosis, unstable 
angina, worsening angina, new angina, heart failure, resuscitated cardiac arrest, new diagnosis 
of cancer, MRU, cor onary  artery  by[CONTACT_541649].
…
A detailed description of outcomes to be anal yzed for this study  will be provided in the 
separate statistical anal ysis plan.
New Text:
The secondary  efficacy  outcomes are: 
a) a composite of coronary  heart disease deat h, myocardial infarction, ischemic stroke or acute 
limb ischemia; and 
b) a composite of cardiovascular death, m yocardial infarction, ischemic stroke or acute limb 
ischemia.  
c)mortality  by [CONTACT_55544].
Other efficacy  outcomes include the evaluation of res ponses recorded for the SAGE, MoCA, 
DSS, and EQ -5D inventories and the following:  individual components of the primary  and 
secondary  outcomes, hospi[INVESTIGATOR_059],  revascularization , amputation, stent thrombosis, 
unstable angina, worsening angina, new angina , heart failure, resuscitated cardiac arrest, 
venous thromboembolism , new diagnosis of cancer, MRU, coronary  artery by [CONTACT_834385].
Section 7.5.1 E6 Definition of (serious) adverse event
This section was changed as a result of Modification 11. 
Old T ext:
A serious adverse event (SAE) is classified as an y untoward medical occurrence that, at an y 
dose, results in death, is life -threatening, requires inpatient hospi[INVESTIGATOR_4967], results in persistent or significa nt disability  / incapacity  is a 
congenital anomal y / birth defect and/or is another medically important serious event 
representing a significant hazard, which is comparable to the aforementioned criteria. A 
surgical procedure or hospi[INVESTIGATOR_834286]. However, the condition 
for which the surgery  or hospi[INVESTIGATOR_834251].
New Text:
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 167of 205
Note:  If a subject is hospi[INVESTIGATOR_834191] a procedure that was planned or anticipated prior to 
the subject signing the informed consent, the hospi[INVESTIGATOR_059]/procedure is considered part of 
medical  history  or a therapeutic intervention and is not the result of an (S)AE unless the 
severit y has worsened or changed unexpectedly . Additionally , a procedure is not an (S)AE, 
but the reason for the procedure may  be an (S)AE.
Section [IP_ADDRESS] Protocol -specific exceptions to SAE reporting
This section was changed as a result of Modifications 1and 12. 
Old Text:
Rivaroxaban has been extensively  studied in Phase 2 and 3 clinical studies involving more 
than 70,000 patients and its overall adverse event profile has been well described. 
…
Secondary  and tertiary  efficacy  outcomes
oCardiovascular hospi[INVESTIGATOR_834254] (unstable, worsening or new) 
oHeart failure
oResuscitated cardiac arrest
oNew diagnosis of cancer 
oCoronary  artery  by[CONTACT_541649]
…
In addition, events that are exp ected to occur with high frequency in the population under 
study  and for which no safet y signal arose from more than 70,000 patients alread y studied in 
clinical trials with rivaroxaban will be captured on the CRF only , will be waived from 
unblinding, and b e will be exempted from expedited reporting.  
New Text:
Rivaroxaban has been extensively  studied in Phase 2 and 3 clinical studies involving more 
than 80,000 patients and its overall adverse event profile has been well described.  
…
Secondary  and tertiary  efficacy  outcomes
oCoronary  heart disease death
oIschemic stroke
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 168of 205
oAcute limb ischemia
oCardiovascular hospi[INVESTIGATOR_834254] (unstable, worsening or new) 
oHeart failure
oResuscitated cardiac arrest
oNew diagnosis of cancer 
oCoronary  artery  by[CONTACT_541649]
…
In addition, events that are expected to occur with high frequency  in the population under 
study  and for which no safet y signal arose from more than 80,000 patients alr eady studied in 
clinical trials with rivaroxaban will be captured on the CRF only , will be waived from 
unblinding, and be will be exempted from expedited reporting.  
8.3.2 Secondary efficacy outcomes
This section was changed as a result of Modification 1.
Old Text:
The secondary  efficacy  outcomes are:
The composite of outcomes ---myocardial infarction, stroke, cardiovascular death , 
revascularization, venous thromboembolism, and cardiovascular hospi[INVESTIGATOR_059]
Mortality  (all-cause)
New Text:The secondary  efficacy  outcomes are (in the following order):
The composite of outcomes ---coronary  heart disease death, my ocardial infarction, 
ischemic stroke, acute limb ischemia
The composite of outcomes ---cardiovascular death, myocardial infarction, ischemic 
stroke, acute limb ischemia
Mortality  (all-cause)
Section 8.3.3 Tertiary and other efficacy outcomesThis section was changed as a result of Modification 1. 
Old Text:
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 169of 205
The tertiary  efficacy  outcomes are:
Subject -reported SAGE, MoCA, DSS, and EQ -5D
Individual components of the primary  and secondary  outcomes
Hospi[INVESTIGATOR_059] 
Amputation
Stent thrombosis
Unstable angina 
Worsening angina 
New angina 
Heart failure 
Resuscitated cardiac arrest
New diagnosis of cancer
MRU
Coronary  artery  by[CONTACT_834386]:
The tertiary  efficacy  outcomes are:
Subject -reported SAGE, MoCA, DSS, and EQ -5D
Individual components of the primary  and secondary  outcomes
Hospi[INVESTIGATOR_834287]
Hospi[INVESTIGATOR_059]
Revascularization
Amputation 
Stent thrombosis
Unstable angina 
Worsening angina 
New angina 
Heart failure 
Venous thromboembolism
Resuscitated cardiac arrest
New diagnosis of cancer
MRU
Coronary  artery  by[CONTACT_834387] 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 170of 205
Section 8.3.6  Subgroup variables
This section was changed as a res ult of Modification 16.
Added Text:
Any prior CABG (y es, no), further subdivided as CABG day s 4-7 before 
randomization and other prior CABG   
Section 8.4 Statistical and analytical plans
This section was changed as a result of Modification 2. 
Added Text:
Testing strategy 
Each of the rivaroxaban -based treatment groups will first be compared to the common aspi[INVESTIGATOR_834196], followed by  [CONTACT_834352]. Figure [ADDRESS_1158662] logical restrictions will be 
imposed, i.e., the null hypo theses will be split into two branches corresponding to the tests for 
rivaroxaban 2.5 mg plus aspi[INVESTIGATOR_248] (h ypotheses H 1A, H2A, H3A, H4A) and to the tests for 
rivaroxaban 5.0 mg (h ypotheses H 1B, H2B, H3B, H4B).  A null hy pothesis within each branch 
can be test ed if and onl y if the immediately  preceding null hy pothesis is rejected, e.g., 
hypothesis H 2A, is “testable” if and onl y if h ypothesis H 1Ais rejected. Figure 1, these logical 
restrictions are represented by  [CONTACT_802795].
Figure 8-1: Hypothesis testing problem
Multiple hy potheses testing will be performed according to a mixture gatekeepi[INVESTIGATOR_834197] a truncation fraction of γ= 0.9, which controls the 
family wise error rate at the pre -assigned level of significance α= 5% in the s trong sense.  The 
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 171of 205
Hochberg- based gatekeepi[INVESTIGATOR_834198] (2011, 2013) was recently  proposed in 
Brechenmacher et al., 2011.  Details for the setting of this study  will be described in the SAP.  
Section 8.4.1 Analysis of the primary efficacy outcome
This section was changed as a result of Modification 2. 
Old Text:The 2 comparisons will be performed using 2 separate stratified log -rank tests.  A step-up 
Dunnett procedure( 0,0) analogous to the Hochberg procedure will be used to control the 
overall ty pe I error level of 5%.  The as ymptotically  normall y distributed log -rank test 
statistics will be ordered | t|(1)< |t|(2)and compared to suitably  defined critical values in a 
stepwise fashion starting with the smaller test statistic | t|(1). If |t|(1)≥ c1= 1.96, i.e. if the larger 
of the two p-values is not greater than the 2- sided 5% ty pe I error level, then both hy potheses 
will be rejected. Otherwise, the null hy pothesis corresponding to the smaller test statistic | t|(1)
will be retained and the larger test statistic | t|(2)will be compared to the larger critical value c2
= 2.223, corresponding to a test at the 2 -sided 2.63% ty pe I error level.  P roton pump inhibitor
use (3 strata levels: not randomized to a proton pump inhibitor ; pantoprazole 40 mg od; 
pantoprazole placebo) will be used as a stratification factor.  Stud y center will not be used as a 
stratification factor.   There will be no formal comparison between the rivaroxaban 2.5 mg bid 
+ aspi[INVESTIGATOR_248] 100 mg od and rivaroxaban 5 mg bid + aspi[INVESTIGATOR_834201].
……
The trial success will be determined based on the totality  of evidence for significance, 
magnitude, and direct ion of treatment effect from the anal ysis of primary  and secondary  
efficacy  outcomes.  If the rivaroxaban-based treatment groups and aspi[INVESTIGATOR_834288] y different in the anal ysis of the primary  efficacy  outcome but convincing 
eviden ce of the superiority  of either of the 2 rivaroxaban -based antithrombotic regimens (e.g. 
a reduction of [ADDRESS_1158663] deviations) is observed in the anal ysis of secondary  efficacy  
outcomes, then such extreme differences will provide persuasive evidence of sup eriorit y of 
rivaroxaban- based antithrombotic therap y over aspi[INVESTIGATOR_248] -based therap y.
New Text:
The [ADDRESS_1158664] with 
the pre -specified truncation parameter γ = 0.9 at =0.05 will be used. Further details will be 
described in the SAP.   Proton pump inhibitor use (3 strata levels: not randomized to a proton 
pump inhibitor ; pantoprazole 40 mg od; pantopra zole placebo) will be used as a stratification 
factor.  Stud y center will not be used as a stratification factor.  There will be no formal 
comparison between the rivaroxaban 2.5 mg bid + aspi[INVESTIGATOR_248] 100 mg od and rivaroxaban 5 mg 
bid + aspi[INVESTIGATOR_834201].
…
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 172of [ADDRESS_1158665] from the anal ysis of primary  and secondary  
efficacy  outcomes.  
Section 8.4.2 Analysis of the secondary efficacy outcomes
This section was changed as a result of Modification 2. 
Old Text:
Analy sis of the secondary  efficacy  outcomes will be based on the intention -to-treat principle 
(Section 8.2) and will use a similar approach as described in Section 8.4.1. Both comparisons 
of the rivaroxaban- based treatment groups to the common aspi[INVESTIGATOR_834289] 2 -sided 5% ty pe I error level.  There will be no adjustment of secondary  
analyses for multiple testing.
New Text:Analy sis of the secondary  efficacy  outcomes will be based on the intention -to-treat principle 
(Section 8.2) and will use a similar approach as described in Section 8.4.1.  The famil y-wise 
error rate will be controlled using the truncated and/or regular Hochberg tests as described i n 
Section 8.4and more detailed in the SAP.
Section 8.5 Planned interim analysisThis section was changed as a result of Modification 3.
Old Text:Given these conservative monitoring boundaries and only  2 interim anal yses, the ty pe I error 
level adjustment for the final anal ysis will be negligible.  If the results are clear with one 
intervention, but not for the second intervention, the DSMB may  decide to continue 
evaluation of both or one rivaroxaban treatment arms.  I f the study  is continued with both 
interventions, then the type I error levels specified in Section 8.4.1 will be used in the final 
analysis; if the decision is made to continue with only  one intervention, the final comparison 
will be made at the 5% t ype I error level . 
The Steering Committee will review overall blinded event rates to ensure that they  meet 
protocol projections.  If overall event rates are lower than expected, consideration will be 
given to increasing the sample size or extending the study  duration without knowledge of any  
treatment effect.  The trial will aim to enroll about one-third subjects with PAD; this will be 
monitored during the trial and steps may  be taken to adjust the proportion during the trial.
New Text:
Given these conservative monitoring boundaries and only  2 interim anal yses, the ty pe I error 
level adjustment for the final anal ysis will be negligible.  If the results are clear with one 
intervention, but not for the second intervention, the DSMB may  decide to continue 
evaluation of both or one rivaroxaban treat ment arms.  I f the study  is continued with both 
interventions, then the type I error levels specified in Section 8.4will be used in the final 
analysis; if the decision is made to continue with only  one intervention, the final comparison 
will be made as fo llows: 
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 173of 205
If one intervention was stopped earl y for efficacy , the multiple testing procedure for 
the final anal ysis will be performed as described in Section 8.4 with the assumption 
that the p -value for the primary  efficacy  outcome of the arm that was stoppe d earl y for 
overwhelming efficacy  is smaller than 0.025. For secondary  outcomes, the p -values 
will be obtained from log-rank tests based on all available data for the stopped arm 
(data from confirmation anal ysis 6 months after respective interim look) and the 
complete data from the comparator arm.
If one intervention was stopped earl y for futility , the final anal ysis will be performed 
when at least 1,513 *subjects in the 2remaining arms have experienced an event.
The final analy sis will be performed according to the multiple testing strategy  as 
described in Section 8.4. P- values for the primary and secondary  hypotheses for the 
intervention stopped early will be obtained from the log- rank tests based on all 
available data for the stopped arm and the complet e data from the comparator arm. It 
can be assumed that for the stopped intervention the corresponding p -value of the 
primary  efficacy  outcome will be greater than 0.05. Thus, for the intervention stopped 
early for futility  the primary  and none of the secon dary outcomes can achieve 
statistical significance at the overall t ype I error level of 5% .  
*The whole study was planned to be stopped when at least 2,[ADDRESS_1158666] 826 + 
687 = 1,[ADDRESS_1158667].  The trial will aim to enroll about one-quarter subjects with PAD; 
this will be monitored during the trial and steps may be taken to adjust the prop ortion 
during the trial.
Section 8.6 Determination of sample size
This section was changed as a result of Modification 4. 
Old Text:In this trial, it is planned to randomize at least 21,[ADDRESS_1158668] 90% power to detect a 20% relative risk reduction (RRR) for 
each of the 2 rivaroxaban -based treatment groups vs. the common aspi[INVESTIGATOR_834205].  The 
total number of events needed is shown in Table 8 –1 for different scenari os depending on the 
assumed annual event rate in the aspi[INVESTIGATOR_34209].  Due to the event -driven study  design, the 
number of randomized subjects, length of enrollment and total study  duration may  vary .  If 
recruitment is going extremely  well, a larger number of subjects may  be recruited.  All 
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 174of [ADDRESS_1158669] 10% must be added to the total number below.
Assumptions for antithrombotic treatment randomization were:
3-arm stud y with 1:1:1 randomization
In total, a minimum of 21,400 subjects are randomized (approximately  7,134 subjects 
per treatment group)
2-sided ty pe I error level of 2.7% for each of the two comparisons to control the 
overall ty pe I error level of 5%
Constant annual event rate in aspi[INVESTIGATOR_834207] 3.0% and 4.0%
Effect size: 20% relative risk reduction to be detected for each comparison
Intention- to-treat anal ysis: all subjects randomized are included in the analy sis as 
randomized and the follow -up period for each subject is as long as possible from 
randomization until the date of the Final Follow -up Visit for each subject
Length of recruitment period about 2.5 years 
Early discontinuation of study drug: about 6% and 4% in the 1st and 2nd 6 -month 
periods, and 3% in the 6 -month periods thereafter
The expected total number of observed events and the estimated power for each of the two comparisons are display ed in Table 8−1. 
Table 8-1.  Events calculations
Assu med annual event
rate in aspi[INVESTIGATOR_834257] (years)Estimated power for one 
comparisonExpected total number 
of events
3.0% 4.5 85.1% 1,642
5.0 89.2% 1,909
3.5% 4.5 90.2% 1,907
5.0 93.4% 2,215
4.0% 4.5 93.7% 2,171
5.0 96.0% 2,[ADDRESS_1158670] a true relative risk reduction of 20% in each of the rivaroxaban arms with at least 90% power, it isplanned to randomize at least 21,[ADDRESS_1158671] 50 subjects.
Assumpt ions for pantoprazole randomization are: 
Annual event rate for major upper gastrointestinal complications (overt or occult 
bleeding, s ymptomatic gastroduodenal ulcers or erosions, obstruction or perforation) 
in the range of 1.6% to 2.2%
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 175of 205
At least 12,840 subjects included in the study  are not proton pump inhibitor users and 
they are randomized to pantoprazole treatment and control groups in 1:1 ratio
2-sided ty pe I error level of 5%
Effect size: 50% relative risk reduction to be detected
Intention- to-treat a nalysis: all subjects randomized are included in the analy sis as 
randomized and the follow -up period for each subject is as long as possible from 
randomization until the date of the Final Follow -up Visit for each subject
Under these assumptions, the expected total number of major upper gastrointestinal complications is between 450 and 730, depending on the observed event rates and the total 
study  duration. The estimated power for the detection of the true relative risk reduction of 
about 50% for major upper gastrointestinal complications for pantoprazole 40 mg od vs. 
pantoprazole placebo is close to 100% for all scenarios considered.
Sample size estimation was based on the method by [CONTACT_834355] ( 40) implemented in Power 
Analy sis and Sample Size (PASS) software, version 11.0.7, and on a Statistical Anal ysis 
System (SAS) macro provided by  J. Shih (1995).( 41)  In addition, simulations were 
performed to confirm that the Dunnett step -up testing procedure as described in Section 8.4.1
for the analy sis of the primary  efficacy  outcome keeps the overall ty pe I error level of 5%.  
SAS calculations and simulations were performed using SAS software, version 9.2 (SAS 
Institute Inc, Cary, NC, [LOCATION_003]).
New Text:
In this trial, it is planned to randomize at least 27,[ADDRESS_1158672] 90% power to detect a 20% relative risk reduction (RRR) for 
each of the 2 rivaroxaban -based treatment groups vs. the common aspi[INVESTIGATOR_834205].  The 
total number of events needed is shown in Table 8 –1 for different scenari os depending on the 
assumed annual incidence rate for the primary  outcome in the aspi[INVESTIGATOR_834206] 6 (integrated protocol Version 2.0), dated 
03JUL 2014.  Due to the event -driven stud y design, the numbe r of randomized subjects, 
length of enrollment and total study  duration may  vary .  If recruitment is going extremel y 
well, a larger number of subjects may  be recruited.  All numbers below refer to the minimum 
number of events to be observed after successfu l completion of the run -in period.  For the 
total number of subjects to be enrolled in the run -in period, at least 10% must be added to the 
total number below.
Original assumptions for antithrombotic treatment randomization were:
3-arm stud y with 1:1:1 randomization
In total, a minimum of 21,400 subjects are randomized (approximately  7,134 subjects 
per treatment group) according to a 1:2:3:4:4 pattern within 2.5 y ears
2-sided ty pe I error level of 2.7% for each of the two comparisons to control the 
overall ty pe I error level of 5%
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 176of 205
Constant annual incidence rate in aspi[INVESTIGATOR_834207] 3.0% and 4.0%
Effect size: 20% relative risk reduction to be detected for each comparison
Intention- to-treat anal ysis: all subjects randomized are included in the anal ysis as 
randomized and the follow -up period for each subject is as long as possible from 
randomization until the date of the Final Follow -up Visit for each subject
Length of recruitment period about 2.5 y ears 
Early discontinuation of study  drug: about 6% and 4% in the 1st and 2nd 6- month 
periods, and 3% in the 6 -month periods thereafter
The expected total number of observed events and the estimated power for each of the two comparisons are display ed in Table 8−1. 
Table 8-1.  Events calculations
Assu med annual 
incidence rate in 
aspi[INVESTIGATOR_834208] (years)Estimated power for one 
comparisonExpected total number 
of events
3.0% 4.5 85.1% 1,642
5.0 89.2% 1,909
3.5% 4.5 90.2% 1,907
5.0 93.4% 2,215
4.0% 4.5 93.7% 2,171
5.0 96.0% 2,[ADDRESS_1158673] a true relative risk reduction of 20% in each of 
the rivaroxaban arms with at least 90% power, it wasplanned to randomize at least 21,[ADDRESS_1158674] 50 subjects.
The ori ginally  planned sample size of 21,400 and 5 y ear study  duration was based on an 
annual primary  incidence rate in the control group of 3.5% and 90% power to detect a relative 
risk reduction of 20% in each of the rivaroxaban arms. Based on an observed incide nce rate of 
2.9% as of JUL  2015, it is now planned to randomize at least 27,400 subjects. This new 
sample size will maintain current stud y timelines and 90% power to detect a 20% relative risk 
reduction in each of the rivaroxaban arms, based on the followi ng revisions to the original 
assumptions:  
Overall length of recruitment period about 3 to 3.5 y ears and taking observed 
randomization times up to July  2015 into account
2-sided overall t ype I error level of 5% using a truncated Hochberg test (γ = 0.9) fo r 
the testing of the 2primary  hypotheses
Constant overall incidence rate of about 2.9% per y ear, resulting in a constant 
incidence rate of about 3.3% per year for the aspi[INVESTIGATOR_834209] a 20% 
relative risk reduction for both hy potheses
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 177of 205
Censori ng due to non -CV death at an event rate of almost 1% per year
Assumptions for pantoprazole randomization are: 
Annual incidence rate for major upper gastrointestinal complications (overt or occult 
bleeding, s ymptomatic gastroduodenal ulcers or erosions, ob struction or perforation) 
in the range of 1.6% to 2.2%
At least 16,440 subjects included in the study  are not proton pump inhibitor users and 
they are randomized to pantoprazole treatment and control groups in 1:1 ratio
2-sided ty pe I error level of 5%
Effect size: 50% relative risk reduction to be detected
Intention- to-treat anal ysis: all subjects randomized are included in the analy sis as 
randomized and the follow -up period for each subject is as long as possible from 
randomization until the date of the Final Follow -up Visit for each subject
Under these assumptions, the expected total number of major upper gastrointestinal complications is between 570 and 780, depending on the observed event rates and the total 
study  duration. The estimated power for the detection of the true relative risk reduction of 
about 50% for major upper gastrointestinal complications for pantoprazole 40 mg od vs. 
pantoprazole placebo is close to 100% for all scenarios considered.
Sample size estimation was based on the method by [CONTACT_834355] ( 40) implemented in Power 
Analy sis and Sample Size (PASS) software, version 11.0.7, and on a Statistical Anal ysis 
System (SAS) macro provided by  J. Shih (1995).(41) In addition, simulations were performed 
to confirm that the mixture gatekeepi[INVESTIGATOR_834290] 8.4for the analy sis 
of the primary  efficacy  outcome keeps the overall ty pe I error level of 5%.  SAS calculations 
and simulations were performed using SAS software, version 9.2 (SAS Institute I nc, Cary , 
NC, [LOCATION_003]).
Section 9.3  Data processing
This section was changed as a result of Modification 18.
Added Text:
Visit attendance
Section [ADDRESS_1158675]
This section was changed as a result of Modification 12. 
Deleted Text:Dmitrienko A, Tamhane A, Bretz F (editors). Multiple Testing Problems in Pharmaceutical 
Statistics. Chapman and Hall/CRC, 2009.
Dunnett CW and Tamhane AC. A Step-Up Multiple Test Procedure. Journal of the American 
Statistical Association, 1992 87(417):162-170.
Added Text:
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 178of [ADDRESS_1158676] for clinical trial applications. Journal of Biopharmaceutical 
Statistics, 2011; 21: 748-767.
Dmitrienko, A, Tamhane, AC. Mixtures of multiple testing procedures for gatekeepi[INVESTIGATOR_834291]. Statistics in Medicine, 2011; 30: 1473 -1488.
Dmitrienko, A, Tamhane, AC. General theory  of mixture procedures for gatekeepi[INVESTIGATOR_007]. 
Biometrical Journal, 2013; 55: 402-419.
Bonaca MP, Bhatt DL , Cohen M, Steg PG, Storey RF, Jensen EC, et al.  Long-term use of 
ticagrelor in patients with prior myocardial infarction.  N Engl J Med 2015; 372:1791 -1800. 
Mauri L , Kereiakes DJ, Yeh RW, Driscoll -Shempp P, Cutlio DE, Steg PG, et al.  Twelve of 
30 months of dual antiplatelet therap y after drug- eluting stents.  N Engl J Med 2014; 
371:2155-66. 
Palmerini T, Benedetto U, Bacchi -Reggiani L, Della Riva D, Biondi- Zoccai G, Feres F, et al.  
Mortality  in patients treated with extended duration dual antiplatelet therapy after drug -eluting 
stent implantation: a pairwise and Bay esian network meta -analysis of randomised trial.  
Lancet 2015;385;2371 -82. 
Patel MR, Mahaffey  KW, Garg J, Pan G, Singer DE, Hacke W, et al.  Rivaroxaban versus 
warfarin in nonvalvular atrial fibrillation.  N Engl J Med 2011;Sep 8;36 5(10):883 -91.
Section 14.1 COMPASS MIND Substudy
This section was changed as a result of Modification 17.
Old Text :
Hypotheses:…
Pre-specified secondary  outcomes would consider the effect of rivaroxaban on (1) non- lacunar 
covert brain infarcts; (2) all incident strokes, including clinical strokes (anticipated rate 
1.2%/y r among peripheral arterial disease patients and 0.8%/ yr among subjects with CAD), 
and all covert strokes; ( 3a) functional decline (Standard Assessment of Global -Activities in 
the Elderl y [SAGE]) and [ 3b] cognitive decline (Montreal Cognitive Assessment [MoCA] and 
digit sy mbol substitution).  Exploratory  anal yses will examine the predictive value of 
biomarkers (C -reactive protein, nt- proBNP) as indepe ndent predictors of covert brain infarcts.
Design: A phase II trial seeking evidence of efficacy  in which a convenience sample of 1500 
COMPASS participants over age 65 undergo will be invited to participate –500 assigned to 
each treatment arm, but balanc ed for age, prior stroke, and hy pertension.  Participants will 
undergo limited brain MRI sequences (Fluid Attenuated Inversion Recovery  [FLAIR]), T-1, 
T-2, and T -2* GRE sequences at entry and near end -study  coupled with assessment of 
function (SAGE), and c ognition (MoCA, digit s ymbol substitution).  Recruitment will occur 
at COMPASS sites with access to high -quality  (>1.0 Tesla) reasonabl y-priced MR imaging.  
Images will be transmitted to the central MR imaging center via discs.  Two -stage central 
interpret ation blinded to treatment will be carried -out, with all incident covert infarcts 
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 179of 205
confirmed b y a second independent interpreter.  The  has experience with collection and 
analysis of brain MRIs performed in substudies of several randomized trials:  AVER ROES, 
PURE, APOLLO, and (planned) TIPS [ADDRESS_1158677] DNA collected at baseline and blood collected at baseline and at the 1 
month visit. DNA and blood collections are optional.(Section7.1.1, [IP_ADDRESS] and [IP_ADDRESS].1) The 
samples will be processed , and aliquots will be shipped for long -term storage in liquid 
nitrogen at the coordinating center in  Canada.  Blood samples will be 
processed and stored in such a way to allow future anal ysis of these aliquots for selected 
biomarkers, s ome of which have been observed in other studies to be predictors of stroke, and 
others which have a plausible association with cardiovascular outcomes.  Detailed information concerning blood collection, processing, storage, and shippi[INVESTIGATOR_834292].
New Text:
Hypotheses: 
…
Pre-specified secondary  outcomes would consider the effect of rivaroxaban on (1) non- lacunar 
covert brain infarcts; (2) volume of white matter hy perintensities; (3) all incident strokes, 
including clinical strokes (anticipated rate 1.2%/ yr among peripheral arterial disease patients 
and 0.8%/ yr among subjects with CAD), and all covert strokes; ( 4a) functional decline 
(Standard Assessment of Global- Activities in the Elderly  [SAGE]) and [ 4b] cognitive decline 
(Montreal Cognitive Assessment [MoCA] and digit sy mbol substitution).  Exploratory  
analyses will examine the predictive value of biomarkers (C- reactive protein, nt- proBNP) as 
independent predictors of covert brain infarcts.Design: A phase II trial seeking e vidence of efficacy  in a convenience sample of 1500 
COMPASS participants with readable baseline MRI  scans, 500 assigned to each treatment 
arm, but balanced for age, prior stroke, and h ypertension.  Participants will undergo limited 
brain MRI  sequences (Fluid Attenuated Inversion Recovery  [FLAI R]), T -1, T-2, and T -2* 
GRE sequences after randomization and near end- study  coupled with assessment of function 
(SAGE), and cognition (MoCA, digit sy mbol substitution).  Recruitment will occur at 
COMPASS sites with access to high -quality  (>1.0 Tesla) reasonabl y-priced MR imaging.  
Images will be transmitted to the central MR imaging center via discs.  Two -stage central 
interpretation blinded to treatment will be carried -out, with all incident covert infarcts 
confirmed b y a second independent interpreter.  The  has experience with collection and 
analysis of b rain MRIs performed in substudies of several randomized trials:  AVERROES, 
PURE, APOLLO, and (planned) TIPS [ADDRESS_1158678] DNA collected at baseline and blood 
collected at baseline and at the 1 month visit. DNA and blood collections are 
optional.(Section7.1.1, [IP_ADDRESS] and [IP_ADDRESS].1). The samples will be processed, and aliquots 
will be shipped for long- term storage in liquid nitrogen at the coordinating center in  
 Canada.  Blood samples will be p rocessed and stored in such a way to allow future 
analysis of these aliquots for selected biomarkers, some of which have been observed in other 
studies to be predictors of stroke, and others which have a plausible association with 
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 180of 205
cardiovascular outcomes. Detailed information concerning blood collection, processing, storage, and shippi[INVESTIGATOR_834258].
13.3 Amendment 11
13.3.1 Overview changes to the study
The following changes are made to Protocol Version 3.0. Administrative and editorial corrections are made throughout the document. L ong-term open -label extension (L TOLE) is 
added and changes are made to COMPASS trial after early  termination of rivaroxaban/aspi[INVESTIGATOR_834293].
Modification 1: Name [CONTACT_834399]. LT OLE, MACE and 
PPI[INVESTIGATOR_834294].
Rationale:  replaces  as the sponsor’s  
for the COMPASS trial.Sections affected:
Title page
Signature [CONTACT_8152]’s medically  responsible person
List of abbreviations
Modification 2: Adding LTOLE.Rationale: On February  6, [ADDRESS_1158679] recommended 
discontinuation of the rivaroxaban/aspi[INVESTIGATOR_834110] a clear 
benefit of one of the two rivarox aban -containing arms. Final rivaroxaban/aspi[INVESTIGATOR_834295] -up 
visits were performed during the second quarter of 2017. The protocol was amended to make rivaroxaban plus aspi[INVESTIGATOR_834296] .
Sections affe cted:
Synopsis
Section 1.1 Background
Section 1.2 Study  rationale
Section 1.3 Benefit- risk assessment
Section 2 Study  objectives
Section 3.1 Study  committees
Section 4.1 Design overview
Section 4.2 Primary  efficacy  and safet y variables
Section 4.3 Justification of the design
Section 4.4 Final follow -up visit and end of study
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 181of 205
Section 5.1 Eligibility
Section 5.2 Discontinuation of subjects from stud y treatment
Section 6.1 Treatments to be administered
Section 6.3 Treatment assignment
Section 6.4.1 Dos e modifications
Section [IP_ADDRESS] Guidance for the treatment of subjects who require an invasive 
procedure
Section [IP_ADDRESS] Guidance for the treatment of subjects who require coronary artery 
by[CONTACT_10956]
Section [IP_ADDRESS] Guidance for the treatment of subjects who develop an acute coronary  
syndrome and those who require percutaneous coronary  intervention with stenting
Section [IP_ADDRESS] Guidance for the treatment of subjects who overdose on study 
rivaroxaban/rivaroxaban placebo
Section [IP_ADDRESS] Guidance for the treatment of subjects who experience a major bleed
Section [IP_ADDRESS] Guidance for the treatment of subjects who develop a stroke and who 
are being considered for reperfusion therap y
Section 6.5 Blinding
Section 6.6 Drug logistics and accountability
Section 6.[ADDRESS_1158680] -study  therapy
Section 6.9 Prior and concomitant therap y
Section 6.9.1 Combined CYP 3A4 and p- glycoprotein inhibitors and CYP 3A4 
inducers
Section 6.9.2 Clopi[INVESTIGATOR_7745] (or an y other non -study  antiplatelet treatment)
Section 6.9.3 Anticoagulant tre atment
Section 7.1 Schedule of procedures
Section 7.1.1 Tabulated overview
Section 7.1.2 Timing of assessment
Section 7.3 Efficacy
Section 7.5 Safety
Section 8.4 Statistical and anal ytical plans
Section 9.2 Monitoring
Section 10 Premature termination of the study
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 182of 205
Section 11.[ADDRESS_1158681] information and consent
Modification 3: Changes made to COMPASS trial after earl y termination of 
rivaroxaban/aspi[INVESTIGATOR_834189].
Rationale: Due to early  termination of rivaroxaban/aspi[INVESTIGATOR_834189], a final follow up 
rivaroxaban/aspi[INVESTIGATOR_834297]. No washout visit for pantopraz ole/placebo arms will be needed due to the short 
half-life of pantoprazole.
Sections affected:
Section 4.1 Design overview
Section 7.1 Schedule of procedures
Section 7.1.1 Tabulated overview
Section [IP_ADDRESS] End of washout telephone visit ([ADDRESS_1158682] Final Follow -up Visit ± 5 
days)
13.3.2 Changes to protocol text
In this section, all affected protocol sections are detailed; the sequence of the sectio ns follows 
the structure of the original protocol. In the display of modifications, the “old text” refers to 
the protocol version preceding this amendment and “new text” display s the updated text. 
Deletions are crossed out and additions are underlined. Cor rections of t ypi[INVESTIGATOR_834298].
Modification 1: Name [CONTACT_834400]. LTOL E,MACE and 
PPI[INVESTIGATOR_834294].
Sponsor Clinical Leader:Old text:
Global Clinical Development
[COMPANY_015], Inc.
[ADDRESS_1158683], [PO_BOX]
Whippany , NJ  [ZIP_CODE]
[LOCATION_002]
Tel: 
New text:
 
Bayer U.S. LLC
Development, Pharmaceuticals
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 183of 205
Thrombosis & Hematology  Therapeutic Area
[ADDRESS_1158684]., Location 2095B
Parsippany , New Jersey  [ZIP_CODE] [LOCATION_003]
Tel: 
Signature [CONTACT_8152]’s medically responsible person
[INVESTIGATOR_382420]:
Name:
[CONTACT_834401]:Name :
[INVESTIGATOR_267448] 2: Adding LTOLE.
Synopsis
Study objectivesObjective for Long -Term  Open -Label Extension (LTOLE)
To make rivaroxaban 2.5 mg twice daily (bid) + aspi[INVESTIGATOR_248] 100 mg once daily 
(od) available to COMPASS trial subjects until the rivaroxaban treatment is 
commercially available for this indication or for approximately [ADDRESS_1158685] drugs
      Dose(s)
      Duration of treatm entLTOLE
Rivaroxaban 2.5 mg bid + aspi[INVESTIGATOR_248] 100 mg od
LTOLE: approximately 3 years
Reference drugsLTOLE: no reference drug
Diagnosis and main criteria for 
inclusionLTOLE: all subjects randomized to the COMPASS trial willing to consent to 
LTOLE are eligible unless the subjects developed a condition considered by 
[CONTACT_834321].
Study designLTOLE: open label uncontrolled study
MethodologyLTOLE: initiation v isit and a follow -up period
Type of controlLTOLE: none
Number of subjectsLTOLE: COMPASS trial subjects are potentially eligible.
Prim ary variableLTOLE: the same primary safety and efficacy variables will be collected in LTOLE.
Plan for statistical analysisLTOLE: all statistical analyses will be descriptive.
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 184of [ADDRESS_1158686] of abbreviations
New text:
Lb
LTOLEPoundLong -term open -label extension
MACE Major adverse cardiac event
MD Medical director/doctor
PPI [INVESTIGATOR_834299] 1.1 Background
New text:
…… In the (partial factorial) randomization, patients who do not have a continuous need for 
use of a PPI[INVESTIGATOR_834234] 40 mg od or placebo for the 
prevention of major upper gastrointestinal complications, and then randomized to receive 
rivaroxaban in combination with aspi[INVESTIGATOR_248], rivaroxaban alone, or aspi[INVESTIGATOR_264086].
Long -Term Open -Label Extension –amended
On February  6, 2017, the COMPASS Data Safety  Monitoring Board (DSMB) recommended 
discontinuation of the rivaroxaban/aspi[INVESTIGATOR_834110] a clear 
benefit of one of the two rivaroxaban -containing arms. The DSMB recommendation was 
made because for rivaroxaban 2.5 mg bid + aspi[INVESTIGATOR_248] 100 mg od , the z -value (test statistic of the 
log-rank test) for efficacy  had crossed the critical value for earl y efficacy  as outlined in the 
DSMB charter consistently  over a 3- month pe riod, and the z -value for rivaroxaban 5 mg bid 
had reached conventional significance for efficacy . The Steering Committee concurred with 
the recommendation of the DSMB, and the sponsor decided to stop the rivaroxaban/aspi[INVESTIGATOR_834300] y based on the recommendation of the DSMB and the Steering Committee. 
The sponsor is making rivaroxaban 2.5 mg bid + aspi[INVESTIGATOR_248] 100 mg od available earl y for 
COMPASS trial subjects as part of a long- term open -label extension (LTOLE) protocol 
amendment. The dedicated LTOLE sections in this document describe LTOL E activities only ; 
activities related to the pantoprazole/placebo arm remain unchanged with the exception of the 
removal of the washout visit. L TOLE activities will be coordinated with those of the ongoing 
pantoprazole/placebo arms of the trial where possible until pantoprazole/placebo part of the 
trial is completed.
Section 1.2 Study rationaleNew text:1.2.[ADDRESS_1158687] of rivaroxaban 2.5 mg bid + aspi[INVESTIGATOR_248] 
100mg od over existing standard treatment with aspi[INVESTIGATOR_248] , the sponsor will offer the 
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 185of 205
rivaroxaban 2.5 mg bid + aspi[INVESTIGATOR_248] 100 mg od to trial subjects in a long -term open -label 
extension (L TOLE) until the rivaroxaban treatment is commercially  avail able for this 
indication or for approximately  [ADDRESS_1158688] .
In COMPASS, the combination rivaroxaban 2.5mg bid + aspi[INVESTIGATOR_248] 100mg od compared to 
aspi[INVESTIGATOR_248] 100mg alone:
Reduced the relative risk for the primary  composite of stroke, m yocardial infarction 
and cardiovascular death by  24% (p<0.0001)
Increased the risk of ISTH modified major bleeding sig nificantl y (HR 1.70, 95% CI  
1.40- 2.05, p<0.[ZIP_CODE])
No significant increase was found in intracranial or fatal bleeds
Reduced the risk for pre -specified net clinical benefit, a composite of outcomes of 
irreversible harm, significantly  (HR 0.80, 95% CI 0.70-0.91, p=0.[ZIP_CODE])
Rivaroxaban 5.0 mg BID alone compared to 100 mg aspi[INVESTIGATOR_264086]:
Did not significantl y reduce the hazard for the primary outcome (HR 0.90, 95% CI  
0.79- 1.03, p=0.11), but increased major bleeding
Findings were consistent across the majorit y regions and subgroups.
Section 1.3 Benefit -risk assessment
New text:
…...  I n the COMPASS trial, the efficacy  of pantoprazole will be compared with placebo for 
the prevention of upper gastrointestinal bleeding, ulceration, obstruction or perforation in 
subjects randomized to the combination of rivaroxaban and aspi[INVESTIGATOR_248], rivaroxaban alone, or aspi[INVESTIGATOR_264086], using a partial factorial design.
Long -Term Open -Label Extension –amended
Rivaroxaban 2.5mg bid + aspi[INVESTIGATOR_248] 100mg od has demonstrated superior efficacy  on reducing 
major adverse cardiac event (MACE) in patients with CAD/PAD as compared to aspi[INVESTIGATOR_834301]-specified net clinical benefit significantl y (refer to Section 1.2.4). 
Therefore, the sponsor aims to make rivaroxaban 2.5 mg bid + aspi[INVESTIGATOR_248] 100 mg od available in 
a long -term open -label extension .
Section 2 Study objectives
New text:Substudy objectives
The COMPASS -MIND substudy  will examine the effect of the antithrombotic therapi[INVESTIGATOR_834132], thereby [CONTACT_834388]. COMPASS -MIND will be conducted 
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 186of 205
concurrently  with the main study  in a subset of subjects at selected centers.  A detailed 
description is included in Section 14.1.
Objective for Long- Term Open -Label Extension – amended
The objective of LTOLE is to make rivaroxaban 2.5 mg bid + aspi[INVESTIGATOR_248] [ADDRESS_1158689]. 
Primary , secondary  and tertiary  efficacy  and safety  outcomes as described above will be 
collected in the LTOLE.
Section 3.1 Study committees
New text:
…...  The study  chair and/or the principal investigators will attend the open portion of the 
meeting to provide reports and respond to questions concerning the stud y. 
Long -Term Open -Label Extension − amended
Outcome events for LTOLE will be collected in a descriptive way , and no adjudication will be 
performed. 
The DSMB will not monitor the LTOLE and will conclude responsibilities when the 
pantoprazole/placebo treatment is completed.
Section 4.1.1 Design overview
New text:Subjects randomized Day  4-7 after CABG surgery  will undergo computed t omograph y (CT)  
angiograph y at [ADDRESS_1158690] angiography  (e.g., contrast allergy , estimated 
glomerular filtration rate <30 ml/min).  I n the event th e subject undergoes an invasive 
coronary  angiography  at approximately  [ADDRESS_1158691] 
angiogram may  not be required.
Long -Term Open -Label Extension − amended
The long- term open -label extension (L TOLE) will provide open- label rivaroxaban 2.5mg bid 
+ aspi[INVESTIGATOR_248] 100mg od to COMPASS subjects until it is commercially  available or for 
approximately  [ADDRESS_1158692]. The implementation of L TOLE is an amendment to the COMPASS trial. 
For inclusion and exclusion criteria, see Section 5.1.3; for treatment related details, see 
Section 6.1.3 (Treatment to be administered), Section 6.6 (Drug logistics and a ccountabilit y), 
and Section 6.8 (Post -study  therapy ). 
The LTOLE will involve an initiation visit and a follow -up period. 
Treatment initiation visits can be scheduled as soon as the LTOLE has received regulatory  
and ethics approvals, the site has signed a contract amendment, and the drug is available at the 
site. Before entering LTOL E, informed consent is needed. 
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 187of 205
For detailed procedures and variables, see Section 7.1.1 (Tabulated overview of LTOLE) and 
Section [IP_ADDRESS] (Timing of assessments in LTOLE).The same efficacy  and safet y outcomes as 
in the COMPASS tri al will be collected in the LTOL E. All statistical analyses will be 
descriptive. 
Section 4.2 Primary efficacy and safety variables
New text:
The primary  safet y outcome for the rivaroxaban randomization is a composite of: 
fatal bleeding, and/or 
symptomat ic bleeding in a critical area or organ, such as intracranial, intraspi[INVESTIGATOR_1304], 
intraocular, retroperitoneal, intraarticular or pericardial, or intramuscular with 
compartment s yndrome, or bleeding into the surgical site requiring re -operation, 
and/or 
bleeding leading to hospi[INVESTIGATOR_834137] -Term Open -Label Extension − amended
The same primary  efficacy  and safet y outcomes collected in the COMPASS trial will be 
collected during the LTOLE visits.
Section 4.3 Justification of the design
New text:4.3.2 Design rati onale for Long -Term Open -Label Extension
Due to the clinical efficacy of rivaroxaban 2.5mg bid + aspi[INVESTIGATOR_248] 100mg od (see Section 1.2.4), 
participation in the LTOLE will be offered to all subjects who meet the LTOL E 
Inclusion/Exclusion criteria defined in Sec tion 5.1.3.
Section 4.4 Final follow -up visit and end of study
New text:
For each participating European Union (EU) country , the end of the study  according to the EU 
Clinical Trial Directive will be reached when the telephone call at the end of the [ADDRESS_1158693] for all centers in the respective country  has occurred.  The 
end of the study as a whole will be reached as soon as the end of the stud y according to the 
above definition has been reached in all participating countries (EU and non- EU).
Long -Term Open -Label Extension − amended
The final visits of L TOLE will begin, per country , when the duration reaches [ADDRESS_1158694] the final visit may  be conducted at 
the next scheduled visit.
Section 5.1 Eligibility
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 188of 205
New text:
5.1.3 Long -Term Open -Label Extension – amended
All subjects from COMPASS trial will be invited to join LTOLE as long as they  continue to 
meet the COMPASS eligibility  criteria (refer to sections 5.1.1 and 5.1.2) plus the specific 
ones for LTOLE (refer to section s [IP_ADDRESS] and [IP_ADDRESS]). All LTOLE subjects must provide 
written informed consent to participate in LTOLE.
[IP_ADDRESS] Inclusion criteria
All subjects randomized to the COMPASS trial willing to consent to L TOLE are 
eligible unless the subjects developed a condition considered b y the investigator as 
exclusionary . 
Subjects who have given their written informed consent to participate in the L TOLE 
after having received adequate information prior to any  LTOLE specific procedures.
[IP_ADDRESS] Exclusion criteria
Subjects should not be included if, in the judgement of the investigator, they  have 
developed a condition which should exclude them from recei ving LTOLE study  
medication. For example if the subject has developed atrial fibrillation or had a severe 
allergic rash while in the study , which subsided when drug was stopped and returned 
when drug was reinitiated.
Section 5.2 Discontinuation of subjects from study treatment
New text:Section 5.2.[ADDRESS_1158695] should come for a final 
visit within approximately 3 months, but follow the PPI  [INVESTIGATOR_834302].
Section 6.1 Treatments to be administeredNew text:6.1.3 Treatment in Long- Term Open -Label Extension
The LTOLE treatment will be open-label rivaroxaban 2.5 mg bid + aspi[INVESTIGATOR_248] 100 mg od.
Section 6.3 Treatment assignmentNew text:
The  randomization and drug management sy stem will assign the subject a unique 
number for each medication that corresponds to one of the treatments listed in Table 4−1.
Long -Term Open -Label Extension − amended
All subjects in the L TOLE will receive the same treatment of rivaroxab an 2.5 mg bid + 
aspi[INVESTIGATOR_248] 100 mg od.
Section 6.4.1 Dose modifications
[COMPANY_003]
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 189of 205
New text:
……  For example, if study  rivaroxaban/rivaroxaban placebo is interrupted, study  
aspi[INVESTIGATOR_248]/aspi[INVESTIGATOR_834303]/pantoprazole placebo should be continued.
Long -Term Open -Label Extension − amended
No dose modifications will be conducted in the LTOL E.
Section [IP_ADDRESS] Guidance for the treatment of subjects who require an invasive 
procedure
New text:
A two-unit single donor platelet transfusion in subjects treated with the combination of aspi[INVESTIGATOR_834304] y to generate thromboxane and thereby [CONTACT_834389][INVESTIGATOR_248]. (29)
Long -Term Open -Label Extension − amended
The same guidance will apply  to LTOLE.
Section [IP_ADDRESS] Guida nce for the treatment of subjects who require coronary artery 
by[CONTACT_834390]:
……I n all cases, the goal should be to resume study  antithrombotic drugs within 14 day s and 
prior to being discharged from hospi[INVESTIGATOR_307].  
Long -Term Open -Label Extension − amended
The same guidance will apply  to LTOLE. For subjects who are scheduled to undergo CABG, 
LTOLE treatment can be initiated four days after CABG and at least [ADDRESS_1158696] administration of an y anticoagulant (including DVT proph ylaxis). 
Section [IP_ADDRESS] Guidance for the treatment of subjects who develop an acute coronary 
syndrome and those who require percutaneous coronary intervention with ste nting
New text:
……When switching back to originall y allocated study anticoagulant, interim study 
anticoagulant therap y should be stopped. 
Long -Term Open -Label Extension − amended
Study  rivaroxaban should be interrupted in subjects who require anticoagula nt or dual 
antiplatelet therap y because of an acute coronary syndrome or need for percutaneous coronary 
intervention with stenting. Standard antiplatelet therapy, including loading doses of aspi[INVESTIGATOR_60463] (or prasugrel or ticagrelor) can be administered according to usual practice.  
Study  aspi[INVESTIGATOR_834164]. All subjects should resume rivaroxaban 2.5 mg bid + aspi[INVESTIGATOR_834305]- study  dual antiplatelet therap y is stopped and they are not being treated with non -
study  anticoagulants.
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 190of 205
Section 6. 4.2.4 Guidance for the treatment of subjects who overdose on study 
rivaroxaban/rivaroxaban placebo
New text:
……If available, consideration may be given to the use of a specific reversal agent.
Long -Term Open -Label Extension − amended
The same guidance will apply  to LTOLE. 
Section [IP_ADDRESS] Guidance for the treatment of subjects who experience a major bleed
New text:
……Rivaroxaban cannot be dialy zed as it is highly  protein bound. If available, consideration 
may be given to the use of a specific reversal agent.
Long -Term Open -Label Extension − amended
The same guidance will apply  to LTOLE.
Section [IP_ADDRESS] Guidance for the treatment of subjects who develop a stroke and who are 
being considered for reperfusion therapy
New text:
……Endovascul ar therapy  with clot extraction can proceed whether or not the subject is 
receiving rivaroxaban without the need to unblind.
Long -Term Open -Label Extension − amended
The decision to use reperfusion therapi[INVESTIGATOR_014] (including intravenous, intra -arterial thromboly sis, 
or mechanical endovascular approaches) in acute ischemic stroke should follow local practice, 
experience, and guidelines. At present there are limited data to gu ide treatment in this setting 
in subjects taking rivaroxaban. The following guidance is intended to aid clinical decision 
making in this setting. 
At or around the time of the peak drug levels (we suggest in the first 6 hours after a dose), 
clinicians may  consider to avoid thromboly sis. If it is possible to obtain a rivaroxaban anti- Xa 
level in this time period, clinicians may  use this information to decide on the appropriateness 
of starting thrombol ysis. 
Section 6.5 Blinding
New text:
……All subjects shoul d resume study treatments after recovery if it is medically appropriate 
to do so and should be followed until the end of the study .
Long -Term Open -Label Extension –amended
The LTOLE is open label and no blinding procedures are applicable to the L TOLE.
Section 6.6 Drug logistics and accountability
New text:
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 191of 205
Written instructions on medication destruction will be made available to affected parties as applicable.
Long -Term Open -Label Extension -amended
Investigator staff will continue to access the  randomization and drug management 
system to dispense study  medication. LTOLE treatment will be provided in appropriatel y 
labelled medication kits that identify  the treatment. All L TOLE treatment will be stored at the 
site in accordance with GCP and Good Manufac turing Practices (GMP) requirements and the 
instructions given b y the clinical supplies department of the sponsor or its affiliates. Receipt, 
distribution, return and destruction (if an y) of the study  drug must be properly  documented 
according to the agree d and specified procedures.
Section 6.[ADDRESS_1158697] -study therapy
New text:
At the conclusion of treatment with study  medication, the study  staff should encourage the 
subject to resume treatment with open -label aspi[INVESTIGATOR_834168].
Long -Term Open -Label Extension − amended
At the conclusion of LTOL E treatment, subject’s will be directed to their usual care phy sician 
for appropriate treatment.  
Section 6.9 Prior and concomitant therapy
New text:
…...  Study  aspi[INVESTIGATOR_248]/aspi[INVESTIGATOR_834306] y.  
Long -Term Open -Label Extension − amended
During the LTOLE, all subjects should continue to receive an y ongoing medications, with the 
exception of the subject’s own aspi[INVESTIGATOR_834307]. Subjects may  receive all medications that their treating phy sicians believe 
are necessary . If subjects develop a need for treatments that may  interfere with the efficacy  or 
safet y of LTO LE treatment or for treatmen ts that are taken in place of LTOLE treatment, they  
must temporarily discontinue the relevant study  drug (rivaroxaban or aspi[INVESTIGATOR_834172]) until 
such time that the interacting treatment is discontinued.
Section 6.9.1 Combined CYP 3A4 and p -glycoprotein inhi bitors and CYP 3A4 inducers
New text:…...  If an y of these treatments are needed, randomized study  rivaroxaban/rivaroxaban 
placebo must be temporarily  discontinued and open- label aspi[INVESTIGATOR_834246].   
Long -Term Open -Label Extension − amended
The same guidance applies to LTOLE. No placebo will be used. 
Section 6.9.2 Clopi[INVESTIGATOR_7745] (or any other non- study antiplatelet treatment)
New text:
[COMPANY_003]
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 192of 205
…… Additional guidance is provided in Section [IP_ADDRESS].  
Long -Term Open -Label Extension − amended
The same gui dance applies to L TOLE. No placebo will be used. 
Section 6.9.3 Anticoagulant treatment
New text:
If therapeutic anticoagulation is required, subjects should start therapeutic anticoagulation 
immediately , irrespective of the timing of the last dose of stud y rivaroxaban.  
Long -Term Open -Label Extension − amended
Subjects who develop a need for anticoagulant therapy (e.g., thromboprophy laxis in 
subjects undergoing major orthopedic surgery , acute venous thromboembolism, atrial 
fibrillation, mechanical aortic valve replacement) must discontinue L TOLE medication. 
Guidance for converting see below:
Converting from rivaroxaban to oral anti -coagulants
Rivaroxaban affects INR, so INR measurements made during co -administration with oral 
anticoagulant may not be useful for determining the appropriate dose of oral anticoagulant. 
One approach is to discontinue rivaroxaban and begin both a parenteral anticoagulant and oral 
VKA at the time the next dose of rivaroxaban would have been taken.
Converting from rivaroxaban to parenteral anti -coagulants
Discontinue rivaroxaban and give the first dose of parenteral anticoagulant at the ti me that 
the next rivaroxaban dose would be taken.
Study rivaroxaban can be restarted at the discretion of the investigator in subjects who 
no longer have a need for non- study  anticoagulant therapy  (e.g., after completion of 
anticoagulant thromboprophy laxis or anticoagulant treatment for venous thromboembolism). 
Guidance for restarting see below:
Converting patients from VKAs to rivaroxaban
When converting patients from VKAs to rivaroxaban, INR values will be falsely  elevated 
after the intake of rivaroxaban. The INR is not valid to measure the anticoagulant activity  
of rivaroxaban, and therefore should not be used. 
Converting patients from parenteral anticoagulant to rivaroxaban
For patients currentl y receiving a parenteral anticoagulant, start rivaroxaban 0 to 2 hours 
before the time of the next scheduled administration of the parenteral drug (e.g. LMWH) or at 
the time of discontinuation of a continuously  administered parenteral drug (e.g. intravenous 
unfractionated heparin).
Section 7.1 Schedule of procedur es
New text:
Long -Term Open -Label Extension − amended
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 193of 205
A tabulated overview of the procedures conducted during the LTOLE is provided in 
Table 7−3, and the procedures and their timing are described in more detail in Section [IP_ADDRESS].
7.1.1 Tabulated overview……
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 194of 205
Section 7.1.1 Tabulated overview
New text:
Table 7 −3 Schedule of LTOLE Procedures
Visita1 2 3 4 5 6 Final LTOLE visite
Timingb06m 1y 1.5y 2y 2.5y 3y/
commercial availablef
Windows ± 4w ± 4w ± 4w ± 4w ± 4w ± 4w
Informed consent X
Inclusion/exclusion criteria X
Concomitant medications X X
Pregnancy test if pre -menopausal X
Serum creatinine cX
Outcomes X X X X X X
Adverse events dX X X X X X
Study drug dispensed X X X X X X
Study drug accountability X X X X X X
Study drug adherence X X X X X X
Questionnaires (MoCA, DSS, SAGE, EQ -5D) X
a.LTOLE visits may be combined with PPI [INVESTIGATOR_834185], and the visit window may be adjusted accordingly. 
b.Clinic visits should be scheduled as close to the specified interval as possible, and preferably within the defined window.  If it is not possible for the subject to 
return within the visit "window," especially due to unforeseen circumstance beyond the con trol of the subject or the study center, then the visit should be 
scheduled as close to the interval as is convenient for the subject and study center. 
c.If not available in the [ADDRESS_1158698] is on LTOLE treatment and will stop it at this visit and will be suggested to start non -study antithrombotic treatment at physician’s discretion. 
f.If the commercial availability in a country is achieved earlier than [ADDRESS_1158699] at the next scheduled visit; if a participant stops LTOLE treatment, a final visit should be scheduled immediately.
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 195of 205
Section 7.1.2 Timing of assessment
New text:[IP_ADDRESS] Long- Term Open -Label Extension − amended
The LTOLE protocol amendment requires clinic visits at initiation and every  6 months 
thereafter. For the COMPASS trial subjects continuing in the pantoprazole versus placebo 
randomization, L TOLE visits are recommended to coincide with the ongoing visits for 
pantoprazole comparison. If regulatory  and ethics approval is obtained shortly  after a 
pantoprazole versus placebo follow -up visit, an additional visit is recommended to evaluate 
eligibility  and, if appropriate, initiation of L TOLE treatment.
[IP_ADDRESS].1 Initiation of Long- Term Open -Label Extension − amended
The COMPASS trial subjects will be invited to participate in the LTOLE. Eligibility  for 
LTOLE is defined in Section 5.1.3. 
The objective of the LTOLE in itiation visit is to evaluate eligibility  of COMPASS trial 
subjects for LTOLE. Initiation activities include:
Obtain written informed consent 
Review inclusion and exclusion criteria 
Record concomitant medications
Conduct pregnancy  test (serum or urine) f or premenopausal subjects
Obtain results of serum creatinine (if not available in within prior 1 y ear)
Dispense study  drug
[IP_ADDRESS].2 Follow -up of Long- Term Open -Label Extension − amended
Subjects will be seen in the clinic every  6 months. Follow -up visit a ssessments include:
Record outcomes 
Record adverse events
Assess adherence to study drug
Perform study  drug accountability  (pi[INVESTIGATOR_692])
Dispense study  medication
[IP_ADDRESS].3 Final visit of Long- Term Open -Label Extension − amended
The final visits of L TOLE w ill begin, per country , when the duration reaches [ADDRESS_1158700] the final visit may  be conducted at the next scheduled 
visit. The final visit assessments include:
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 196of 205
Record outcomes
Record adverse events
Assess adherence to study  drug
Perform study  drug accountability  (pi[INVESTIGATOR_692])
Record concomitant medication
Administer questionnaires (MoCA, DSS, SAGE, EQ- 5D)
In the case of permanent discontinuation of L TOLE treatment, the subject will be called in for 
a final visit.
7.2 Population characteristics ……
Section 7.3 Efficacy
New text:
The outcome for the pantoprazole randomization is a composite of overt bleeding of 
gastroduodenal origin confirmed b y endoscop y or radiograph y, overt upper gastrointestinal 
bleeding of unknown origin, bleeding of presumed occult gastrointestinal origin with 
documented decrease in Hb of 2 g/dL, symptomatic gastroduodenal ulcer, gastrointestinal 
pain with underly ing multiple gastroduodenal erosions, and gastrointestinal obstruction, or
perforation .
Long -Term Open -Label Extension − amended
The same primary , secondary and tertiary  efficacy outcomes collected during the COMPASS 
trial will be collected during the LTOLE.
Section 7.5 Safety
New text:
The known side effect profile of rivaroxaban can be found in the Investigator Brochure (IB), 
which is updated on a regular basis.  An y new, relevant information about side effects of 
rivaroxaban will be provided to the subject by  [CONTACT_680923].
Long -Term Open -Label Extension − amende d
The safet y collection requirements for the COMPASS trial will remain unchanged for the 
LTOLE.
Section 8.4 Statistical and analytical plans
New text:
…… This method for date estimation has been used in many  studies and is recommended b y 
Dubois and Hebert (2001). 
8.4.8 Long- Term Open -Label Extension – amended
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 197of [ADDRESS_1158701] . Further details will be included in a separate SAP. 
The same subgr oup variables as in the COMPASS trial will apply  to LTOLE.
Section 9.2 Monitoring
New text:
The investigator and the head of the medical institution (where applicable) agrees to allow the 
monitor, auditors, and inspectors direct access to all relevant documents.
Long -Term Open -Label Extension –amended
The same details will apply  toLTOLE. An y specific considerations for LTOL E will be 
detailed in the Site Management Coordination Plan.
Section 10 Premature termination of the study
New text:…
If the stud y conduct (e.g. recruitment rate; drop-out rate; data qualit y; protocol 
compliance) does not suggest a proper completion of the trial within a reasonable time 
frame as agreed upon b y the Steering Committee.
Long -Term Open -Label Extension –amended
The same premature termination reasons will apply  to LTOLE with the exception of the 
interim analy sis.
Section 11.[ADDRESS_1158702] information and consent
New text:
……Any  revised written informed consent form and written information must receive the 
IEC/IRB`s approval / favorable opi[INVESTIGATOR_19349].
Long -Term Open -Label Extension − amended
Documented informed consent will be required for the L TOLE.
Modification 3: Changes made to COMPASS trial after earl y termination of 
rivaroxaban/aspi[INVESTIGATOR_834189].Section 4.1 Design overview
New text:
……Ba yer Global Pharmacovigilance will continue to follow the reported AEs until stabilized 
or resolved.
Amended after early termination of rivaroxaban/aspi[INVESTIGATOR_834308]/placebo 
follow -up visit, due to the short half -life of pantoprazole.
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 198of 205
Section 7.1 Schedule of procedures
New text:
A tabulated overview (Table 7 −1) of the procedures conducted in each of these periods is 
provided in Section 7.1.1 and the procedures and their timing are described in more detail in 
Section 7.1.2. 
Early termination of rivaroxaban/aspi[INVESTIGATOR_834176] − amended
On February  6, 2017, the COMPASS Data Safety  Monitoring Board (DSMB) recommended 
discontinuation of the rivaroxaban/aspi[INVESTIGATOR_834177]. The PPI  [INVESTIGATOR_834178]. 
Another update h as been added to the revised schedule of evaluation. Specifically , the 
pantoprazole/placebo washout call previously included in the table was removed as shown in 
Table 7−2 . 
Section 7.1.1 Tabulated overview
New text:
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59-7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 199of 205
Table 7 −2 Schedule of evaluations after DSMB recommendation in Feb 2017
Follow -up Rivaroxaban/ Aspi[INVESTIGATOR_834179]/placeboPantoprazole/placeboj
VisitjFinal Rivaroxaban/ 
Aspi[INVESTIGATOR_834180] -upRivaroxaban/ Aspi[INVESTIGATOR_834181]/ Placebo Follow -up Final Pantoprazole/ 
Placebo Follow -up 
Timing [ADDRESS_1158703] Rivaroxaban/ 
Aspi[INVESTIGATOR_834182]6 m post Rivaroxaban/ Aspi[INVESTIGATOR_834183] -up and 6 monthly  thereafterExpected in  2018, 
endpoint dependent
WindowsgMar –15 May  2017 ± 5d ± 4w ± 4w
Complete outstanding re -consents X
Physical measurementsaX X
Concomitant medications X X
Diet and activity questionnaires
MoCA, DSS, and SAGEh X X X
EQ-5DbX X
CT coronary angiographycX if 1yr not done yet
MRI braindX
Outcomes X X X X
Adverse eventseX X X X
Study drug dispensediXiX
Study drug adherence X X X
Study drug accountability X X X
Abbreviations:  w = week; m = month; y = year; d = day; DNA = deoxyribonucleic acid; MoCA =Montreal Cognitive Assessment; DSS = Digit Symbol 
Substitution test; SAGE = Standard Assessment of Global -Activities in the Elderly; EQ-5D = European Quality of Life-5 Dimensions questionnaire; CT = 
computed tomography; MRI = magnetic resonance imaging; CABG = coronary artery by[CONTACT_9292]
a.Weight, height, waist and hip circumference, heart rate, ankle -brachial blood pressure index
b.Using the Eur opean Quality of Life -[ADDRESS_1158704] angiography will be performed at 1 year or later in all subjects who are randomi zed Day 4 -7 after CABG to evaluate graft patency  (except in subjects 
those with specific contraindications). In the event the subject undergoes an invasive coronary angiography at [ADDRESS_1158705] dose of study treatment
f.Telephone visits
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59-7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 200of [ADDRESS_1158706] to 
return within the visit "window," especially due to unforeseen circumstance beyond the con trol of the subject or the study center, then the visit should be 
scheduled as close to the interval as is convenient for the subject and study center. 
h. Also to be administered at the next study clinic visit after each outcome event
i.Applicable only for su bjects ongoing with pantoprazole/placebo
j.For subjects from the PPI [CONTACT_14455], follow up visits will continue regardless of early stoppage of the rivaroxaban/aspi[INVESTIGATOR_834184], and there will be no 
washout visit.
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 201of 205
Section 7.1.2 .5 End of washout telephone visit ([ADDRESS_1158707] Final Follow -up Visit ± 5 
days)
New text:
The washout visit will be conducted b y stud y staff via telephone interview.  Washout visit 
assessments include:
Record outcomes 
Record adverse events (if appropriate, complete the Hospi[INVESTIGATOR_834188])
Amended after early termin ation of rivaroxaban/aspi[INVESTIGATOR_834309].
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 202of 205
14. Appendices
14.1 COMPASS MIND substudy -amended
Magnetic resonance imaging (MRI) substudy evaluating the incidence of clinically silent 
brain infarcts and subclinical brain ischemia  (COMPASS -MIND) 
Background: Clinically -evident strokes are the tip of the iceberg of vascular injury  to the 
brain.( 42)During the past de cade, improvements in, and wider application of, magnetic 
resonance imaging (MRI) make it clear that subclinical (i.e., covert) strokes are more frequent than clinically -evident brain infarcts. In population -based cohorts with a mean age of 65 
years, the prevalence of covert strokes is between 15% and 20% (i.e., several times the 
prevalence of s ymptomatic brain infarcts).  Covert strokes are not benign; they  are associated 
with cognitive and functional decline and are harbingers of future clinical strokes. Guidelines 
under development are likely  to recommend that patients discovered to have covert strokes be 
treated aggressivel y regarding secondary  prevention.
Figure 14–1: Covert brain infarct (arrow) on MR imaging (T -1 sequence)
Most covert brain infarcts in population -based studies are small subcortical strokes (often 
called lacunar infarcts) (see Figure 14–1) for which hy pertension is the dominant risk factor. 
Because of their small size, such strokes are clinically  unapparent if they  do not involve motor 
or sensory  tracts. In subjects with clinical vascular disease that will comprise the COMPASS 
trial cohort, the spectrum and underl ying pathogenesis of covert strokes is unknown and may  
well be different from those in population- based studies.
There are no published randomized trials aimed at prevention of covert strokes. The 
AVERROES trial compared the novel oral anticoagulant api[INVESTIGATOR_834310] 1,185 patients who underwent brain MR imaging a t entry . Covert brain infarcts were seen in 20%. 
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 203of 205
The trial was terminated after onl y one year of follow -up due to efficacy, and the precipi[INVESTIGATOR_834311] -out resulted in repeat MR imaging in only  80% of those having an MRI  at entry .
The AVERROES MRI  substudy  (unpublished) was thus underpowered to determine the effect 
of api[INVESTIGATOR_834312].
Prior epi[INVESTIGATOR_834313] y associated with the future development of cardiovascular events, including 
clinically  evident strokes. Several of these markers (e.g., C -reactive protein) have been 
incorporated into clinical risk prediction models which assist clin icians in determining which 
patients are at low, moderate, or high risk of suffering a stroke. Further, our understanding of 
the mechanism of action of antithrombotic drugs has been increased b y studying the effect of 
these therapi[INVESTIGATOR_834314] s associated with atherothrombosis. The 
COMPASS -MIND substudy  provides a unique opportunity  to examine biomarker as 
predictive of covert brain infarction and to understand how antiplatelet therapi[INVESTIGATOR_834315]. The main ob jective of COMPASS- MIND biomarker 
testing is to assess the association between selected biomarkers and the risk of overt and especiall y covert stroke in patients with established CAD and PAD . Markers to be measured 
include inflammatory  markers (such as C- reactive protein), markers of neuronal injury  (such 
as my elin basic protein, S -100B, neuron -specific enolase) and several miscellaneous markers 
(such as troponin, nt -proBNP) that have been shown to be powerful predictors of stroke in 
patients with atrial fibrillation.  DNA collected in these same patients will enable exploration of the genetic determinants of stroke, including etiologic subt ypes of stroke (cardioembolic, 
large vessel, small vessel disease) and in particular covert subcortical ischemia that is 
demonstrated on brain MRI  and is associated with cognitive decline.
Hypotheses:
1. Treatment with rivaroxaban will reduce the incidence of covert brain infarcts (detected by  
[CONTACT_834391]. end -study  MRIs) compared with aspi[INVESTIGATOR_834316].
2.  The addition of rivaroxaban to aspi[INVESTIGATOR_834317] 
(detected b y blinded comparison of initial vs. end -study MRIs) compared with aspi[INVESTIGATOR_834318].
Pre-specified secondary  outcomes would consider the effect of rivaroxaban on (1) non-lacunar 
covert brain infarct s; (2) volume of white matter hy perintensities; (3) all incident strokes, 
including clinical strokes (anticipated rate 1.2%/ yr among peripheral arterial disease patients 
and 0.8%/ yr among subjects with CAD
159),and all covert strokes ; (4a) functional decline
(Standard Assessment of Global -Activities in the Elderly  [SAGE ]) and [4b] cognitive decline 
(Montreal Cognitive Assessment [MoCA] and digit sy mbol substitution).160  Exploratory  
                                                
159Text modified/added as per Amendment 6. (See Section 13.1.2 )
160Sentence revised with Amendment 8.  (See Section 13.2.2 )
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 204of 205
analyses will examine the predictive value of biomarkers (C -reactive protein, nt-proBNP) as 
independent predictors of covert brain infarcts.
161Design: A phase II trial seeking evidence of efficacy  in a convenience sample of 1500 
COMPASS participants with readable baseline MRI  scans, 500 assigned to each treatment 
arm, but balanced for age, prior stroke, and h ypertension. Participants will undergo limited 
brain MRI  sequences (Fluid Attenuated Inversion Recovery  [FLAI R]), T -1, T-2, and T -
2*GRE sequences after randomization and near end -study  coupled with assessment of 
function (SAGE), and cognition (MoCA, digit s ymbol substitution).   Recruitment will occur 
at COMPASS sites with access to high -quality  (>1.0 Tesla159) reasonably -priced MR imaging.  
Images will be transmitted to the central MR imaging center via discs.  Two -stage central 
interpretation blinded to treatment will be carried -out, with all incident covert infarcts 
confirmed b y a second independent interpreter.  The has experience with collection and 
analysis of brain MRIs performed in substudies of several randomized trials:  AVERROES, 
PURE, APOLLO, and (planned) TIPS [ADDRESS_1158708] DNA collected at baseline and blood 
collected at baseline and at the 1 month visit.162DNA and blood collections are 
optional. (Section 7.1.1 , [IP_ADDRESS] and [IP_ADDRESS].1 )159.The samples will be processed, and aliquots 
will be shipped for long -term storage in liquid nitrogen at the coordinating center in  
 Canada.  Blood samples will be processed and stored in s uch a way to allow future 
analysis of these aliquots for selected biomarkers, some of which have been observed in other 
studies to be predictors of stroke, and others which have a plausible association with 
cardiovascular outcomes.  Detailed information co ncerning blood collection, processing, 
storage, and shippi[INVESTIGATOR_834258].
Power :  There is insufficient information in the literature to accuratel y estimate the incidence 
of covert brain infarcts for the COMPASS study  cohort, bu t given a 3%/ year incidence in 
population -based cohorts of similar age, 5%/ yr in the aspi[INVESTIGATOR_834319] a conservative estimate. 
Given a sample size of 1500 participants randomized to 1 of 3 treatment arms (i.e. 500 
patients in each treatment group), there wil l be approximately  70% power to assess a 
treatment effect of rivaroxaban of 45%.  For the key  pre-specified secondary  analy sis of the 
effect of rivaroxaban on the combined clinical and covert ischemic strokes with estimated incidence of 7% per year, the st udy power would be 0.[ADDRESS_1158709] a 40% reduction and 0.[ADDRESS_1158710] a 35% reduction.  About 5% of participants will not undergo the second MRI  due to 
acquiring a contraindication (e.g., pacemaker), death or refusal, so the power will be slightly  
less.  Th ese power calculations are based on a conservative estimate of the incidence of covert 
brain infarcts during aspi[INVESTIGATOR_505825] y in the COMPASS population, and higher rates would 
result in increased statistical power. 
Implications:  The COMPASS MRI  substudy  is the first randomized trial of an anticoagulant 
to prevent covert brain infarcts in patients with atherosclerotic vascular disease. Evidence that 
rivaroxaban reduces covert stroke better than or in addition to aspi[INVESTIGATOR_834320] e an immense 
                                                
161Sentences revised with Amendments 6 and 8.  (See Sections 13.1.2 and 13.2.2 )
162Sentence revised with Amendment 8.  (See Section 13.2.2 )
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
Integrated Clinical Study Protocol
BAY 59 -7939/[ZIP_CODE]
12 SEPT 2017 Version 4.0 Page: 205of [ADDRESS_1158711].  Within COMPASS trial, the MRI  substudy  offers an 
opportunity  to develop evidence of rivaroxaban efficacy  for a separate clinical indication 
applicable to a burgeoning population.
[COMPANY_003]